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1
As long as human beings have recognized and suffered from disease, there has been a quest for 
cures and therapies. Historically, natural product extracts served as the main source of drugs. 
In the second half of the nineteenth century, the first isolation of biologically active molecules 
from these extracts succeeded, and soon after that the first synthesis of the pharmaceutical 
drug aspirin took place [1]. Due to enormous progress in all fields related to pharmaceutical 
sciences, the art of drug discovery has evolved greatly in the 20th and 21st century. We are 
now able to synthesize large chemical libraries of up to millions of synthetic small molecules, 
which can be screened against the target of interest in order to identify potential drug 
candidates [2]. As a consequence, it is not a surprise that for one particular target many 
different drug-like molecules are discovered. This is also the case for the chemokine receptor 
CCR2, a receptor that is involved in a large variety of diseases ranging from autoimmune and 
metabolic diseases to atherosclerosis and pain. Despite major efforts of the pharmaceutical 
industry and synthesis of many inhibitors, there is at this moment no clinically effective drug 
available that targets this receptor. In order to improve current drug candidates, one would 
benefit from understanding their mechanism of action at a molecular level, which is often 
incomplete in the current process of drug discovery. In this thesis we therefore zoom in at 
the molecular level of CCR2, and reveal novel insights in mechanisms of action of existing 
as well as novel drug-like molecules. These findings serve as a fundament for future drug 
discovery programs, and will be equally relevant for understanding the outcomes of current 
drug candidates in later stages of development. 
In order to grasp the relevance of the research and the concepts that will be discussed in 
this thesis, first of all the world of G protein-coupled receptors (GPCRs) will be introduced, 
the protein family to which CCR2 belongs. The activation and inhibition of GPCRs will be 
outlined, as well as their role in physiology and disease. This brings us to the receptor of 
interest, CCR2, a member of the GPCR subfamily of chemokine receptors. Finally the current 
status of drug discovery targeting CCR2 will be addressed, followed by the outline of the aim 
and contents of this thesis.
G protein-coupled receptors 
Classification and structure
GPCRs comprise the largest family of membrane receptors in mammalian cells; the human 
genome has been estimated to encode approximately 800 GPCRs [3]. GPCRs are located at 
the cell surface and transduce an extracellular signal into an intracellular response. They are 
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expressed in nearly all organs and tissues of the human body, and therefore they regulate a 
broad range of physiological processes. The structure of a GPCR consists of an extracellular 
N-terminus and an intracellular C-terminus with seven transmembrane-spanning α-helices, 
resulting in three extra- and intracellular loops (Fig. 1) [4]. The understanding of the 
3D-conformational structure has substantially increased since attempts to crystallize GPCRs 
became more successful; we now have snapshots of at least 23 different GPCRs available at 
the time of writing of this introduction, including those for the chemokine receptors CXCR4 
and CCR5 [5, 6]. According to the IUPHAR Committee on Receptor Nomenclature and Drug 
Classification, the superfamily of GPCRs is divided in six classes based on their functional 
similarity and sequence homology [7]. Each family generally shares over 25% sequence 
identity in the transmembrane core region, with specific sets of highly conserved residues 
and motifs. The largest and most studied subfamily is formed by the class A rhodopsin-like 
receptors, to which the chemokine receptors belong. The remaining classes are the class 
B secretin receptor family, class C metabotropic glutamate/pheromone receptors, class 
D fungal mating pheromone receptors, class E cyclic AMP receptors and class F frizzled/
smoothened like receptors. In addition, for ~15% of all GPCRs the endogenous ligand is at 














Fig. 1. Schematic representation of GPCRs embedded in the cell membrane. Upon ligand binding and 
receptor activation, signal transducing proteins like G proteins, GRKs and β-arrestins can bind at the 
intracellular side.
GPCR signalling in health and disease
Upon activation due to ligand binding at the extracellular side of the GPCR, the receptor 
undergoes conformational changes that allow recruitment of intracellular signalling proteins 
(Fig. 1) [8]. These signalling proteins subsequently become activated and start a downstream 
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signal transduction cascade. Multiple types of signalling proteins have been associated with 
GPCRs, among which the family of G proteins is most ubiquitous and best characterised [9]. 
There are four members of the family of heterotrimeric G proteins, being Gs, Gi, Gq, G12/13, 
which individually consist of a Gα, Gβ and Gγ subunit (Fig. 1) [10]. Activation of G proteins 
results in an exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) 
in the alpha subunit, which is followed by dissociation of the activated Gα and Gβγ subunits. 
These subunits can activate a wide variety of signalling molecules, of which adenylyl cyclase 
(AC), the MAP kinase pathways and phospholipase C (PLC) are most prominent [11]. Second 
messengers, including cyclic AMP, inositol triphosphate and calcium ions, then turn on a 
range of effector systems to change the behavior of the cell, ranging from morphological 
changes and secretion of molecules, to the regulation of gene transcription. 
Besides G proteins, GPCRs can bind and activate other cytosolic proteins such as G 
protein-coupled receptor kinases (GRKs) and β-arrestins (Fig. 1) [9]. GRKs and β-arrestins 
orchestrate GPCR activities at three different levels [12]. First of all they induce silencing, 
which is the functional uncoupling of the receptor from its G protein by a mechanism known 
as desensitisation. In addition they mediate receptor trafficking, characterized by receptor 
internalization, resensitisation and/or degradation. Finally, they can induce signalling, via the 
activation or inhibition of intracellular signalling pathways independently of heterotrimeric 
G proteins. 
Together, these signalling proteins determine the response of a cell to an extracellular 
stimulant. Due to the great divergence in GPCRs this can vary from the regulation of the heart 
rate to the perception of odors and flavors. All of these processes are carefully fine-tuned, and 
therefore malfunctioning of any GPCR can result in severe diseases. Since GPCRs comprise a 
large protein-family, and are involved in the most prevalent disease areas including cancer, 
obesity, diabetes and cardiac dysfunction, approximately one third of the pharmaceuticals on 
the market today target these proteins [13]. 
Ligands for G protein-coupled receptors
Activation and inhibition of GPCRs
GPCRs are very flexible membrane proteins and their conformation varies from an inactive 
state (R) to several active states (R*) [14, 15]. The ratio between active and inactive states 
is dependent on the type of GPCR and its cellular environment. Some are naturally present 
with high proportions in an active state; these GPCRs signal without any ligand binding, a 
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phenomenon that is named ‘constitutive activity’ or ‘basal activity’ [16, 17]. The ratio 
between active and inactive states is affected by binding of ligands at the extracellular face of 
the GPCR. Agonist ligands preferentially bind to and stabilize the active state R* of a receptor, 
resulting in an increase in receptor activity and signalling (Fig. 2A+B). Some ligands behave as 
partial agonists; these ligands activate the receptor, but cannot elicit the maximum possible 
response that is induced by a full agonist (Fig. 2B). These partial agonists have been reported 
to stabilize a distinct conformational state of the receptor compared to full agonists [18, 19]. 
Others propose that partial agonists are able to dynamically bind with multiple orientations 
to a receptor, which results in active and inactive populations of receptors of which the 
ratio determines the level of the response [20]. Inverse agonists preferentially bind to the 
inactive state R and reduce the receptor activity (Fig. 2A+B) [21]. Again, a distinction can be 
made between full and partial inverse agonists [22, 23]. Neutral antagonists prevent GPCR 
activation, but bind equally well to active as well as inactive conformations, and therefore 
these ligands do not affect the basal activity of the receptor (Fig. 2A+B) [21]. 
 
Fig. 2. (A) The preference of different ligands to bind to the inactive (R) and/or active (R*) receptor 
state. (B) Receptor activation upon binding of a full agonist, partial agonist, neutral antagonist or inverse 
agonist.
This classical view of receptor signalling has been refined during the past couple of 
years, since we began to appreciate that one GPCR is able to activate multiple signalling 
proteins, via different active states [15]. It is now evident that certain ligands are able to 
stabilize a specific active state of a GPCR, and the first structural basis for this phenomenon 
was recently reported for the serotonin 5-HT1B/2B and the β2-adrenergic receptors [24, 25]. This 
can result in ligand-directed signalling via one specific pathway, named ‘functional selectivity’ 
or ‘biased signalling’ [26]. In extreme cases it might occur that a certain ligand for one GPCR 
is an agonist for signalling pathway A, while it behaves as an antagonist for signalling pathway 
B. This concept is also applicable to chemokine receptors and is therefore important to take 
into account during drug discovery, as will be further discussed in Chapter 2. 
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Orthosteric and allosteric ligands 
The endogenous ligands for the GPCR superfamily are very diverse, ranging from peptide 
hormones, lipids and nucleotides to odorants and ions [7]. The binding site of these 
endogenous ligands is called the “orthosteric” binding site. Especially since the introduction 
of small molecule and peptide drugs, it was discovered that multiple ligand binding sites are 
present on GPCRs. If a ligand binds to the same binding site as the endogenous ligand, it is 
named an orthosteric ligand. In contrast, when it binds to a topographically distinct site from 
where the endogenous ligand binds, it is named an ‘allosteric’ ligand [27]. This term has been 
derived from the Greek word ‘allo’, which means ‘other’. Allosteric ligands can exert a variety 
of effects at a functional level [28]. Allosteric agonists can activate GPCRs by themselves 
without the presence of any orthosteric ligand. In addition, since the allosteric site is different 
from the orthosteric site, a GPCR is in some cases able to simultaneously bind both orthosteric 
and allosteric ligands. Allosteric ligands are thereby able to alter the binding and/or signalling 
properties induced by the ligand at the orthosteric site and are accordingly named allosteric 
modulators, which can be further classified as allosteric enhancers (or positive allosteric 
modulators - PAMs) and allosteric inhibitors (or negative allosteric modulators – NAMs). Since 
the binding pocket of chemokine receptors is quite large and the size of synthetic drugs very 
small compared to the endogenous chemokine protein ligand, allosteric modes of action 
are often observed for this family of GPCRs [5, 29]. In this thesis two novel allosteric binding 
pockets were discovered, located within the core domain and at the intracellular side of 
CCR2, as described in Chapters 4 and 5.
Ligand-receptor binding kinetics 
In order to activate or inhibit signalling events via a GPCR, a ligand first needs to bind to the 
receptor [30]. Both agonists and antagonists bind to the receptor with a certain association 
rate (kon), followed by their release of binding from the receptor with dissociation rate koff 
(Scheme 1). The strength of binding is represented by the parameter Ki, which stands for 
the affinity of a ligand for its receptor, and is determined by the ratio koff/kon (Scheme 1). 
This affinity can be easily measured in pharmacological assays, and drug discovery programs 
classically optimize this equilibrium parameter to end with high affinity ligands that are put 
forward in the drug development cycle. The affinity of a ligand is a very important measure, 
but next to that the concept of individually optimizing kon and koff has gained more and more 
attention during the last decade [31, 32]. Importantly, affinity is measured in a closed system 
(in vitro) at equilibrium, whereas in open systems like the human body (in vivo) the drug 
and target can have fluctuating concentrations [33]. This discrepancy may make equilibrium 
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measurements less appropriate to predict the effect of a drug in vivo. It would be better 
suited to additionally measure the lifetime of the drug-target complex, represented by the 
term ‘residence time’ that can be calculated as the reciprocal of koff (Scheme 1) [34].
Scheme 1. Binding of a ligand (L) to the receptor (R) with association rate kon, and dissociation of L from 
R with dissociation rate koff. The affinity (Ki) and residence time (RT) can be derived from these rate 
constants.
Several studies have indicated that long residence time ligands can contribute to 
improved efficacy, reduced side effects and a longer duration of action. The latter would 
enable once-daily dosage forms as opposed to multiple doses and thus increases patient 
compliance [35-39]. Examples are the angiotensin II subtype-1 (AT1) receptor antagonist 
olmesartan for treatment of hypertension [40, 41], and the neurokinin-1 (NK1) receptor 
antagonist aprepitant for prevention of acute and delayed chemotherapy-induced nausea 
and vomiting [42]. In addition, the rate at which a drug binds to a target receptor is crucial to 
the onset of the drug effect, therefore quick binding of a drug to its target is preferred [43]. 
The residence time of a ligand can be measured in kinetic binding assays upon 
radiolabelling the compound of interest [44]. However, this is labor intensive and cost-
inefficient, and therefore a method to determine the residence time of unlabelled ligands was 
invented in 1984 by Motulsky and Mahan [45]. It took twenty years before this competition 
association assay was picked up by a larger audience, but nowadays it is applied to assess 
ligand binding kinetics at many GPCRs [32, 36, 39, 46]. Based on this method a higher 
throughput screening assay was developed in our laboratory, named the ‘dual point kinetic 
assay’, which facilitates the screening for long residence time ligands [47]. In Chapter 6 we 
applied both of these assays to study the residence time of antagonists for CCR2, to stimulate 
drug discovery based on kinetic profiles next to affinity in order to eventually improve clinical 
efficacy. 
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Chemokine receptors and their ligands 
The chemokine receptor family
The chemokine receptor CCR2 belongs to the GPCR subfamily of chemokine receptors. 
They are predominantly expressed on immune cells and serve an important role in the host 
immune response against invading pathogens [48, 49]. Approximately 23 different chemokine 
receptors are known to date, and these can be activated by one or several of the 48 different 
chemokine ligands. Chemokines are small peptides of 70 to 120 amino acid residues, which 
are classified into four families according to the interaction pattern of the cysteine residues 
in their N-terminus: XC, CC, CXC and CX3C, where C represents a cysteine bridge and X/X3 
stands for one or three non-cysteine residues (Fig. 4) [50]. 
Chemokine receptor binding and activation are generally thought to occur via a two-
step process in which the first step is governed by binding of the large peptide ligand to the 
N-terminus and extracellular loops of the GPCR protein [51]. Subsequently, the N-terminus of 
the chemokine is well-positioned to interact with the transmembrane (TM) domains, leading 
to activation of the receptor [52].
Chemokines can be divided into two functional groups: homeostatic chemokines that are 
involved in leukocyte homing, and inflammatory chemokines that are produced in inflamed 
tissue by resident and infiltrating cells [53]. Several chemokines have both a homeostatic 
and inflammatory function. The secretion of chemokines evokes a chemokine gradient 
that results in chemotaxis: direct migration of cells expressing the appropriate chemokine 
receptor towards the chemokine ligand [54]. More details of the functions and the regulation 
of the chemokine receptor system are described in Chapter 2.
Fig. 3. The structure of chemokine families XC, CC, CXC and CX3C. Disulfide bridges are represented by 
the dotted lines. 
The chemokine receptor CCR2
In 1994 CCR2 was fully cloned and characterized by Charo and co-workers [55]. It exists in two 
alternatively spliced forms: CCR2a and CCR2b [56]. CCR2b is the predominantly expressed 
variant on which the current study was focussed, therefore I refer to this variant as “CCR2” in 
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this thesis. CCR2 is abundantly expressed on immune cells such as monocytes, natural killer 
cells and T-lymphocytes and can be bound by eight different inflammatory chemokines, being 
CCL2, CCL7, CCL8, CCL11, CCL13, CCL16, CCL24 and CCL26 [57-60]. CCL2 is the most studied 
chemokine for CCR2, and is unique among the seven CCR2 chemokines since it is the only 
ligand that binds exclusively to CCR2. Intracellular signalling pathways that are activated by 
CCR2 are mainly driven by Gi proteins and β-arrestins [61]. Further downstream the activation 
of kinase cascades including extracellular signal-regulated kinase (ERK) 1/2 and Akt, as well as 
calcium signalling have been reported. Notably, the different chemokines have been reported 
to preferentially activate specific signalling pathways over others, implying that the concept 
of biased-signalling is applicable to this receptor, as discussed in Chapter 2 [61-63]. 
CCR2 as drug target
CCR2 is involved in a variety of diseases characterized by inflammation. Increased levels 
of CCL2 have been found associated to atherosclerosis, and CCR2 knock-out mice show a 
reduction in lesion size in the arterial wall [64, 65]. Several studies have shown that CCR2 on 
monocytes and macrophages mediates their recruitment to the atherosclerotic lesion and 
thereby contributes to plaque formation [66]. In addition, CCL2 and CCR2 are both highly 
expressed in the dorsal root ganglion (DRG) and on astrocytes and microglial cells in the 
peripheral and central nervous system during chronic pain states [67]. Knock-out of CCR2 in 
mice was found to diminish development of chronic pain states like neuropathic pain, and 
therefore many companies search for CCR2 antagonists as pain-reducing agents since no 
therapies are currently available for this disease [68]. Rheumatoid arthritis is characterized 
by inflammation in the joints, and again increased expression of CCL2 and CCR2-expressing 
macrophages has been found at these sites [69]. From these examples it seems that both 
CCR2 and its ligands are associated to different disease states through a common mechanism 
of action, which is a combination of direct activation of CCR2 in the cells of the target tissue 
and recruitment of circulating inflammatory cells into the tissue. Other diseases for which an 
important role of CCR2 and its chemokines has been reported include cancer [70], asthma 
[71], fibrosis [72], diabetes [73] and multiple sclerosis [74].   
CCR2 inhibition by small molecule antagonists or monoclonal antibodies has been 
evaluated in a number of clinical trials targeting all the diseases mentioned above [75]. 
Unfortunately the majority of these trials failed, with the predominant reason being 
a lack of efficacy in Phase II. On-going trials include studies with the antagonists CCX140 
and PF-04634817 for diabetic nephropathy [76, 77], and PF-04136309 for pancreatic 
adenocarcinoma [78]. The only marketed drugs for chemokine receptors at this moment 
are the CCR5 antagonist maraviroc and the CXCR4 antagonist AMD3100 [79, 80]. Maraviroc 
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inhibits entry of human immunodeficiency virus (HIV) into CCR5-positive cells, and AMD3100 
is used to mobilize human hematopoietic stem cells from the bone marrow. Notably, both 
these conditions are not related to inflammatory diseases, highlighting the difficulty to 
intervene in those pathologies.
This thesis
Aim
The aim of the study was to provide a detailed insight in the molecular mechanism of action of 
CCR2 antagonists in order to improve drug discovery targeting this receptor. Three separate 
binding pockets via which CCR2 can be modulated were discovered, and different routes that 
lead to insurmountable antagonism of this receptor were revealed. In this thesis these results 
will be discussed in view of the complexity of the chemokine system. They should provide the 
reader with insights that will hopefully lead to the development of clinically effective drugs 
in the long term. 
Outline
The family of chemokine receptors and their endogenous chemokines will be more extensively 
introduced and discussed in Chapter 2. This chapter is particularly devoted to the so-called 
biased-signalling of chemokines and its implications for drug discovery.
Chapter 3 is focused on small molecule antagonists for CCR2, for which multiple binding 
sites were discovered. This chapter presents four orthosteric antagonists, including INCB3344, 
and two allosteric antagonists, including CCR2-RA-[R].
The binding site of the allosteric antagonist CCR2-RA-[R] was discovered to be located 
at the intracellular side of the receptor. Chapter 4 presents the amino acid residues in the 
receptor involved in binding of CCR2-RA-[R], which were revealed by means of an experimental 
and computational approach. 
Besides the orthosteric and allosteric binding sites of the antagonists in Chapters 3 and 
4, yet another binding site for CCR2 small molecule inhibitors was discovered. Modulation 
of CCR2 via this site by amiloride analogues as well as sodium ions is described in Chapter 5.
Chapter 6 is focused on the discovery of novel orthosteric antagonists. This chapter 
describes how the residence time of CCR2 antagonists was increased by specific and small 
structural changes. This type of structure-kinetics relationships (SKR) should be incorporated 
in hit-to-lead optimization in order to increase the discovery of clinically effective CCR2 
antagonists. 
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The research presented in these chapters reveals that binding sites for small molecule 
ligands are present throughout the entire transmembrane domain of CCR2. Therefore this 
thesis literally presents the ins and outs of ligand binding to CCR2. These results and its 
forthcoming opportunities for drug discovery are concluded and discussed in Chapter 7. 
General Introduction  |  19
1
References
1. Schroder, A., Prinzhorn, A., Kraut, K., Uber salicylverbindungen. Annalen der Chemie und 
Pharmacie, 1869. 150(1): p. 1-20.
2. Mayr, L.M. and Bojanic, D., Novel trends in high-throughput screening. Curr Opin Pharmacol, 
2009. 9(5): p. 580-8.
3. Lagerstrom, M.C. and Schioth, H.B., Structural diversity of G protein-coupled receptors and 
significance for drug discovery. Nat Rev Drug Discov, 2008. 7(4): p. 339-57.
4. Venkatakrishnan, A.J., et al., Molecular signatures of G-protein-coupled receptors. Nature, 
2013. 494(7436): p. 185-94.
5. Wu, B., et al., Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide 
antagonists. Science, 2010. 330(6007): p. 1066-71.
6. Tan, Q., et al., Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc 
complex. Science, 2013. 341(6152): p. 1387-90.
7. Davenport, A.P., et al., International Union of Basic and Clinical Pharmacology. LXXXVIII. G 
protein-coupled receptor list: recommendations for new pairings with cognate ligands. 
Pharmacol Rev, 2013. 65(3): p. 967-86.
8. Preininger, A.M., J. Meiler, and H.E. Hamm, Conformational flexibility and structural dynamics 
in GPCR-mediated G protein activation: a perspective. J Mol Biol, 2013. 425(13): p. 2288-98.
9. Ritter, S.L. and R.A. Hall, Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev 
Mol Cell Biol, 2009. 10(12): p. 819-30.
10. Downes, G.B. and N. Gautam, The G protein subunit gene families. Genomics, 1999. 62(3): p. 
544-52.
11. Hamm, H.E., The many faces of G protein signaling. J Biol Chem, 1998. 273(2): p. 669-72.
12. Reiter, E. and R.J. Lefkowitz, GRKs and beta-arrestins: roles in receptor silencing, trafficking 
and signaling. Trends Endocrinol Metab, 2006. 17(4): p. 159-65.
13. Rask-Andersen, M., M.S. Almen, and H.B. Schioth, Trends in the exploitation of novel drug 
targets. Nat Rev Drug Discov, 2011. 10(8): p. 579-90.
14. Leff, P., The two-state model of receptor activation. Trends Pharmacol Sci, 1995. 16(3): p. 89-
97.
15. Bouvier, M., Unraveling the structural basis of GPCR activation and inactivation. Nat Struct 
Mol Biol, 2013. 20(5): p. 539-41.
16. Cotecchia, S., et al., Regions of the alpha 1-adrenergic receptor involved in coupling to 
phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad 
Sci U S A, 1990. 87(8): p. 2896-900.
17. Costa, T. and S. Cotecchia, Historical review: Negative efficacy and the constitutive activity of 
G-protein-coupled receptors. Trends Pharmacol Sci, 2005. 26(12): p. 618-24.
18. Kobilka, B.K. and X. Deupi, Conformational complexity of G-protein-coupled receptors. Trends 
Pharmacol Sci, 2007. 28(8): p. 397-406.
19. Bhattacharya, S., et al., Ligand-stabilized conformational states of human beta(2) adrenergic 
receptor: insight into G-protein-coupled receptor activation. Biophys J, 2008. 94(6): p. 2027-
42.
20. Bock, A., et al., Dynamic ligand binding dictates partial agonism at a G protein-coupled 
receptor. Nat Chem Biol, 2014. 10(1): p. 18-20.
21. Kenakin, T., Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol 
Pharmacol, 2004. 65(1): p. 2-11.
20  |  Chapter 1
22. Labarre, M., et al., Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. 
Eur J Pharmacol, 2000. 406(1): p. R1-3.
23. Yanagawa, M., T. Yamashita, and Y. Shichida, Glutamate acts as a partial inverse agonist to 
metabotropic glutamate receptor with a single amino acid mutation in the transmembrane 
domain. J Biol Chem, 2013. 288(14): p. 9593-601.
24. Wacker, D., et al., Structural features for functional selectivity at serotonin receptors. Science, 
2013. 340(6132): p. 615-9.
25. Liu, J.J., et al., Biased signaling pathways in beta2-adrenergic receptor characterized by 
19F-NMR. Science, 2012. 335(6072): p. 1106-10.
26. Stallaert, W., A. Christopoulos, and M. Bouvier, Ligand functional selectivity and quantitative 
pharmacology at G protein-coupled receptors. Exp Opin Drug Discov, 2011. 6(8): p. 811-25.
27. May, L.T., et al., Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol 
Toxicol, 2007. 47: p. 1-51.
28. Christopoulos, A. and T. Kenakin, G protein-coupled receptor allosterism and complexing. 
Pharmacol Rev, 2002. 54(2): p. 323-74.
29. Scholten, D.J., et al., Pharmacological modulation of chemokine receptor function. Br J 
Pharmacol, 2012. 165(6): p. 1617-43.
30. Kenakin, T., Principles: receptor theory in pharmacology. Trends Pharmacol Sci, 2004. 25(4): p. 
186-92.
31. Vauquelin, G. and S.J. Charlton, Long-lasting target binding and rebinding as mechanisms to 
prolong in vivo drug action. Br J Pharmacol, 2010. 161(3): p. 488-508.
32. Dowling, M.R. and S.J. Charlton, Quantifying the association and dissociation rates of 
unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol, 2006. 148(7): p. 927-
37.
33. Hulme, E.C. and M.A. Trevethick, Ligand binding assays at equilibrium: validation and 
interpretation. Br J Pharmacol, 2010. 161(6): p. 1219-37.
34. Copeland, R.A., D.L. Pompliano, and T.D. Meek, Drug-target residence time and its implications 
for lead optimization. Nat Rev Drug Discov, 2006. 5(9): p. 730-9.
35. Tummino, P.J. and R.A. Copeland, Residence time of receptor-ligand complexes and its effect 
on biological function. Biochemistry, 2008. 47(20): p. 5481-92.
36. Slack, R.J., et al., Pharmacological characterization of GSK1004723, a novel, long-acting 
antagonist at histamine H(1) and H(3) receptors. Br J Pharmacol, 2011. 164(6): p. 1627-41.
37. Sykes, D.A., M.R. Dowling, and S.J. Charlton, Exploring the mechanism of agonist efficacy: a 
relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. 
Mol Pharmacol, 2009. 76(3): p. 543-51.
38. Casarosa, P., et al., Preclinical evaluation of long-acting muscarinic antagonists: comparison of 
tiotropium and investigational drugs. J Pharmacol Exp Ther, 2009. 330(2): p. 660-8.
39. Fleck, B.A., et al., Binding kinetics redefine the antagonist pharmacology of the corticotropin-
releasing factor type 1 receptor. J Pharmacol Exp Ther, 2012. 341(2): p. 518-31.
40. Oparil, S., et al., Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the 
control of essential hypertension. J Clin Hypertens, 2001. 3(5): p. 283-91, 318.
41. Le, M.T., et al., Molecular characterisation of the interactions between olmesartan and 
telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol, 2007. 151(7): p. 952-
62.
42. Lindstrom, E., et al., Neurokinin 1 receptor antagonists: correlation between in vitro receptor 
interaction and in vivo efficacy. J Pharmacol Exp Ther, 2007. 322(3): p. 1286-93.
43. Zhang, R. and F. Monsma, Binding kinetics and mechanism of action: toward the discovery and 
development of better and best in class drugs. Exp Opin Drug Discov, 2010. 5(11): p. 1023-9.
General Introduction  |  21
1
44. Maguire, J.J., R.E. Kuc, and A.P. Davenport, Radioligand binding assays and their analysis. 
Methods Mol Biol, 2012. 897: p. 31-77.
45. Motulsky, H.J. and L.C. Mahan, The kinetics of competitive radioligand binding predicted by 
the law of mass action. Mol Pharmacol, 1984. 25(1): p. 1-9.
46. Guo, D., et al., Functional efficacy of adenosine A(2)A receptor agonists is positively correlated 
to their receptor residence time. Br J Pharmacol, 2012. 166(6): p. 1846-59.
47. Guo, D., et al., Dual-point competition association assay: a fast and high-throughput kinetic 
screening method for assessing ligand-receptor binding kinetics. J Biomol Screen, 2013. 18(3): 
p. 309-20.
48. Zlotnik, A. and O. Yoshie, The chemokine superfamily revisited. Immunity, 2012. 36(5): p. 705-
16.
49. Esche, C., C. Stellato, and L.A. Beck, Chemokines: key players in innate and adaptive immunity. 
J Invest Dermatol, 2005. 125(4): p. 615-28.
50. Alexander, S.P., A. Mathie, and J.A. Peters, Guide to Receptors and Channels (GRAC), 5th 
edition. Br J Pharmacol, 2011. 164 Suppl 1: p. S1-324.
51. Monteclaro, F.S. and I.F. Charo, The amino-terminal domain of CCR2 is both necessary and 
sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation 
by a pseudo-tethered ligand. J Biol Chem, 1997. 272(37): p. 23186-90.
52. Pease, J.E., et al., The N-terminal extracellular segments of the chemokine receptors CCR1 and 
CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain 
is essential for efficient receptor activation. J Biol Chem, 1998. 273(32): p. 19972-6.
53. Moser, B., et al., Chemokines: multiple levels of leukocyte migration control. Trends Immunol, 
2004. 25(2): p. 75-84.
54. Tanino, Y., et al., Kinetics of chemokine-glycosaminoglycan interactions control neutrophil 
migration into the airspaces of the lungs. J Immunol, 2010. 184(5): p. 2677-85.
55. Charo, I.F., et al., Molecular cloning and functional expression of two monocyte chemoattractant 
protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad 
Sci U S A, 1994. 91(7): p. 2752-6.
56. Wong, L.M., et al., Organization and differential expression of the human monocyte 
chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in 
receptor trafficking. J Biol Chem, 1997. 272(2): p. 1038-45.
57. Berkhout, T.A., et al., Cloning, in vitro expression, and functional characterization of a novel 
human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds 
and signals through the CC chemokine receptor 2B. J Biol Chem, 1997. 272(26): p. 16404-13.
58. Combadiere, C., et al., Monocyte chemoattractant protein-3 is a functional ligand for CC 
chemokine receptors 1 and 2B. J Biol Chem, 1995. 270(50): p. 29671-5.
59. Ogilvie, P., et al., Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood, 
2001. 97(7): p. 1920-4.
60. Myers, S.J., L.M. Wong, and I.F. Charo, Signal transduction and ligand specificity of the human 
monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells. J Biol 
Chem, 1995. 270(11): p. 5786-92.
61. Berchiche, Y.A., et al., Different effects of the different natural CC chemokine receptor 2b 
ligands on beta-arrestin recruitment, Galphai signaling, and receptor internalization. Mol 
Pharmacol, 2011. 79(3): p. 488-98.
62. O‘Boyle, G., et al., Chemokine-mediated inflammation: Identification of a possible regulatory 
role for CCR2. Mol Immunol, 2007. 44(8): p. 1944-53.
63. Ogilvie, P., et al., Unusual chemokine receptor antagonism involving a mitogen-activated 
protein kinase pathway. J Immunol, 2004. 172(11): p. 6715-22.
22  |  Chapter 1
64. Boring, L., et al., Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in 
the initiation of atherosclerosis. Nature, 1998. 394(6696): p. 894-7.
65. Szalai, C., et al., Involvement of polymorphisms in the chemokine system in the susceptibility 
for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G 
genotype in CAD patients. Atherosclerosis, 2001. 158(1): p. 233-9.
66. Gautier, E.L., C. Jakubzick, and G.J. Randolph, Regulation of the migration and survival of 
monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler 
Thromb Vasc Biol, 2009. 29(10): p. 1412-8.
67. Abbadie, C., Chemokines, chemokine receptors and pain. T Immunol, 2005. 26(10): p. 529-34.
68. Abbadie, C., et al., Impaired neuropathic pain responses in mice lacking the chemokine 
receptor CCR2. Proc Natl Acad Sci U S A, 2003. 100(13): p. 7947-52.
69. Gaffo, A., K.G. Saag, and J.R. Curtis, Treatment of rheumatoid arthritis. Am J Health Syst 
Pharm, 2006. 63(24): p. 2451-65. 
70. Conti, I. and B.J. Rollins, CCL2 (monocyte chemoattractant protein-1) and cancer. Semin 
Cancer Biol, 2004. 14(3): p. 149-54.
71. Batra, J. and B. Ghosh, Genetic contribution of chemokine receptor 2 (CCR2) polymorphisms 
towards increased serum total IgE levels in Indian asthmatics. Genomics, 2009. 94(3): p. 161-
8.
72. Seki, E., et al., CCR2 promotes hepatic fibrosis in mice. Hepatology, 2009. 50(1): p. 185-97.
73. Weisberg, S.P., et al., CCR2 modulates inflammatory and metabolic effects of high-fat feeding. 
J Clin Invest, 2006. 116(1): p. 115-24.
74. Mahad, D.J. and R.M. Ransohoff, The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and 
experimental autoimmune encephalomyelitis (EAE). Semin Immunol, 2003. 15(1): p. 23-32.
75. Struthers, M. and A. Pasternak, CCR2 antagonists. Curr Top Med Chem, 2010. 10(13): p. 1278-
98.
76. Chemocentryx product pipeline. Available from: http://www.chemocentryx.com/product/
overview.html.
77. Pfizer product pipeline as of Nov 2013. Available from: http://www.pfizer.com/research/
science_and_technology/product_pipeline.
78. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01413022.
79. Lieberman-Blum, S.S., H.B. Fung, and J.C. Bandres, Maraviroc: a CCR5-receptor antagonist for 
the treatment of HIV-1 infection. Clin Ther, 2008. 30(7): p. 1228-50.
80. De Clercq, E., Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, 
Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther, 
2010. 128(3): p. 509-18.
 
Chapter 2





Trends in Immunology 2014 35(6):243-252
24  |  Chapter 2
Abstract
Chemokine receptors are widely expressed on a variety of immune cells and play a crucial 
role in normal physiology as well as in inflammatory and infectious diseases. The existence of 
23 chemokine receptors and 48 chemokine ligands guarantees a tight control and fine-tuning 
of the immune system. Here, we discuss the multiple regulatory mechanisms of chemokine 
signalling at a systemic, cellular, and molecular level. In particular, we focus on the impact of 
biased signalling at the receptor level; an emerging concept in molecular pharmacology. An 
improved understanding of these mechanisms may provide a framework for more effective 
drug discovery and development at a target class that is so relevant for immune function.
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Regulation of the chemokine system 
Chemokines are the most important regulators of leukocyte trafficking and play a central role 
in the immune system [1]. They act via abundantly expressed chemokine receptors, which 
belong to the family of G protein-coupled receptors (GPCRs) (Box 1), on a wide variety of 
immune cells. Activation of these chemokine receptors induces migration and differentiation 
of immune cells, which both are essential processes during innate and adaptive immune 
responses [2]. 
Box 1. Chemokine receptors as GPCRs
GPCRs 
•	 With >800 members, GPCRs are the largest family and most diverse group of cell surface 
receptors and the most common target for therapeutic drugs [8].
•	 The GPCR structure consists of an extracellular N-terminus, an intracellular C-terminus and 
seven transmembrane (TM) helices, connected by three cytoplasmic and three extracellular 
loops [9].
•	 Ligand binding mostly takes place in a pocket formed by the seven helices close to the 
extracellular side of the receptor; it induces a conformational change at the intracellular side of 
the receptor that results in receptor activation and subsequent signalling [10].
•	 At the intracellular side different effector proteins can bind and transduce signals, among which 
are G proteins and β-arrestins [11]. 
Chemokine receptors
•	 Chemokine receptors belong to the class A Rhodopsin-like family of GPCRs.
•	 23 different chemokine receptors have been identified that can be activated by ~48 chemokine 
ligands [IUPHAR/BPS Guide to Pharmacology, http://www.guidetopharmacology.org, accessed 
on 07-02-2014]. 
•	 Four subclasses of chemokine ligands have been identified on the basis of the pattern of 
conserved cysteine residues (C, CC, CXC and CX3C) [12]. 
•	 Chemokine receptors have been classified as C, CC, CXC and CX3C receptors based on the 
chemokine subclass ligand that they bind. 
•	 Most chemokine receptors bind multiple chemokines, and most chemokines can bind to and 
activate multiple chemokine receptors.
•	 The chemokine receptors ACKR1 (DARC), ACKR2 (D6), ACKR3 (CXCR7) and ACKR4 (CCX-CKR) are 
so-called decoy receptors that predominantly scavenge chemokine ligands from the extracellular 
environment, although some of these also couple to β-arrestins [13]. 
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The chemokine-directed immune response involves a complex network of reactions 
that are carefully fine-tuned at multiple levels throughout the body (Fig. 1). At the systems 
level this involves spatiotemporal and tissue-specific expression of chemokine receptors 
and their ligands. At the cellular level the chemokine receptor signal can be modulated by 
coexpression of many differentially expressed proteins on immune cells. Finally, there is 
growing evidence of biased signalling at the molecular level for chemokine receptors, which 
implies that different chemokine ligands activate different intracellular pathways although 
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expressed receptors
Fig. 1. Schematic representation of the structure of this review. The chemokine receptor-mediated 
immune response is discussed at a systems, cellular and molecular level.
With regard to this bias at the receptor level, novel mechanistic insights have been 
attained lately due to the advances in X-ray crystallography and NMR methods to resolve the 
structure of membrane proteins, such as GPCRs. Several structures of chemokine receptors 
have been elucidated now, among which are chemokine CXC receptor (CXCR)1, CXCR4 and 
chemokine CC receptor (CCR)5 [3-5]. In addition, for the serotonin 5-hydroxytryptamine 
(HT)1B/2B and the β2-adrenergic receptors a structural basis for biased signalling was reported 
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[6, 7]. Similar mechanisms for ligand bias are likely to be present for the family of chemokine 
receptors, since these are particularly prone to biased signalling due to the presence of 
multiple endogenous chemokine ligands.   
So far there has only been limited success in clinical trials targeting chemokine receptors. 
We propose therefore to consider chemokine regulation and bias at multiple levels in order to 
better understand their intricacies. Thus, in this review we present a summary of chemokine 
receptor signalling at a systems, cellular, and molecular level. Immunologists should be aware 
of the bias that can be introduced at a molecular level, whereas pharmacologists need to 
keep in mind that their target molecule could be modulated or expressed differently at a 
systems level.
Regulation of chemokine expression and receptor activation
The human chemokine system consists of approximately ~23 receptors and 48 ligands 
[IUPHAR/BPS Guide to Pharmacology, http://www.guidetopharmacology.org, accessed on 
07-02-2014], of which the classically signalling chemokine receptors are presented in Fig. 
2. Most chemokine receptors can be activated by multiple chemokines, and one chemokine 
often has the ability to activate multiple receptors. Although previously regarded as 
redundant, the unique expression patterns of the various chemokines suggest that they form 
the basis for a specific and fine-tuned functioning of the immune system [1]. This is not only 
important in normal physiology, but also during certain immunopathological disease states, 
as illustrated by the CCR2 receptor and its ligands. CCR2 can be activated by the chemokine 
ligands chemokine CC ligand (CCL)2/monocyte chemotactic protein (MCP)-1, CCL7/MCP-3, 
CCL8/MCP-2, CCL11/eotaxin, CCL13/MCP-4, and CCL16/human CC chemokine (HCC)-4. Most 
studies have been focused on the CCL2–CCR2 interaction because CCL2 is the endogenous 
ligand with the highest affinity for CCR2. Nevertheless, in infectious diseases, CCL7 has 
been found to be crucial for monocyte recruitment to inflammatory sites mediated through 
CCR2 [14]. An example of distinct expression patterns observed in immunopathology is the 
regulation of the CCR4 ligands CCL17/thymus- and activation-regulated chemokine (TARC) 
and CCL22/macrophage-derived chemokine (MDC), which are not expressed in healthy skin 
tissue [15]. However, in inflamed skin lesions, CCL17 is detected on endothelial cells, whereas 
CCL22 is only presented by dendritic cells [15]. This distinct chemokine expression pattern 
has been demonstrated in diseases ranging from psoriasis to atopic dermatitis, therefore, this 
could be a general feature underlying the disease state. In general the balance, timing, and 
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pattern of chemokine expression appears to regulate the generation of immune-cell-specific 
responses in health and disease [16]. 
In addition to the difference in release and production of chemokines among various 
tissues, their in vivo availability also depends on the interaction of chemokines with specific 
glycosaminoglycan (GAG) chains that are presented at the cell surface as part of membrane 
proteoglycans. The binding of chemokines to GAGs allows immobilization, accumulation, 
and retention of chemokines on cell surfaces near their sites of production in order to 
provide directional signals to migrating cells [17]. In addition, GAG interactions are involved 
in the transport of chemokines across cell surfaces. GAGs may selectively bind chemokines 
and therefore fine-tune the immune response, because they display varying affinities for 
specific chemokines and are differentially expressed in time and location on specific cell 
types and tissues [18]. Furthermore, cells and tissues can alter the expression of GAGs 
in pathophysiology. This has been observed upon inflammatory stimuli in diseases of the 
gastrointestinal tract as well as in multiple different tumours [19, 20]. GAGs might even be 
directly involved in signalling, since their attached core proteins that span the membrane can 
undergo tyrosine phosphorylation and thereby contribute to signal transduction, as reported 
for CXCL12/SDF-1 and the proteoglycan syndecan-4 [21]. Although they are a crucial factor 
for chemokine signalling, the exact functional consequences of chemokine-GAG interactions 
and the level of specificity are still largely speculative. 
Not only GAGs can alter the availability of chemokines, but also chemokine receptors 
themselves. A certain group of chemokine receptors, known as atypical chemokine receptors 
(ACKRs) [13], have been proposed to act mainly as chemokine ligand scavengers [22, 23]. 
Furthermore, under certain circumstances the G protein-coupled chemokine receptors have 
been demonstrated to become uncoupled from G protein signalling. For example, dendritic 
cells and monocytes treated with anti-inflammatory interleukin (IL)-10 express ‘uncoupled’ or 
‘nonsignalling’ CCR1, CCR2 and CCR5, which can scavenge their corresponding inflammatory 
chemokines in vitro as well as in mice [24]. Another study demonstrated both in vitro and in 
vivo that apoptotic leukocytes express ‘silent’ CCR5 receptors, scavenging CCR5 ligands, and 
thereby contributing to the resolution of inflammation in a mouse model of peritonitis [25]. 
Therefore expression of a certain chemokine receptor does not always imply a contribution 
to the disease state. In fact, one might speculate that a pharmacological blockade of these 
receptors can increase free chemokine levels and therefore result in enhanced pathology. 
Altogether the examples above illustrate that the expression of chemokines and their 
receptors varies over time and between different conditions, and studies of mechanisms and 
outcomes associated with this differential expression in a number of disease states have been 
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reviewed previously [26, 27]. As noted above, it is clear that expression of chemokines and their 
receptors does not necessarily imply a role as stimulator or enhancer of a pathophysiological 
state, which is an important factor to consider while developing antagonists targeting the 
chemokine system. Besides the regulation of chemokines and their receptors throughout the 
body, there is substantial evidence that chemokine receptors modulate each other within a 
















































































Fig. 2. Overview of the family of chemokines and chemokine receptors. The green inner circle represents 
those chemokine receptors for which some form of biased signalling has been documented. This is 
not (yet) the case for the chemokine receptors in the blue outer circle. The black dots represent the 
chemokine ligands that have been shown to bind to a given chemokine receptor. The group of atypical 
chemokine receptors (ACKRs) is not depicted in this figure.
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Regulation of chemokine receptor signalling in immune cells
Chemokine receptors are expressed by immune cells in both the innate and adaptive 
compartments, including B and T lymphocytes, monocytes and neutrophils [28]. Distinct 
expression profiles characterize the different leukocyte subtypes. For example in T helper 
(Th) cells, several chemokine receptors are associated with the Th1 phenotype (including 
CXCR3 and CCR5), whereas others are associated with the Th2 phenotype (including CCR4 
and CCR8). This phenomenon is likely related to their discriminate functions in response to 
viral and bacterial pathogens or during allergic reactions [29, 30]. In the case of monocytes, 
a different repertoire of chemokine receptors can be expressed depending on environmental 
factors and stimuli. Lipopolysaccharide (LPS) downregulates CCR1, CCR2, and CCR5 
expression in monocytes, whereas IL-2 stimulates CCR2 expression [31]. In addition, CCR7 is 
upregulated upon immunogenic stimulation, possibly to facilitate lymph-node homing [32, 
33]. Tight regulation of the different chemokine receptors on immune cells therefore shapes 
the immune cell response.
The majority of immune cells express multiple chemokine receptors simultaneously. At a 
cellular level, chemokines can counteract each other or display synergy, thereby reducing the 
inflammatory response or increasing the selectivity of cell recruitment [34, 35]. For example, 
via heterologous receptor desensitization or internalization one chemokine can lower the 
responsiveness of a cell to other chemokines binding to a distinct chemokine receptor 
[36]. This phenomenon has been studied in human peripheral blood T cells, which express 
CCR5 and CXCR4 [37]. Upon simultaneous addition of their chemokines CCL4/macrophage 
inflammatory protein (MIP)-1β, CCL5/regulated on activation, normal T cell expressed and 
secreted (RANTES), and CXCL12, the capacity of CXCL12 to induce chemotaxis in vitro is 
suppressed. This crosstalk does not involve the internalization of the receptor, but rather a 
cross-desensitization via a decrease in phosphorylation of downstream signalling proteins. 
The rich chemokine environment surrounding the leukocytes during inflammatory conditions 
can therefore induce different cellular responses than determined in assays that only reflect 
the behaviour of one particular chemokine receptor and ligand [38].
Chemokines can also modulate signalling responses through other chemokine receptors 
due to the presence of heterodimeric or hetero-oligomeric receptor complexes [39]. This 
has been demonstrated for several chemokine receptors, among which CCR2, CCR5, and 
CXCR4 [40-42]. In CCR2-CCR5 heterodimers, the CCR5 ligands CCL3/MIP-1α, CCL4, and CCL5 
were able to displace CCL2 from CCR2 [42]. This so-called negative cooperativity was further 
analysed in different in vitro assays to confirm the allosteric nature of this displacement via 
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heterodimers [41]. The relevance for immune cell functioning has been demonstrated as well, 
because negative binding cooperativity takes place in hetero-oligomeric complexes between 
the binding pockets of CCR2, CCR5, and CXCR4 in T cells and monocytes that endogenously 
express these receptors [40]. As a result, the recruitment of these cells mediated by the 
CXCR4 agonist CXCL12 in mice could be inhibited by antagonists of CCR2 and CCR5. 
Within immune cells, the magnitude and duration of the signal depends on the 
exposed chemokine concentration and on (subsequent) chemokine receptor desensitization, 
phosphorylation, and internalization. These processes are regulated via G protein-coupled 
receptor kinases (GRKs) and β-arrestins [43]. On the intracellular side of the cell, the different 
repertoires of these adaptor proteins regulate the eventual cellular effects. In RBL-2H3 cells 
stably expressing both receptors, it has been shown that CXCR1 and CXCR2 couple to distinct 
GRK isoforms [44]. CXCR1 predominantly couples to GRK2, whereas CXCR2 interacts with 
GRK6 to negatively regulate receptor sensitization and trafficking, eventually affecting cell 
signalling [44, 45]. The role of GRK6 in neutrophil recruitment was further demonstrated in 
studies using wild type and GRK6-/- knockout mice [44]. In addition, different types of immune 
cells express different types of GRKs and β-arrestins; the levels of which may also vary, adding 
another layer of bias and fine-tuning of the response of chemokines and their receptors [46, 
47]. 
Thus, there are multiple co-receptors and adaptor proteins that define the eventual 
chemokine receptor signal. In order to study the effect of a chemokine or potential drug 
candidate, it is important to include cell types and tissues that reflect the in vivo situation more 
so than cell lines, devoid of physiological context, with heterologous receptor expression. 
Biased signalling through chemokine receptors
At the molecular level yet another type of bias is present in the chemokine system, because 
chemokine receptors are capable of differentially signalling in a ligand-specific manner. This 
biased signalling, also called functional selectivity, refers to agonist ligands that favour the 
activation of a certain intracellular signalling pathway over another [48]. The following sections 
discuss the multiple intracellular signalling routes that can be activated by chemokines. The 
aim is to give a comprehensive overview of the biased signalling events that have been 
reported for chemokine receptors so far, illustrating that the chemokine system is extensively 
fine-tuned at the receptor level already. 
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GPCR signalling
GPCRs transduce the effects of many extracellular signals/ligands (whether those are 
chemokines or other hormones and neurotransmitters) to intracellular pathways and signalling 
routes (Fig. 3). They bind to and activate heterotrimeric G proteins that consist of a Gα, Gβ, and 
Gγ subunit, for which 21, 6, and 12 different types are present in humans, respectively [49]. 
Activation of these G proteins modulates the production of second messenger molecules 
such as cyclic AMP (cAMP), intracellular calcium (Ca2+) and inositol phosphates (IPs), which 
control further downstream effectors like protein kinase (PK)C and Akt. GPCR activation 
and consequently G protein-mediated signalling are terminated via phosphorylation of the 
GPCR by GRKs. The phosphorylated receptor recruits β-arrestins, of which various subtypes 
exist. This association often results eventually in receptor internalization to the cytosol, 
effectively impeding further signalling from the receptor. After receptor coupling, β-arrestins 
are also able to transduce signals themselves, for example via subsequent activation of the 
extracellular signal-regulated kinase (ERK) pathway [50]. For the purpose of the present 
discussion, we focus on the major signalling pathways via G proteins and β-arrestins to 
illustrate the phenomenon of biased signalling through chemokine receptors in functions of 
the immune system. 
In case of extreme signal bias through GPCRs, one ligand may mainly activate G 
proteins, whereas another ligand only activates β-arrestins. This results in different cellular 
effects (‘texture’) although both ligands act via the same receptor; a process which has 
been extensively studied and discussed for GPCRs in general, as reviewed by Kenakin and 
Christopoulos [51]. Biased signalling does not only comprise distinct signalling via either G 
proteins or β-arrestins, but also includes more subtle differences in the activation of other 
downstream signalling proteins. For example, ligands can discriminate between different 
types of G proteins, whereas others differently affect signalling events like ERK activation 
or Ca2+ mobilization. It is important to note that pathway activation depends also on the 
expression level of the receptor as well as the cellular expression and availability of signalling 
molecules, which result in cell-specific differences (Fig. 3).
Advances in structural biology have led to an accumulating understanding of the 
underlying mechanisms. The first structural features in a GPCR crystal structure that are 
responsible for biased signalling were recently revealed for the serotonin receptors 5-HT1B 
and 5-HT2B [6]. Conformational changes at the intracellular side in their helix VI and helix VII 
were reported to be responsible for G protein signalling or β-arrestin signalling, respectively 
[6, 52, 53]. In addition to the ‘snapshots’ of bias in crystal structures, the emerging field of 
protein molecular dynamics further contributes to our understanding of ligand bias. Such 
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studies have simulated at the atomic level how small perturbations at the more extracellularly 
located ligand binding site can lead to large conformational changes at the intracellular side 
of the receptor [54]. Importantly, not only do we start to understand the molecular features 
of biased signalling, we now also recognize its implications as it may lead to the development 

























Fig. 3. Schematic representation of biased signalling through chemokine receptors. The extent of 
signalling via signalling proteins 1-7 is represented by the thickness of the arrows. (A) Chemokines A 
and B bind to the same chemokine receptor in immune cell 1, but activate distinct signalling pathways. 
A signals predominantly via proteins 2 and 3, whereas B signals mainly via protein 5. (B) Immune cell 2 
expresses signalling proteins different from immune cell 1, which results in differential signalling profiles 
for chemokines A and B. 
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The chemokine receptor family is prone to ligand-induced biased signalling, because 
most chemokine receptors can be activated by multiple chemokines. Interestingly, this is 
different from many other GPCRs with only one endogenous ligand, where ligand bias has 
largely been observed for synthetic agonists only. In several studies the activation of multiple 
pathways has been compared among the different chemokines, and for certain chemokine 
receptors a biased signalling pattern was discovered (Fig. 2 and 3). These receptors include 
CCR1 [56-59], CCR2 [60-62], CCR5 [63-65], CCR7 [66-68], CCR10 [57] and CXCR3 [57, 69]. With 
the exception of the homeostatic chemokine receptor CCR7, all are inflammatory chemokine 
receptors that bind multiple chemokines. The following sections discuss the biased signalling 
through each of these receptors individually. 
Biased signalling through CC chemokine receptors 
CCR1. The expression of CCR1 is known to coincide with the G protein subtypes Gi/o, G14 and 
G16 [70]. Four chemokines, CCL3, CCL5, CCL7, and CCL15/HCC-2, were found to differentially 
activate these G protein subtypes in COS-7 cells or HEK293 cells transfected with CCR1, 
resulting in different intracellular levels of cAMP, ERK, and IP [56]. More specifically, CCL15 
was discovered to be the only chemokine ligand that did not signal via G14 and G16. The 
inability of CCL15 to activate CCR1 as effectively as the others could potentially be caused 
by its long N-terminal region. The N-terminal region is responsible for receptor activation, 
whereas the N-loop region is responsible for receptor binding. CCL15 can bind the receptor 
with high affinity due to its structural homology to other CC chemokines in the N-loop 
region, but its extended N-terminal region largely precludes subsequent receptor activation 
[58]. Further support comes from the finding that neither CCL14/HCC-1 nor CCL23/myeloid 
progenitor inhibitory factor (MPIF)-1, both having a long N-terminal region, can activate 
CCR1 despite sufficient binding affinity [56]. Another study on CCR1 agonism examined a 
total of eight different chemokine ligands, and reported that CCL8 was a poor G protein-
activator whereas CCL4 was proposed to act as an in vivo inhibitor of CCR1 in the leukaemia 
cell line HL-60 because it showed only marginal receptor activation in functional assays [59]. 
In CCR1-transfected HEK293 cells, CCL5 and CCL23 have been identified as G protein-biased 
chemokines compared to CCL3, while CCL5, CCL15, and CCL23 display bias for internalization 
following β-arrestin recruitment [57]. All these different studies illustrate that CCR1 is heavily 
prone to biased signalling.
CCR2. The CCR2 receptor has been reported to bind eight chemokines, namely CCL2, 
CCL7, CCL8, CCL11, CCL13, CCL16, CCL24/eotaxin-2 and CCL26/eotaxin-3. Berchiche et al. 
studied the Gi activation and β-arrestin recruitment profiles of these different ligands in 
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HEK293 cells transfected with CCR2 [60]. Overall, the potency and efficacy rank orders of G 
protein activation and β-arrestin recruitment were comparable. However, when the β-arrestin 
subtypes 1 and 2 were compared, the weak arrestin recruiters CCL8 and CCL13 were found 
to show bias towards β-arrestin 2. Interestingly, the study also reported the kinetics of the 
CCR2-β-arrestin complexes. CCL7 had a high potency to recruit β-arrestin, but with a short 
half-life of the signal, whereas CCL8 and CCL13 induced weak but stable signals over time. 
These differences in kinetic patterns are additional factors leading to signal bias that deserve 
more attention; it has been reported for other GPCRs that this can be an underlying factor 
for differential signalling as well as signal termination [71]. Besides the signalling properties 
of the different CCR2 ligands, it was reported that CCL2, CCL7 and CCL13 induce homodimer 
formation of CCR2, whereas the other chemokines do not [60]. The formation of dimers, 
hetero- or homo-, is yet another mechanism to create bias in signalling and should therefore 
be taken into account when interpreting signal bias of any chemokine receptor. 
CCR5. The signalling properties of CCL3, CCL4, CCL5, CCL8, and CCL13 via CCR5 have 
been investigated in cAMP accumulation and Ca2+ mobilisation assays in CHO cells stably 
expressing CCR5. The potency rank order of chemokine ligands was similar between the 
two assays, however, CCL13 was completely unable to affect cAMP concentrations [63]. The 
Ca2+ responses were G protein-dependent, except for CCL3 that produced a Ca2+ signal in a 
partly G protein-independent manner. These results illustrate that the CCR5 chemokines act 
differently. Interestingly, other groups that used different cell systems, including RBL-2H3 and 
COS-7 cells expressing CCR5, reported different rank orders of signalling efficiencies [65, 72]. 
This indicates cell-type specific effects or differential activation of the various intracellular 
effectors by these chemokines (Fig. 3). It further emphasizes that the choice of cell lines 
must be an important parameter; primary cell lines and immune cells may better represent 
an in vivo relevant bias in signalling. The underlying mechanism for the differential effects 
of CCR5 ligands has been addressed in studies that focused on the structural determinants 
at the receptor level. Biased signalling could be a result of ligand-specific induction of 
phosphorylation sites and thereby specific recruitment of GRKs, which differs among the 
CCR5 chemokine ligands [65]. A mutagenesis study further explored molecular determinants 
of CCR5-induced signalling. Residues in helix VI and VII were identified that are responsible 
for causing biased signalling [64]. In the crystal structures of the serotonin receptors it was 
the orientation of these same helices that was found to induce biased signalling [6]. It would 
be very interesting to determine if these structural features can be translated to other 
chemokine receptors as well, which would be helpful for drug development targeting these 
receptors.
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CCR7. CCL19/Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC) and CCL21/
secondary lymphoid tissue chemokine (SLC) are the endogenous agonists for CCR7. They 
are equally active in promoting G protein activation, Ca2+ mobilization, and chemotaxis 
[67, 68]. However, in terms of β-arrestin recruitment and subsequent internalization of the 
receptor they behave differently. It was found that β-arrestin 3 was responsible for CCR7 
internalization in the T cell lymphoma cell line HuT78 after stimulation with CCL19, which 
was not the case for CCL21-induced internalization [66]. Although both ligands allowed 
recruitment of β-arrestin 2, only CCL19 led to redistribution of β-arrestin-2 into endocytotic 
vesicles and classical receptor desensitization in HEK293 cells stably expressing CCR7 [67]. 
The underlying mechanism for this difference in β-arrestin recruitment was found to be a 
differential recruitment of GRKs that phosphorylate CCR7. CCL19 activates both GRK3 and 
GRK6 whereas CCL21 activates GRK6 only. Kohout and co-workers have reported findings 
that support this differential recruitment of GRKs, revealing that CCL19 induces specific 
phosphorylation sites on CCR7 in HEK293 cells [68]. 
CCR10. CCL27/cutaneous T cell-attracting chemokine (CTACK) and CCL28/mucosae-
associated epithelial chemokine (MEC) are the two endogenous chemokines for CCR10. 
Both ligands are capable of G protein signalling measured by cAMP accumulation, but only 
CCL27 is capable of recruiting β-arrestin and internalizing the receptor [57]. In the same 
study it was assessed that CCL28 displayed a higher efficacy for migration of peripheral blood 
mononuclear cells (PBMCs). The biased signalling of CCL28 was speculated to be causal for 
this effect, explained by the lack of β-arrestin signalling and internalization that could result 
in prolonged and unopposed G protein activation [57]. 
Biased signalling through CXC chemokine receptors and ACKRs
CXCR3. CXCR1, CXCR2 and CXCR3 are the three CXC chemokine receptors that can each bind 
to multiple chemokines, but thus far biased signalling has only been reported for CXCR3. The 
activation of CXCR3 by CXCL9/monokine induced by gamma-interferon (MIG), CXCL10/IP-10 
and CXCL11/interferon-inducible T cell alpha chemoattractant (I-TAC) has been investigated 
in a label-free impedance-based cellular assay [69]. For this technique, low-voltage currents 
run through microelectrode sensors at the bottom of a plate to which cells are attached. 
Changes in impedance upon ligand addition are continuously measured, and reflect receptor 
activation in the absence of a chemical or biological biosensor within the cell. Using this 
technique Watts et al. showed that CXCL9 behaved as a biased CXCR3 agonist in HEK293 cells 
stably expressing CXCR3, stimulating solely G protein-dependent pathways [69]. However, 
another study compared cAMP accumulation, β-arrestin recruitment and internalization 
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in classical functional assays with HEK293 cells transfected with CXCR3, and reported the 
opposite finding of CXCL9 being β-arrestin biased [57]. In addition CXCL11 was biased 
towards internalization. Apparently, CXCR3 is subject to biased signalling, of which the extent 
and nature may be determined by the different receptor expression levels and cellular assays 
used (Fig. 3). Although future studies will ascertain whether biased signalling through other 
CXC receptors exists, we would hypothesize that this is likely, because, for example, CXCR2 
binds seven different chemokine ligands. 
ACKRs. It should be noted that the ACKRs [13] such as ACKR1 (Duffy antigen/receptor 
for chemokines (DARC)), ACKR2 (D6), ACKR3 (CXCR7) and ACKR4 (chemocentryx chemokine 
receptor (CCX-CKR)) can bind a wide variety of chemokine ligands, with up to 18 ligands for 
ACKR1. These receptors were initially regarded as non-signalling decoy receptors because 
of their inability to activate typical G protein-signalling pathways, and therefore ACKRs were 
proposed to only scavenge ligands or function as co-receptors [22]. However, some recent 
studies have shown that these ACKRs can signal predominantly through β-arrestins. The 
chemokines CXCL11 and CXCL12 induce β-arrestin-2 recruitment to ACKR3 transfected in 
CHO cells, and a small molecule ACKR3 ligand has been reported to induce this β-arrestin-2 
recruitment with even higher potency and efficacy [73]. Another study also reported that 
CXCL12 induces β-arrestin-2 recruitment to ACKR3 in HEK293 cells transfected with ACKR3, 
as well as rat vascular smooth muscle cells (VSMCs), which results in downstream activation 
of ERK [74]. These signalling properties were discovered to be important in physiologically 
relevant cell lines, since the ACKR3-mediated migration of rat VSMCs was found to be 
a β-arrestin-mediated process [74]. Besides ACKR3, ACKR2 can also recruit β-arrestins, 
however, further evidence of subsequent signalling remains to be elucidated for this 
receptor [75]. Given these reports of β-arrestin recruitment and signalling through ACKRs, 
it has been proposed that these receptors should be regarded as a subfamily of β-arrestin-
biased GPCRs. However, there is now one case reported of ACKR3 signalling via Gi/o in primary 
rodent astrocytes and human glioma cells [76]. This finding reveals the presence of thus far 
hidden properties of ACKRs, and the exact role and significance of ACKR-mediated signalling 
remains an open question for future research. ACKRs serve homeostatic functions by clearing 
chemokines from circulation and tissues [77], and in addition viruses and parasites are 
capable of modulating the expression of ACKRs to elude chemokines [78]. These receptors 
are therefore important for innate and adaptive immunity, emphasizing the necessity to 
resolve their functioning.
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Concluding remarks
Here, we have discussed the regulation and bias in chemokine expression and signalling at a 
systems, cellular and molecular level. The presented evidence implies that the focus on only 
one natural ligand of a chemokine receptor as a prototype agonist is insufficient; neither 
should we focus on one single chemokine receptor in vitro because there might be several 
other receptors that determine the fate of the immune cell in vivo. 
Over the past few years the ‘drugability’ of chemokine receptors has been reviewed 
and questioned [79]. The family of chemokine receptors is involved in a wide variety of 
diseases, mostly characterized by chronic inflammation. Although >50% of these receptors 
have been examined in clinical trials in the past decade, only two drugs targeting chemokine 
receptors have been approved by the regulatory authorities. The CCR5 antagonist maraviroc 
inhibits entry of HIV into CCR5-positive cells [80], and the CXCR4 antagonist AMD3100 is 
used to mobilize human haematopoietic stem cells from the bone marrow [81]. Notably, 
neither of these conditions is an inflammatory disease, nor is biased signalling involved. 
Possible reasons for the failure of other drug candidates targeting chemokine receptors 
are: i) lack of efficacy due to inappropriate disease models; ii) lack of efficacy due to poor 
pharmacokinetics such as binding to serum components; and iii) off-target (side) effects. 
The complexity at multiple levels of the chemokine system is another factor that introduces 
challenges for effective intervention in disease states (Box 2). Integration of these issues in 
early stages of drug discovery and development programs is necessary in order to develop 
clinically effective drugs with an acceptable benefit/risk profile. The clinical relevance of 
biased ligands is illustrated by the µ-opioid receptor agonist TRV130, which has recently been 
tested in Phase I studies and is entering Phase II in 2014 for the treatment of acute pain 
[82]. TRV130 causes G protein signalling with similar potency and efficacy as morphine, but 
with far less β-arrestin recruitment and receptor internalization [83]. Subsequent studies in 
mice have demonstrated that this bias results in higher analgesic efficacy, less gastrointestinal 
dysfunction, and less respiratory suppression than morphine. 
In summary we have reviewed the regulation of and bias in chemokine receptor 
signalling that should be taken into account by immunologists as well as pharmacologists (Fig. 
1). The expression profile of chemokine ligands at the target tissue should be determined and 
considered in order to design appropriate in vitro studies, taking into account the differential 
expression profiles in health and disease. This is important given the aforementioned data that 
reported crucial and different roles between chemokine ligands that bind to one chemokine 
receptor. In addition, the growing evidence of biased signalling through chemokine receptors 
shows that we cannot restrict ourselves to incorporate one chemokine ligand only, because 
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the effect of drug candidates in the presence of other chemokine ligands might be different. 
Although heterologous cell systems can be used at the start of a project, the function of the 
chemokine receptor and impact of a drug should be studied in physiologically relevant cells 
as early as possible, because coexpressed proteins and receptors can modulate the behaviour 
and response of a chemokine receptor. It is hoped that this review will help in designing such 
experiments.
Box 2. Chemokine signalling: implications for drug discovery in immunology 
The complexity of the chemokine receptor family and its ligands should be considered during 
drug discovery. Most chemokine receptors are activated by multiple chemokine ligands, which 
should be taken into account upon developing small molecule antagonists. This can be illustrated by 
research on the chemokine receptor CCR1. For this receptor it has been shown that small molecule 
ligands can both act as allosteric enhancers for CCL3 and at the same time as a competitive blockers 
of the binding of CCL5 [84]. This drug-induced bias is important, since chemokines are differentially 
expressed and regulated during immunopathology. 
Not only small molecule ligand, but also short lipidated peptide sequences named pepducins 
have been found to be candidate drugs targeting chemokine receptors. The pepducin ATI-2341 
selectively targets CXCR4 and is an allosteric agonist in vitro as well as in vivo [85]. In a recent 
study it was discovered that ATI-2341 revealed functional selectivity for Gi pathways over G13 and 
β-arrestin [86]. In comparison to the CXCR4 antagonist AMD-3100, which is used in the clinic 
to mobilize haematopoietic stem cells from the bone marrow for transplantation of leukaemia 
patients [81], the pepducin ATI-2341 does not induce the additional undesired mobilization of 
lymphocytes [85]. Whether CXCR4-mediated biased signalling of ATI-2341 with respect to AMD-
3100 is causal for this difference remains a question for further research. 
Besides the pepducins, small molecule ligands can also induce biased signalling upon binding 
to chemokine receptors [64, 69, 87, 88]. For CCR5, the small molecule agonists YM-370749 and 
ESN-196 are able to induce G protein-coupling and activation of Ca2+ responses [87, 88]. However, 
they do not stimulate chemotactic activity but instead induce internalization of CCR5 from the cell 
surface [87, 88]. These ligands are therefore functionally selective CCR5 ligands that act differently 
from the chemokine CCL5. This biased profile of small molecules acting via CCR5 could be of use 
as a novel class of anti-HIV-1 therapeutics, for which internalization of the receptor has been found 
to inhibit viral entry to the cell.
In conclusion, it is important to consider that drugs might differently affect one chemokine 
receptor depending on the chemokine that binds this receptor. In addition, these drugs can exert 
biased signalling via chemokine receptors themselves.  
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Abstract 
The chemokine receptor CCR2 is a G protein–coupled receptor that is activated primarily by 
the endogenous CC chemokine ligand 2 (CCL2). Many different small-molecule antagonists 
have been developed to inhibit this receptor, as it is involved in a variety of diseases 
characterized by chronic inflammation. Unfortunately, all these antagonists lack clinical 
efficacy, and therefore a better understanding of their mechanism of action is warranted. In 
this study, we examined the pharmacological properties of small-molecule CCR2 antagonists 
in radioligand binding and functional assays. Six structurally different antagonists were 
selected for this study, all of which displaced the endogenous agonist 125I-CCL2 from CCR2 
with nanomolar affinity. Two of these antagonists, INCB3344 [N-(2-(((3S,4S)-1-((1r,4S)-4-
(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-
3-(trifluoromethyl)benzamide] and CCR2-RA, were radiolabeled to study the binding site in 
greater detail. We discovered that [3H]-INCB3344 and [3H]-CCR2-RA bind to distinct binding 
sites at CCR2, the latter being the first allosteric radioligand for CCR2. Besides the binding 
properties of the antagonists, we examined CCR2 inhibition in multiple functional assays, 
including a novel label-free whole-cell assay. INCB3344 competitively inhibited CCL2-induced 
G protein activation, whereas CCR2-RA showed a noncompetitive or allosteric mode of 
inhibition. These findings demonstrated that the CCR2 antagonists examined in this study 
can be classified into two groups with different binding sites and thereby different modes 
of inhibition. We have provided further insights in CCR2 antagonism, and these insights are 
important for the development of novel CCR2 inhibitors.
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Introduction 
The CC chemokine receptor 2 (CCR2) is a G protein–coupled receptor that can be activated 
by the endogenous CC chemokine ligands CCL2, CCL7, CCL8, CCL11, and CCL13. CCR2 is 
expressed on monocytes, dendritic cells, activated T lymphocytes, and basophils and plays 
an important role in the immune system [1-3]. These immune cells migrate to increasing 
concentrations of chemokines at sites of inflammation as part of the immune response, also 
known as chemotaxis. Besides this important role in physiology, increased levels of CCR2 
and its ligands can induce severe tissue damage, resulting in a variety of diseases, such as 
multiple sclerosis [4], atherosclerosis [5], rheumatoid arthritis [6] and neuropathic pain [7], 
which makes CCR2 an attractive target for the pharmaceutical industry. 
Chemokines are thought to bind to their receptors in a two-step manner. First, they 
interact with the extracellular side of the receptor, after which the N terminus of the 
chemokine can enter the interhelical binding pocket in the transmembrane (TM) domain to 
activate the receptor [8, 9]. This binding pocket of chemokine receptors has been divided 
into a major binding pocket (TM helices 3, 4, 5, 6 and 7) and a minor binding pocket (TM 
helices 1, 2, 3 and 7) [10]. Small-molecule antagonists (~600 Da) are at least 10-fold smaller 
than the endogenous chemokines (~8600 Da), and therefore at best their binding sites can 
only partly overlap. For CCR2, several mutagenesis studies have provided evidence for the 
binding of small-molecule antagonists in the major and minor pocket [11-13]. These ligands 
often contain a positively charged basic nitrogen that interacts with the conserved negatively 
charged glutamic acid residue (E291) in TM7, which is directly located between the major and 
minor binding pocket [14]. In addition several other CCR2 antagonists have been developed 
that do not possess such a basic nitrogen, and their binding site remains to be elucidated [15]. 
As there is growing evidence of multiple ligand binding sites for other chemokine receptors, 
we sought to determine if CCR2 contains several binding sites as well. 
To gain a better understanding of the interaction of CCR2 and its ligands, we 
examined the binding sites and pharmacological properties of six chemically distinct 
CCR2 antagonists. These antagonists are RS504393 (6-methyl-1′-[2-(5-methyl-2-phenyl-
4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one) [11], BMS22 
(2-[(isopropylaminocarbonyl)amino]-N-[2-[[cis-2-[[4-(methylthio)benzoyl]amino]cyclohexyl]
amino]-2-oxoethyl]-5-(trifluoromethyl)benzamide) [16], Teijin compound 1 (N-[2-[[(3R)-1-
[(4-chlorophenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide) 
[17], INCB3344 [N-(2-(((3S,4S)-1-((1r,4S)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-
4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide] [18], the (R) 
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isomer CCR2-RA-[R] [19] and JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-
5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester] [20] (Fig. 1). In this 
study, for the first time, we provide evidence for two distinct binding sites of small-molecule 
antagonists at the CCR2 receptor. We also discuss the possible biased antagonism of some 
of the compounds. This work contributes to a better understanding of the nature of the 
interactions of diverse ligands at the CCR2 receptor.
Fig. 1. Chemical structures of reference CCR2 small-molecule antagonists. 
Materials and Methods
Chemicals and reagents. CCL2 was purchased from PeproTech (Rocky Hill, NJ) and the CCR2 
antagonists BMS22 [16], RS504393 [11] and Teijin compound 1 [17] were obtained from 
Tocris Bioscience (Bristol, UK). INCB3344, JNJ-27141491 and CCR2-RA-[R] were synthesized 
in-house as described previously [18, 21-23]. [3H]-INCB3344 (specific activity 32 Ci mmol−1) 
was custom-labeled by ViTrax (Placentia, CA), by means of direct titration of the parent ligand. 




(trifluoromethyl)benzamide, but only the first isomer had sufficient affinity to label CCR2 in 
our experiments (see later discussion herein). The racemic radioligand [3H]-CCR2-RA (specific 
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activity 63 Ci mmol−1) was custom-labeled by ViTrax, for which a dehydrogenated precursor 
of CCR2-RA was provided. CCR2-RA was labeled as a racemic mixture of the two isomers (R)-
4-acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 
and (S)-4-acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-
2-one. 125I-CCL2 (2200 Ci/mmol) and guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) 
(1250 Ci/mmol) were purchased from PerkinElmer (Waltham, MA). Bovine serum albumin 
(fraction V) was purchased from Sigma-Aldrich (St. Louis, MO). Bicinchoninic acid (BCA) 
and BCA protein assay reagent were obtained from Pierce Chemical Company (Rockford, 
IL). Tango CCR2-bla U2OS cells stably expressing human CCR2 (U2OS-CCR2) were obtained 
from Invitrogen (Carlsbad, CA). All other chemicals were obtained from standard commercial 
sources.
Cell cultures. U2OS-CCR2 cells were cultured in McCoy’s 5a medium supplemented with 10% 
fetal calf serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 25 mM HEPES, 1 mM 
sodium pyruvate, 100 IU/ml penicillin, 100 µg/ml streptomycin, 100µg/ml G418, 50 µg/ml 
hygromycin, and 125 µg/ml zeocin in a humidified atmosphere at 37 °C and 5% CO2. Cells 
were subcultured twice weekly at a ratio of 1:6 on 10-cm ø or 15-cm ø plates by trypsinization.
Cell membrane preparation. Cells were detached from 15-cm ø plates by scraping into 
5 ml of phosphate-buffered saline and subsequently centrifuged for 5 minutes at 3000g. 
The pellets were resuspended in ice-cold 50 mM Tris-HCl buffer and 5 mM MgCl2, pH 7.4, 
and homogenized with an Ultra Turrax homogenizer (IKA-Werke GmbH & Co. KG, Staufen, 
Germany). Membranes and the cytosolic fraction were separated by centrifugation at 
31,000g in an Optima LE-80 K ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA) at 4 °C for 
20 minutes. The pellet was resuspended in 10 ml of Tris-HCl buffer, and the homogenization 
and centrifugation steps were repeated. Finally, the membrane pellet was resuspended in 50 
mM Tris-HCl buffer and 5 mM MgCl2, pH 7.4, and aliquots of 250 µl were stored at −80 °C. 
Membrane protein concentrations were measured using a BCA protein determination [24].
125I-CCL2 binding assays. Binding assays were performed in a 100-µl reaction volume 
containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonic acid (CHAPS) and 15 µg of membrane protein at 37 °C. 
For homologous competition experiments, increasing concentrations of CCL2 were incubated 
with 0.1 nM or 0.05 nM 125I-CCL2 for 150 minutes. At this concentration, total radioligand 
binding did not exceed 10% of the amount added to prevent ligand depletion. Nonspecific 
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binding was determined with 10 µM INCB3344. Displacement assays were performed with 
0.1 nM 125I-CCL2 using 10 concentrations of competing ligand for 150 minutes of incubation. 
Association experiments were performed with 0.1 nM 125I-CCL2 at different time intervals 
of incubation for 3 hours. Nonspecific binding was determined for every time point with 
10 µM INCB3344. For dissociation experiments, the membranes were first incubated with 
0.1 nM 125I-CCL2 for 2 hours. Dissociation was initiated by the addition of 10 µM INCB3344 at 
different time points. For all experiments, incubations were terminated by dilution with ice-
cold 50 mM Tris-HCl buffer supplemented with 0.05% CHAPS and 0.5 M NaCl. Separation of 
bound from free radioligand was performed by rapid filtration through a 96-well GF/B filter 
plate precoated with 0.25% polyethyleneimine using a PerkinElmer Filtermate-harvester 
(PerkinElmer, Groningen, The Netherlands). Filters were washed 10 times with ice-cold wash 
buffer, and 25 µl of Microscint scintillation cocktail (PerkinElmer) was added to each well; the 
filter-bound radioactivity was determined by scintillation spectrometry using the P-E 1450 
Microbeta Wallac Trilux scintillation counter (PerkinElmer).
[3H]-INCB3344 binding assays. Binding assays were performed in 100-µl reaction volume 
containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% CHAPS, and 10 µg of membrane 
protein at 25°C. Saturation experiments were carried out using nine different concentrations 
of radioligand from 0.5 to 45 nM for 120 minutes of incubation. Nonspecific binding was 
determined at three concentrations of radioligand with 10 µM BMS22. Displacement assays 
were carried out with 1.8 nM [3H]-INCB3344 using 10 concentrations of competing ligand 
for 120 minutes of incubation. Association experiments were performed with 1.8 nM 
[3H]-INCB3344 at different time intervals of incubation for 150 minutes. For dissociation 
experiments, the membranes were first incubated with 1.8 nM [3H]-INCB3344 for 90 
minutes. Dissociation was initiated by adding 10 µM of BMS22 at different time points. In all 
cases, total radioligand binding did not exceed 10% of the amount added to prevent ligand 
depletion. For all experiments, incubations were terminated by dilution with ice-cold 50 mM 
Tris-HCl buffer supplemented with 0.05% CHAPS. Separation of bound from free radioligand 
was performed as described in the section entitled “125I-CCL2 Binding Assays” using uncoated 
96-well GF/B filter plates.
[3H]-CCR2-RA binding assays. Assay conditions were similar to those described for [3H]-
INCB3344 binding assays. Saturation experiments were carried out using 12 different 
concentrations of 0.1–75 nM radioligand for 120 minutes of incubation. Nonspecific 
binding was determined at three concentrations of radioligand with 10 µM JNJ-27141491. 
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Displacement assays were carried out with 3 nM [3H]-CCR2-RA using six concentrations of 
competing ligand for 120 minutes of incubation. Association experiments were performed 
with 3 nM [3H]-CCR2-RA at different time intervals of incubation for 180 minutes. For 
dissociation experiments, the membranes were first incubated with 3 nM [3H]-CCR2-RA for 
90 minutes. Dissociation was initiated by the addition of 10 µM of JNJ-27141491 at different 
time points. In all cases, total radioligand binding did not exceed 10% of the amount added 
to prevent ligand depletion. All experiments were terminated as described in “[3H]-INCB3344 
Binding Assays.”
Tango β-arrestin recruitment assay. The assay was performed using the Tango CCR2-
bla U2OS β-arrestin recruitment assay kit (Invitrogen), following the kit protocol. Tango CCR2-
bla U2OS (U2OS-CCR2) cells were cultured in medium supplemented with 10% dialyzed 
fetal calf serum (Invitrogen) instead of normal serum for two passages prior to the assay. 
Briefly, cells were seeded at a density of 40,000 cells per well in Freestyle Expression Medium 
(Invitrogen) into a black-wall clear-bottom 96-well plate (PerkinElmer). Cells were stimulated 
with increasing concentrations of CCL2 and incubated for 16 hours at 37 °C and 5% CO2. For 
antagonist assays, the cells were exposed to increasing concentrations of compound for 30 
minutes before stimulation with an EC80 concentration (5 nM) of CCL2 for 16 hours at 37 °C 
and 5% CO2. The final dimethylsulfoxide concentration was 0.1% for all assay points. After 
agonist exposure, the cells were loaded with 16 µl LiveBLAzer FRET B/G substrate (Invitrogen) 
for 2 hours at room temperature. After excitation at 400 nm, fluorescence emission values 
at 460 and 535 nm were measured in an EnVision multilabel plate reader (PerkinElmer). The 
ratio of the emission at 460 and 535 nm was calculated for each well.
Label-free whole-cell impedance assay. The xCELLigence RTCA system (Roche Applied 
Science, Mannheim, Germany) was used to perform whole-cell assays [25, 26]. Tango CCR2-
bla U2OS (U2OS-CCR2) cells were cultured in medium supplemented with 10% dialyzed 
fetal calf serum (Invitrogen) instead of normal serum for two passages before the assay. 
Initially, 50 µl of culture medium was added to wells in E-plates 96 to obtain background 
readings, followed by the addition of 50 µl of cell suspension containing 20,000 cells per 
well. The E-plate containing the cells was left at room temperature for 30 minutes before 
insertion into the xCELLigence station in the incubator at 37 °C and 5% CO2. The cell index 
(CI) was monitored overnight every 15 minutes, during which time the cells grew to near 
confluence. After 16–18 hours, the cells were stimulated with increasing concentrations of 
CCL2. For the antagonist assays, cells were first preincubated for 30 minutes with increasing 
concentrations of antagonist or vehicle control that was added in 5 µl of compound solution 
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(final concentration of 0.25% dimethylsulfoxide). Subsequently, cells were stimulated with 
an EC80 concentration (3 nM) of CCL2. Directly after stimulation, the measurement frequency 
was increased to 15-second intervals, followed by 30-second, 1-minute, and 5-minute 
intervals. For data analysis, the CI values were normalized to CI values before ligand addition, 
and baseline was corrected with CI traces obtained from vehicle control-treated cells.
[35S]GTPγS binding assay. Ten micrograms of membranes were diluted in 100 µl of assay 
buffer containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 100 mM NaCl, 1 mM 
EDTA, 0.05% bovine serum albumin, 10 µM GDP, and 10 µg of saponin per assay point. To 
determine the IC50 values of antagonists, the membranes were preincubated with varying 
concentrations of antagonist for 30 minutes at 25 °C. Then CCL2 (10 nM) was added, followed 
by another incubation of 30 minutes; finally, the mixture was incubated for 90 minutes after 
the addition of [35S]GTPγS (0.3 nM). To determine the EC50 value of CCL2, the membranes 
were preincubated with varying concentrations of CCL2 in the absence (control) or presence 
of fixed concentrations of antagonist for 30 minutes at 25 °C. Then [35S]GTPγS (0.3 nM) was 
added, and the mixture was incubated for 90 minutes. For all experiments, the incubation was 
terminated by dilution with ice-cold 50 mM Tris-HCl buffer supplemented with 5 mM MgCl2. 
Separation of bound from free radioligand was performed as described under “125I-CCL2 
Binding Assays” using uncoated 96-well GF/B filter plates.
Data analysis. All experiments were analyzed using the nonlinear regression curve fitting 
program Prism 5 (GraphPad, San Diego, CA). The KD values of [
3H]-INCB3344 and [3H]-CCR2-RA 
were obtained by computer analysis of saturation curves according to the equation bound = 
(Bmax*[L])/([L] + KD), where Bmax is the maximal number of binding sites (pmol/mg) and KD is the 
concentration of radioligand required to reach half-maximal binding. The KD value of 
125I-CCL2 
was calculated from homologous competition experiments using the Cheng-Prusoff equation, 
assuming that unlabeled and labeled CCL2 had identical affinities [27]. The dissociation rate 
constant (koff) was obtained by computer analysis of the exponential decay of radioligand 
binding to the receptor. Association rate constants (kon) were calculated according to the 
equation kon = (kobs − koff)/[L], where kobs, the observed rate constant to approach equilibrium, 
was obtained by computer analysis of the exponential association, and [L] is the amount 
of radioligand used for the association experiments. All experiments were fit according to 
monophasic equations except for dissociation of [3H]-CCR2-RA, which occurred in a biphasic 
manner. From radioligand displacement data, Ki values were calculated from IC50 values using 
the Cheng-Prusoff equation [27]. [35S]GTPγS, β-arrestin recruitment and xCELLigence curves 
were analyzed by nonlinear regression to obtain IC50 or EC50 values, where xCELLigence peak 
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responses were obtained within 5 minutes after the addition of compound using the RTCA 
software 1.2 (ACEA Biosciences, Inc., San Diego, CA). Data shown are the mean ± S.E.M. of at 
least three separate experiments performed in duplicate. Statistical analysis was performed 
with a two-tailed unpaired Student’s t test. Comparison of the means of multiple data sets 




Characterization of 125I-CCL2. In this study, we performed radioligand binding assays for CCR2 
with the labeled endogenous agonist 125I-CCL2 as a tracer ligand. To determine the affinity 
of 125I-CCL2 for CCR2, homologous displacement assays were performed on membranes of 
U2OS cells stably expressing CCR2 (U2OS-CCR2). This resulted in a KD of 0.068 ± 0.014 nM 
and a Bmax of 0.31 ± 0.03 pmol/mg (Fig. 2A; Table 1). Kinetic association and dissociation 
experiments were performed to determine the rate constants kon and koff (Fig. 2B). Both the 
association and dissociation of 125I-CCL2 were best fit by monophasic curves, yielding a kon of 
0.29 ± 0.06 nM−1 min−1 and a koff of 0.033 ± 0.003 min
−1. The calculated kinetic KD value (koff/kon) 
of 0.12 nM thus agreed fairly well with the affinity obtained in the homologous competition 
assay.
Fig. 2. Characterization of 125I-CCL2 binding to membranes of U2OS cells stably expressing CCR2. 
(A) Homologous competition assay of 0.1 nM and 0.05 nM 125I-CCL2 in the presence of increasing 
concentrations of unlabeled CCL2. Nonspecific binding was determined in the presence of 10 µM 
INCB3344. (B) Association and dissociation kinetics of 0.1 nM 125I-CCL2 binding to CCR2 at 37 °C. 
Dissociation was initiated by the addition of 10 μM INCB3344. Association and dissociation rate 
constants were 0.29 ± 0.06 nM-1 min-1 and 0.033 ± 0.003 min-1, respectively. Data were best fitted using a 
one-phase association and one-phase exponential decay function. For all experiments a representative 
graph of one experiment performed in duplicate is shown (see Table 1 for KD, Bmax values). 
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Table 1. Equilibrium binding parameters of 125I-CCL2, [3H]-INCB3344 and [3H]-CCR2-RA, determined on 
U2OS membranes expressing CCR2. 
125I-CCL2 [3H]-INCB3344 [3H]-CCR2-RA
KD (nM) 0.068 ± 0.014
a 0.90 ± 0.03b 5.8 ± 0.2c
Bmax (pmol/mg) 0.31 ± 0.03
a 7.1 ± 0.2b 9.7 ± 0.2c
Data are presented as mean ± S.E.M. of three experiments performed in duplicate.
aHomologous displacement of 125I-CCL2 from CCR2 at 37 ºC.
bSaturation binding of 0.5 - 45 nM [3H]-INCB3344 to CCR2 at 25 ºC.
cSaturation binding of 0.2 - 75 nM [3H]-CCR2-RA to CCR2 at 25 ºC.
Displacement of 125I-CCL2 from CCR2. A panel of reference CCR2 antagonists (Fig. 1) was 
selected for analysis in radioligand displacement assays. U2OS-CCR2 membranes were 
incubated with125I-CCL2 and increasing concentrations of antagonist (Fig. 3A). All antagonists 
fully displaced 125I-CCL2 from the CCR2 receptor, with IC50 values reported in Table 2. INCB3344 
had the highest affinity for CCR2 (IC50 = 5.4 nM), followed by BMS22 (IC50 = 27 nM), CCR2-
RA-[R] (IC50 = 103 nM), RS504393 (IC50 = 132 nM), JNJ-27141491 (IC50 = 172 nM), and Teijin 
compound 1 (IC50 = 220 nM).








Ki ± S.E.M. 
[3H]-CCR2-RA 
displacement
Ki ± S.E.M. 
CCL2
nM nM or % binding
0.19 ± 0.04 79 ± 2%a 77 ± 4%a
INCB3344 5.4 ± 0.8 1.2 ± 0.1 169 ± 17%b*
BMS22 27 ± 4 5.1 ± 1.3 164 ± 16%b*
RS504393 132 ± 25 62 ± 3 157 ± 16%b*
Teijin 220 ± 26 107 ± 10 159 ± 17%b*
JNJ-27141491 172 ± 15 112 ± 3%b* 12 ± 3
CCR2-RA-[R] 103 ± 18 109 ± 1%b* 5.0 ± 0.8
Data are presented as mean ± S.E.M. of at least three experiments performed in duplicate.
aPercentage of radioligand binding in presence of 100 nM CCL2. 100% was determined in the presence 
of buffer and therefore values < 100% represent displacement.
bPercentage of radioligand binding in presence of 1 μM antagonist. 100% was determined in the 
presence of buffer and therefore values >100% represent enhancement
*p< 0.05, Student’s t-test.
The antagonists INCB3344, BMS22, RS504393, and Teijin share structural similarities, whereas 
JNJ-27141491 and CCR2-RA-[R] form a different set of molecules (Fig. 1). We decided to 
tritium-label the two high-affinity racemic compounds INCB3344 and CCR2-RA within the 
two classes, for which we used two unsaturated precursor molecules that we synthesized in-
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house. We anticipated that these two molecules would help us to characterize in more detail 
the binding sites of low-molecular-weight antagonists targeting CCR2.
Fig. 3. Displacement of (A) 125I-CCL2 binding, (B) [3H]-INCB3344 binding and (C) [3H]-CCR2-RA binding 
to U2OS membranes stably expressing CCR2 by increasing concentrations of CCL2 and six reference 
CCR2 antagonists. Results are presented as percentage of bound radioligand for one representative 
experiment performed in duplicate (see Table 2 for affinity values). 
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Characterization of [3H]-INCB3344. Tritium-labeled INCB3344 is a racemic mixture of two 
isomers. In 125I-CCL2 displacement experiments with the isolated unlabeled isomers, we had 
found that the (3S,4S) isomer had an IC50 of 3.8 ± 0.5 nM, whereas the affinity of the other 
isomer was at least 1000-fold lower (IC50 = 4.3 ± 0.9 µM). Since we used low nanomolar 
concentrations (1.8 nM) of [3H]-INCB3344 in the binding studies, we concluded that CCR2 
was solely labeled by the high affinity (3S,4S) isomer.
Saturation binding experiments yielded a KD of 0.90 ± 0.03 nM with a Bmax of 7.1 ± 0.2 
pmol/mg (Fig. 4; Table 1). Equilibrium binding of [3H]-INCB3344 to U2OS-CCR2 membranes 
was reached within 1 hour at 25 °C as assessed with kinetic association experiments (Fig. 
4B). This radioligand was specifically bound to CCR2 as no binding was detected in U2OS 
membranes that do not express CCR2 (data not shown). Dissociation of [3H]-INCB3344 was 
initiated by 10 μM BMS22 and resulted in a dissociation half-life of 53 minutes at 25 °C (Fig. 
4B). Both kinetic studies were best fit by monophasic curves, which confirmed that CCR2 
was labeled by only one of the isomers. From these data, we calculated the association and 
dissociation rate constants, 0.054 ± 0.002 nM−1 min−1 and 0.013 ± 0.002 min−1, respectively, 
which resulted in a kinetic KD of 0.23 nM, in fair agreement with the equilibrium value of 0.90 
nM.
Fig. 4. Characterization of [3H]-INCB3344 binding to membranes of U2OS cells stably expressing CCR2. 
(A) Saturation binding of [3H]-INCB3344 to CCR2. Different concentrations of [3H]-INCB3344 were 
incubated in the presence (nonspecific binding) or absence (total binding) of 10 μM BMS22. Specific 
binding was determined by subtracting the nonspecific binding from the total binding. (B) Association 
and dissociation kinetics of 1.8 nM [3H]-INCB3344 to CCR2 at 25 °C. Dissociation was initiated by the 
addition of 10 μM BMS22. Association and dissociation rate constants were 0.054 ± 0.002 nM-1 min-1 
and 0.013 ± 0.002 min-1, respectively. Data were best fitted using a one-phase association and one-phase 
exponential decay function. For all experiments a representative graph of one experiment performed in 
duplicate is shown (see Table 1 for KD, Bmax values).
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Displacement of [3H]-INCB3344 from CCR2. Homologous displacement by INCB3344 yielded 
a Ki of 1.2 ± 0.2 nM (Fig. 3B;Table 2), which corresponded to the KD that was obtained from 
saturation binding experiments. CCL2 displaced only 21% of bound [3H]-INCB3344 from 
the receptor. The antagonists BMS22, RS504393, and Teijin were able to displace fully [3H]-
INCB3344 from CCR2 with nanomolar affinities, whereas JNJ-27141491 and CCR2-RA-[R] 
did not displace [3H]-INCB3344, which indicates that they bind at different sites at the CCR2 
receptor. At a concentration of 1 μM, JNJ-27141491 and CCR2-RA-[R] rather significantly 
increased [3H]-INCB3344 binding, with 12 and 9% (Student’s t test p < 0.01; Table 2), 
respectively.
Characterization of [3H]-CCR2-RA. CCR2-RA was also tritium-labeled as a racemic mixture 
of two isomers. In 125I-CCL2 displacement experiments, the unlabeled (R) and (S) isomers 
had IC50 values of 103 ± 18 and 216 ± 21 nM, respectively. We therefore cannot exclude that 
CCR2 was labeled to some extent by the lower-affinity isomer, too, although we took care to 
use a low concentration of 3 nM in the displacement assays. Saturation binding experiments 
yielded a KD of 5.8 ± 0.2 nM with a Bmax of 9.7 ± 0.2 pmol/mg (Fig. 5A; Table 1). Equilibrium 
binding of [3H]-CCR2-RA to U2OS-CCR2 membranes was reached within 2 hours at 25 °C as 
assessed with kinetic association experiments after a monophasic fit (Fig. 5B). This radioligand 
was specifically bound to CCR2 as no binding was detected in U2OS membranes that do not 
express CCR2 (data not shown). Dissociation of [3H]-CCR2-RA was initiated by 10 μM of JNJ-
27141491 and resulted in a biphasic dissociation pattern with koff1 and koff2 of 0.24 ± 0.02 
min−1 and 0.029 ± 0.005 min−1, respectively (Fig. 5C).
Displacement of [3H]-CCR2-RA from CCR2. CCL2 displaced only 23% of bound [3H]-CCR2-
RA from the receptor (Fig. 3C; Table 2). The antagonists JNJ-27141491 and the unlabeled 
(R) isomer CCR2-RA-[R] were able to displace fully [3H]-CCR2-RA from CCR2 with nanomolar 
affinities, whereas antagonists INCB3344, BMS22, RS504393, and Teijin did not displace 
[3H]-CCR2-RA, suggesting that they bind at a different site at the CCR2 receptor. In contrast, 
INCB3344, BMS22, RS504393, and Teijin significantly increased [3H]-CCR2-RA binding with 
69, 64, 57, and 59% at a concentration of 1 µM, respectively (Student’s t test p < 0.05; Table 
2).
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Fig. 5. Characterization of [3H]-CCR2-RA binding to membranes of U2OS cells stably expressing CCR2. (A) 
Saturation binding of [3H]-CCR2-RA to CCR2. Different concentrations of [3H]-CCR2-RA were incubated in 
the presence (nonspecific binding) or absence (total binding) of 10 μM JNJ-27141491. Specific binding 
was determined by subtracting the nonspecific binding from the total binding. (B) Association kinetics 
of 3 nM [3H]-CCR2-RA to CCR2 at 25 °C. Data were best fitted using a one-phase association function 
resulting in a kobs of 0.089 ± 0.005 min
-1. (C) Dissociation kinetics of 3 nM [3H]-CCR2-RA to CCR2 at 25 
°C. Dissociation was initiated by the addition of 10 μM JNJ-27141491. Data were best fitted using a 
two-phase exponential decay function, resulting in a koff1 of 0.24 ± 0.02 min
-1 and a koff2 of 0.029 ± 0.005 
min-1. For all experiments a representative graph of one experiment performed in duplicate is shown 
(see Table 1 for KD, Bmax values).
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Functional assays
In addition to radioligand binding experiments, we performed a number of functional assays, 
both G protein–dependent and –independent.
Inhibition of beta-arrestin recruitment to CCR2. We first performed beta-arrestin recruitment 
assays (G protein–independent) to assess the inhibitory potency of all six antagonists. CCL2 
induced beta-arrestin recruitment to CCR2 with an EC50 of 1.4 ± 0.4 nM (n = 4) (Fig. 6A). 
All antagonists were able to inhibit beta-arrestin recruitment induced by 5 nM CCL2 (Fig. 
6B; Table 3). Interestingly, JNJ-27141491 and CCR2-RA-[R] were more potent inhibitors 
of β-arrestin recruitment than were Teijin and RS504393, whereas these antagonists showed 
equal affinities in the 125I-CCL2 displacement assay.
Fig. 6. (A) CCL2-induced beta-arrestin recruitment to U2OS cells stably expressing CCR2. (B) Inhibition 
of CCL2-induced beta-arrestin recruitment to CCR2. Cells were incubated with a concentration of CCL2 
that evoked 80% of the maximum response (5 nM). Increasing concentrations of the antagonists were 
added to determine their IC50 value. For all experiments, basal activity was set at 0%, and the maximum 
response at 100%. Results are presented for one representative experiment performed in duplicate 
(see Table 3 for IC50 values). 
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Table 3. Inhibition of CCL2 induced cellular responses measured in [35S]GTPγS membrane binding assays 
as well as beta-arrestin recruitment and xCELLigence label free whole cell assays. 
Compound [35S]GTPγS binding 
inhibition
IC50 ± S.E.M. (nM)
Beta-arrestin recruitment 
inhibition
IC50 ± S.E.M. (nM)
xCELLigencea
IC50 ± S.E.M. (nM)
INCB3344 2.8 ± 0.8 3.2 ± 0.2 2.0 ± 0.5
BMS22 5.5 ± 1.8 4.8 ± 0.4 21 ± 6*
RS504393 19 ± 7** 68 ± 3 87 ± 15
Teijin 183 ± 48 67 ± 13 292 ± 66*
JNJ-27141491 3.9 ± 1.0** 29 ± 1 25 ± 4
CCR2-RA-[R] 24 ± 3 25 ± 4 64 ± 14*** 
Data are presented as mean ± S.E.M. of three experiments performed in duplicate.
aInhibition of CCL2 was calculated from concentration-response curves derived from peak-analysis of 
CI changes.
*p<0.05, vs. beta-arrestin data; ANOVA, Tukey’s MCT. 
**p<0.05, vs. beta-arrestin and xCELLigence data; ANOVA, Tukey’s MCT.
***p<0.05, vs. [35S]GTPγS and beta-arrestin data; ANOVA, Tukey’s MCT.
Analysis of CCR2 inhibition in an impedance-based label-free whole-cell assay. The 
xCELLigence RTCA system was used to study the activation and inhibition of CCR2 in a 
label-free whole-cell assay. Typically, the addition of CCL2 resulted in an immediate dose-
dependent increase in the CI to a peak level within 5 minutes, followed by a second peak after 
approximately 20 minutes, which then returned to baseline after 1 hour of incubation (Fig. 
7A). Concentration-effect curves were obtained by analysis of the peak level that appeared 
within 5 minutes after stimulation and resulted in an EC50 value of 1.1 ± 0.1 nM for CCL2 
(n = 5) (Fig. 7B). Preincubation with all antagonists resulted in inhibition of the CCL2-induced 
response (Fig. 7C; Table 3). The antagonists were equally potent as inhibitors of CCL2-induced 
impedance effects as they were able to inhibit β-arrestin recruitment, except for Teijin and 
CCR2-RA-[R], which were less potent as inhibitors of the impedance response with IC50 values 
of 292 ± 66 nM and 64 ± 14 nM, respectively.
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Fig. 7. Impedance measurements in the xCELLigence label-free assay for U2OS cells stably expressing 
CCR2. (A) Representative graph of baseline-corrected normalized CI after the addition of different 
concentrations of CCL2. (B) Concentration-response curve for CCL2 derived from peak-height analysis 
of CI changes for the 5-minute interval after application. (C) Inhibition of CCL2-induced impedance 
measurements. Cells were incubated with a concentration of CCL2 that evoked 80% of the maximum 
response (3 nM). Increasing concentrations of the antagonists were added 30 min before agonist 
stimulation to determine their IC50 value, derived from peak-height analysis of CI changes for the 
5-minute interval after the application of CCL2. Results are presented for one representative experiment 
performed in duplicate (see Table 3 for IC50 values).
[35S]GTPγS binding to CCR2. We also performed a G protein–dependent functional assay. 
For this purpose, we used a [35S]GTPγS binding assay on U2OS-CCR2 membranes, where we 
measured G protein activation by CCL2 in the absence or presence of different antagonists 
(Fig. 8). CCL2 stimulated [35S]GTPγS binding with an EC50 value of 5.7 ± 0.9 nM (n = 8; see 
also, Fig. 8, B and C). All antagonists were able to inhibit CCL2-induced G protein activation 
(Fig. 8A; Table 3). Notably, RS504393 and JNJ-27141491 were more potent inhibitors of G 
protein activation than of β-arrestin recruitment or the impedance response evoked by CCL2, 
their IC50 values being 19 ± 7 nM and 3.9 ± 1.0 nM, respectively.
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Fig. 8. [35S]GTPγS binding to membranes of U2OS cells stably expressing CCR2. (A) Inhibition of CCL2-
induced [35S]GTPγS binding by six small molecule antagonists. Membranes were incubated with a 
concentration of CCL2 that evoked 80% of the maximum response (10 nM). Increasing concentrations 
of the antagonists were added to determine their IC50 value. (B,C) Concentration-effect curves of 
CCL2-induced [35S]GTPγS binding. Increasing concentrations of CCL2 were added simultaneously with 
indicated concentrations of INCB3344 (B) or CCR2-RA-[R] (C). For all experiments basal activity was set 
at 0% and the maximum response at 100%. Results are presented as mean percentage ± S.E.M. of three 
experiments performed in duplicate (see Table 4 for pEC50 and Emax values). 
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Based on the displacement data obtained with [3H]-INCB3344 and [3H]-CCR2-RA, 
INCB3344 and CCR2-RA-[R] were selected as representative antagonists for the two putative 
distinct binding sites. To examine their mechanism of inhibition in more detail, we analyzed 
the shift of CCL2-induced [35S]GTPγS binding in the presence of fixed concentrations of 
antagonist. The maximal effect of CCL2 in the presence of CCR2-RA-[R] was significantly 
reduced, whereas CCL2’s potency was slightly, but similarly, decreased at all three antagonist 
concentrations (Fig. 8C; Table 4). In contrast, the addition of INCB3344 markedly decreased 
the EC50 value of CCL2, whereas the efficacy of CCL2 was unaffected (Fig. 8B; Table 4). A 
Schild plot analysis of the INCB3344 data yielded a KB value of 0.4 nM, which is in close 
agreement with the KD value of 0.9 nM determined in the saturation binding assay. Overall, 
these data indicate that INCB3344 behaved as a competitive antagonist, whereas CCR2-RA-
[R] clearly showed noncompetitive antagonism for CCR2 with respect to CCL2, as indicated 
by a decrease in CCL2’s efficacy in the presence of increasing concentrations of CCR2-RA-[R].
Table 4. G protein activation by CCL2 measured by [35S]GTPγS binding. Potency and maximum effect of 
CCL2 in the absence or presence of different concentrations of CCR2-RA-[R]. 
pEC50 ± S.E.M. Emax ± S.E.M. (%)
control 8.3 ± 0.1 104 ± 4
+ 1 nM INCB3344 7.6 ± 0.1* 103 ± 7
+ 3 nM INCB3344 7.0 ± 0.3* 102 ± 14
+ 10 nM INCB3344 6.2 ± 0.9 NDa
+ 10 nM CCR2-RA-[R] 7.7 ± 0.1* 81 ± 6**
+ 30 nM CCR2-RA-[R] 7.7 ± 0.1* 55 ± 4***
+ 100 nM CCR2-RA-[R] 7.6 ± 0.1* 30 ± 3***
aNot determined.
Data are presented as mean ± S.E.M. of at least three experiments (*p<0.05,** p< 0.001, *** p< 0.0001 
vs. control, Student’s t-test) 
Discussion 
Previous studies reported CCR2 and its endogenous ligand CCL2 as major players in a variety 
of diseases [4, 5, 7]. Given this potential role as a drug target, the pharmaceutical industry 
has developed many CCR2 antagonists [15], although without much clinical success. Given 
the variety in chemical scaffolds, it is surprising that little attention, if any, has been paid to 
the binding mode of these ligands to the receptor. Therefore, the present study was designed 
to compare the binding site and mechanism of inhibition for a selection of these antagonists. 
To study the binding of these antagonists to CCR2, we used the radioligand 125I-CCL2 
and the custom-labeled small-molecule radioligands [3H]-INCB3344 and [3H]-CCR2-RA. We 
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found an affinity constant of 0.068 nM for 125I-CCL2, which corresponds to reported data in 
literature (KD 0.05 nM) [28, 29]. In addition, the dissociation rate constant of 
125I-CCL2 from 
U2OS-CCR2 membranes of 0.033 min−1 is in agreement with the previously reported koff of 
0.036 min−1 [28]. [3H]-INCB3344 was previously published and characterized as a radioligand 
for CCR2 [30]. In those studies a KD value of 5 nM was reported for human embryonic kidney 
293 cells stably expressing CCR2. Our experiments with U2OS-CCR2 cells resulted in a 5-fold 
lower KD value of 0.9 nM. This difference could be the result of the different cell type, different 
assay buffer, or the longer incubation time used in our assay.
In this study, [3H]-CCR2-RA is reported as the first allosteric radioligand for CCR2. It was 
characterized as a high-affinity radioligand (KD = 5.8 nM) that reversibly binds to the receptor. 
The biphasic dissociation of [3H]-CCR2-RA from CCR2 could be a result of the racemic nature 
of the radioligand. The Bmax values for [
3H]-CCR2-RA and [3H]-INCB3344 were 31- and 23-
fold higher than for 125I-CCL2. A possible explanation might be that some of the receptors 
present in vesicular structures in the membrane preparations are accessible to membrane-
permeable molecules, such as CCR2-RA and INCB3344, but not to CCL2. In addition, allosteric 
interactions described within chemokine receptor oligomers might modify the apparent 
number of binding sites for some radioligands [31, 32]. Finally, antagonists like CCR2-RA and 
INCB3344 supposedly bind to the G protein–coupled state as well as the uncoupled state 
of the receptor, whereas the agonist CCL2 presumably binds only to the G protein–coupled 
state (i.e., labeling a smaller population of receptors). This was confirmed by experiments in 
the presence of GTP, which uncouples the receptor from its G protein, since these resulted 
in a complete loss of binding of 125I-CCL2, whereas binding of [3H]-INCB3344 and [3H]-CCR2-
RA was not affected (data not shown). Similar extensive differences in Bmax values between 
radiolabeled agonist and antagonist have previously been reported for the CXCR2 chemokine 
receptor [33]. In any case, the three radioligands do not label the same receptor populations, 
which may therefore contribute to the different IC50 values derived from competition 
experiments performed with either CCL2 or a small molecule as a radioligand.
INCB3344 and CCR2-RA-[R] were able to displace fully 125I-CCL2 receptor binding, 
whereas CCL2 was capable only of displacing 21% of [3H]-INCB3344 binding and 19% of [3H]-
CCR2-RA binding. This finding could be explained by the heterogeneity of binding sites and 
the G protein–uncoupling of a fraction of CCR2. In addition, the incomplete displacement 
could suggest that CCL2, INCB3344, and CCR2-RA bind to different sites at CCR2. Given the 
size of INCB3344 (578 Da) and CCR2-RA (352 Da), these ligands can at best only partly overlap 
with the binding site of the large peptide CCL2 (8600 Da).
The three different radioligands were used to study and compare six structurally different 
CCR2 antagonists. All antagonists displaced 125I-CCL2 from the receptor (Fig. 3A; Table 2) with 
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affinities similar to previously reported data [11, 16-18, 20, 21]. BMS22, RS504393, and Teijin 
were also able to displace [3H]-INCB3344 binding, which indicated that these four ligands 
share a common binding site. On the contrary, JNJ-27141491 and CCR2-RA-[R] did not 
displace [3H]-INCB3344 from CCR2 (Fig. 3B). Analogous results were found in the [3H]-CCR2-
RA displacement assay, where INCB3344, BMS22, RS504393, and Teijin did not displace [3H]-
CCR2-RA from CCR2 (Fig. 3C). Therefore, we conclude that there are at least two different 
binding sites for small-molecule antagonists at CCR2. Notably, at high concentrations, JNJ-
27141491 and CCR2-RA-[R] significantly increased [3H]-INCB3344 binding to CCR2, whereas 
INCB3344, BMS22, RS504393, and Teijin significantly increased [3H]-CCR2-RA binding to 
CCR2 (Table 2). This behavior is indicative for allosteric enhancement, best explained by 
the two compounds stabilizing the same conformation of the receptor by binding at two 
topographically different sites [34].
For RS504393, Teijin and BMS22 mutagenesis studies have shown that these molecules 
bind to the major and/or minor binding pocket of CCR2. RS504393 and Teijin interact with the 
highly conserved glutamic acid residue E291 most likely via their basic nitrogen atom [11, 13]. 
For BMS22, the adjacent T292 was found to be important for binding [16], indicating that it 
shares the same binding pocket as RS504393 and Teijin. Notably, for INCB3344 no such data 
has been reported yet and here we established that it binds to the same site as RS504393, 
Teijin and BMS22. The presence of a basic nitrogen in the pyrrolidine ring of INCB3344 
suggests a similar interaction with E291.
The structures of JNJ-27141491 and CCR2-RA-[R] contain different chemical features 
compared with the other antagonists. JNJ-27141491 and CCR2-RA-[R] lack a basic nitrogen, 
have a lower molecular weight, and are acidic. Their exact binding site or sites at CCR2 remain 
to be determined. For several other chemokine receptors, the presence of an allosteric 
binding site has been reported [35]. Whereas some antagonists interact with both the major 
and minor binding pocket in the transmembrane region, others bind exclusively to either one 
of these sites. Given the large size of this binding pocket, the two different binding sites that 
we have identified for CCR2 could both be located in this transmembrane region. In addition, 
an allosteric binding site on the intracellular side of the receptor in the C-terminal domain 
has been identified for the chemokine receptors CXCR2, CCR4 and CCR5 [36-38]. This binding 
site resides close to the site of G protein coupling to the receptor and therefore it is assumed 
that activation of the G protein is prevented in the presence of an antagonist at this site. 
The intracellular antagonists of CXCR2 contain an acidic centre [37], which is also present 
in JNJ-27141491 and CCR2-RA-[R]. In addition, CCR2 and CCR5 are closely related based on 
sequence similarity. Hence, the presence of such an intracellular binding site for CCR2 is not 
unlikely. 
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By means of functional assays, we confirmed that the six compounds described in this 
article are indeed CCR2 antagonists, at the G protein level, in β-arrestin recruitment and in 
a novel label-free impedance-based functional assay (Table 3). Analysis of these differential 
functional responses allowed us to explore whether these ligands show biased antagonism, 
which has been described for allosteric ligands of other G protein–coupled receptors [39, 
40]. Notably, it has been reported that some CCR2 antagonists are capable of discriminating 
between different functional states of the receptor [41]. In our hands, RS504393 and JNJ-
27141491 were slightly more potent inhibitors of G protein activation, whereas Teijin was 
most potent in the β-arrestin recruitment assay. Except for these small but significant 
differences, all antagonists were equally potent among the different functional assays, and 
as such there is little indication of biased antagonism in our assays. As the effect in functional 
assays is dependent on the off-rate of the antagonists, which are at present unknown, we 
realize that it is difficult to compare the three functional assays as their incubation times 
varies from minutes to hours.
We next determined the mechanism of inhibition in a [35S]GTPγS assay for INCB3344 
and CCR2-RA-[R] as representative compounds binding to different binding sites. INCB3344 
behaved as a competitive antagonist, whereas CCR2-RA-[R] showed noncompetitive 
antagonism for CCR2 with respect to CCL2 (Fig. 7). Agonist stimulation after pre-incubation 
with an antagonist can result in submaximal receptor stimulation if the antagonist is not 
sufficiently dissociated to liberate the entire population at the time at which the maximal 
response is measured [42]. Therefore, we coincubated increasing concentrations of CCL2 in 
the presence of fixed amounts of antagonist to rule out insurmountable antagonism resulting 
from slow dissociation kinetics. The mechanism of INCB3344 inhibition was previously 
addressed in a calcium flux assay in human monocytes and a competition binding assay 
using 125I-CCL2 [30]. Both experiments showed a competitive mode of inhibition with respect 
to CCL2. These results are in good agreement with our competitive profile of INCB3344 in the 
[35S]GTPγS assay.
For CCR2-RA-[R], no detailed pharmacological data were previously published except 
for its inhibition of pain behavior in an in vivo model with nerve-injured rats [19]. We now 
provide evidence for a noncompetitive mode of inhibition of CCR2. Based on the results of 
our binding studies, we assume that CCR2-RA-[R] and JNJ-27141491 bind to a similar site at 
CCR2 or at least bind to a site that is distinct from the INCB3344′s binding pocket. Since JNJ-
27141491 was previously described as a noncompetitive antagonist of CCR2, it is likely that 
CCR2-RA-[R] and JNJ-27141491 bind and inhibit CCR2 via a similar mechanism [20]. 
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In summary, we have demonstrated that the CCR2 antagonists examined in this study 
can be classified into at least two groups with a different binding site and thereby a different 
mode of inhibition. Hence, we have provided further insights into CCR2 antagonism, which 
may be relevant for the development of novel CCR2 inhibitors. 
 
68  |  Chapter 3
References
1. Jimenez, F., et al., CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 
and NF-kappa B. J Immunol. 184(10): p. 5571-81.
2. Luster, A.D., Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med, 
1998. 338(7): p. 436-45.
3. Fantuzzi, L., et al., Loss of CCR2 expression and functional response to monocyte chemotactic 
protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the 
regulation of the chemotactic response. Blood, 1999. 94(3): p. 875-83.
4. Mahad, D.J. and R.M. Ransohoff, The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and 
experimental autoimmune encephalomyelitis (EAE). Semin Immunol, 2003. 15(1): p. 23-32.
5. Boring, L., et al., Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in 
the initiation of atherosclerosis. Nature, 1998. 394(6696): p. 894-7.
6. Quinones, M.P., et al., The complex role of the chemokine receptor CCR2 in collagen-induced 
arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 
(Berl), 2005. 83(9): p. 672-81.
7. White, F.A., S.K. Bhangoo, and R.J. Miller, Chemokines: integrators of pain and inflammation. 
Nat Rev Drug Discov, 2005. 4(10): p. 834-44.
8. Pease, J.E., et al., The N-terminal extracellular segments of the chemokine receptors CCR1 and 
CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain 
is essential for efficient receptor activation. J Biol Chem, 1998. 273(32): p. 19972-6.
9. Monteclaro, F.S. and I.F. Charo, The amino-terminal domain of CCR2 is both necessary and 
sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation 
by a pseudo-tethered ligand. J Biol Chem, 1997. 272(37): p. 23186-90.
10. Surgand, J.S., et al., A chemogenomic analysis of the transmembrane binding cavity of human 
G-protein-coupled receptors. Proteins, 2006. 62(2): p. 509-38.
11. Mirzadegan, T., et al., Identification of the binding site for a novel class of CCR2b chemokine 
receptor antagonists: binding to a common chemokine receptor motif within the helical 
bundle. J Biol Chem, 2000. 275(33): p. 25562-71.
12. Berkhout, T.A., et al., CCR2: characterization of the antagonist binding site from a combined 
receptor modeling/mutagenesis approach. J Med Chem, 2003. 46(19): p. 4070-86.
13. Hall, S.E., et al., Elucidation of binding sites of dual antagonists in the human chemokine 
receptors CCR2 and CCR5. Mol Pharmacol, 2009. 75(6): p. 1325-36.
14. Rosenkilde, M.M. and T.W. Schwartz, GluVII:06--a highly conserved and selective anchor point 
for non-peptide ligands in chemokine receptors. Curr Top Med Chem, 2006. 6(13): p. 1319-33.
15. Struthers, M. and A. Pasternak, CCR2 antagonists. Curr Top Med Chem, 2010. 10(13): p. 1278-
98.
16. Cherney, R.J., et al., Discovery of disubstituted cyclohexanes as a new class of CC chemokine 
receptor 2 antagonists. J Med Chem, 2008. 51(4): p. 721-4.
17. Moree, W.J., et al., Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-
aminopyrrolidine series. Bioorg Med Chem Lett, 2008. 18(6): p. 1869-73.
18. Brodmerkel, C.M., et al., Discovery and pharmacological characterization of a novel rodent-
active CCR2 antagonist, INCB3344. J Immunol, 2005. 175(8): p. 5370-8.
19. Bhangoo, S., et al., Delayed functional expression of neuronal chemokine receptors following 
focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization 
of peripheral nociceptors. Mol Pain, 2007. 3(38).
Multiple binding sites for small molecule antagonists at the chemokine receptor CCR2  |  69
3
20. Buntinx, M., et al., Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-
propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imida zole-4-carboxyl acid methyl ester], 
as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J 
Pharmacol Exp Ther, 2008. 327(1): p. 1-9.
21. Zou, D., et al., Novel, acidic CCR2 receptor antagonists: from hit to lead. Letters in Drug Design 
& Discovery, 2007. 4: p. 185-191.
22. Doyon, J., et al., Discovery of potent, orally bioavailable small-molecule inhibitors of the 
human CCR2 receptor. ChemMedChem, 2008. 3(4): p. 660-9.
23. Xue C, M.B., Feng H, Cao G, Huang T, Zheng C, Robinson DJ, Han A 3-Aminopyrrolidine 
derivatives as modulators of chemokine receptors, 2004. Inventors, Incyte Corporation. PCT/
US2003/037946.
24. Smith, P.K., et al., Measurement of protein using bicinchoninic acid. Anal Biochem, 1985. 
150(1): p. 76-85.
25. Xi, B., et al., The application of cell-based label-free technology in drug discovery. Biotechnol 
J, 2008. 3(4): p. 484-95.
26. Yu, N., et al., Real-time monitoring of morphological changes in living cells by electronic cell 
sensor arrays: an approach to study G protein-coupled receptors. Anal Chem, 2006. 78(1): p. 
35-43.
27. Cheng, Y. and W.H. Prusoff, Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 
Biochem Pharmacol, 1973. 22(23): p. 3099-108.
28. Springael, J.Y., et al., Allosteric modulation of binding properties between units of chemokine 
receptor homo- and hetero-oligomers. Mol Pharmacol, 2006. 69(5): p. 1652-61.
29. Samson, M., et al., The second extracellular loop of CCR5 is the major determinant of ligand 
specificity. J Biol Chem, 1997. 272(40): p. 24934-41.
30. Shin, N., et al., Pharmacological characterization of INCB3344, a small molecule antagonist of 
human CCR2. Biochem Biophys Res Commun, 2009. 387(2): p. 251-5.
31. Sohy, D., M. Parmentier, and J.Y. Springael, Allosteric transinhibition by specific antagonists in 
CCR2/CXCR4 heterodimers. The Journal of biological chemistry, 2007. 282(41): p. 30062-9.
32. El-Asmar, L., et al., Evidence for negative binding cooperativity within CCR5-CCR2b 
heterodimers. Molecular pharmacology, 2005. 67(2): p. 460-9.
33. de Kruijf, P., et al., Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 
chemokine receptor. J Pharmacol Exp Ther, 2009. 329(2): p. 783-90.
34. Lazareno, S. and N.J. Birdsall, Detection, quantitation, and verification of allosteric interactions 
of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of 
strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol, 1995. 48(2): p. 362-78.
35. Scholten, D.J., et al., Pharmacological modulation of chemokine receptor function. Br J 
Pharmacol, 2011. 165(6): p. 1617-43.
36. Nicholls, D.J., et al., Identification of a putative intracellular allosteric antagonist binding-site 
in the CXC chemokine receptors 1 and 2. Mol Pharmacol, 2008. 74(5): p. 1193-202.
37. Salchow, K., et al., A common intracellular allosteric binding site for antagonists of the CXCR2 
receptor. Br J Pharmacol, 2010. 159(7): p. 1429-39.
38. Andrews, G., C. Jones, and K.A. Wreggett, An intracellular allosteric site for a specific class of 
antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol, 
2008. 73(3): p. 855-67.
39. Kenakin, T. and L.J. Miller, Seven transmembrane receptors as shapeshifting proteins: the 
impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol 
Rev, 2010. 62(2): p. 265-304.
70  |  Chapter 3
40. Magnan, R., et al., Distinct CCK-2 receptor conformations associated with beta-arrestin-2 
recruitment or phospholipase-C activation revealed by a biased antagonist. Journal of the 
American Chemical Society, 2013. 135(7): p. 2560-73.
41. Kredel, S., et al., High-content analysis of CCR2 antagonists on human primary monocytes. J 
Biomol Screen, 2011. 16(7): p. 683-93.
42. Vauquelin, G., et al., New insights in insurmountable antagonism. Fundam Clin Pharmacol, 
2002. 16(4): p. 263-72.
Chapter 4
Discovery and mapping of an intracellular antagonist 













Molecular Pharmacology 2014 86(4):358-368 
72  |  Chapter 4
Abstract 
The chemokine receptor CCR2 is a G protein-coupled receptor that is involved in many 
diseases characterized by chronic inflammation, and therefore a large variety of CCR2 small 
molecule antagonists has been developed. On the basis of their chemical structures these 
antagonists can be roughly divided into two groups with most likely two topographically 
distinct binding sites. The aim of the current study was to identify the binding site of one such 
group of ligands, exemplified by three allosteric antagonists, CCR2-RA-[R], JNJ-27141491 and 
SD-24. 
We first used a chimeric CCR2/CCR5 receptor approach to obtain insight into the 
binding site of the allosteric antagonists, and additionally introduced eight single point 
mutations in CCR2 to further characterize the putative binding pocket. All constructs were 
studied in radioligand binding as well as functional IP turnover assays, providing evidence for 
an intracellular binding site for CCR2-RA-[R], JNJ-27141491 and SD-24. The most important 
residues for binding were found to be the highly conserved tyrosine Y7.53 and phenylalanine 
F8.50 of the NPxxYX(5,6)F motif, as well as V
6.36 at the bottom of TM-VI and K8.49 in helix-VIII. In 
addition, we found two other residues at locations surrounding this binding pocket, which 
differently affected the three allosteric ligands. 
These findings demonstrate for the first time the presence of an allosteric intracellular 
binding site for CCR2 antagonists. This contributes to an increased understanding of the 
interactions of diverse ligands at CCR2 and may allow a more rational design of future 
allosteric antagonists.
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Introduction 
The chemokine receptor CCR2 is a G protein-coupled receptor (GPCR) that is expressed on 
monocytes, dendritic cells, activated T lymphocytes and basophils, and therefore it plays an 
important role in the immune system [1-3]. These immune cells migrate towards increasing 
concentrations of chemokines at sites of inflammation as part of the immune response, also 
known as chemotaxis. CCR2 is activated by multiple chemokines, including CCL2, CCL7, CCL8, 
CCL11, CCL13 and CCL16. Besides its important role in physiology, increased levels of CCR2 
and its ligands can induce severe tissue damage. This results in a large variety of diseases that 
are characterized by chronic inflammation [4-7], which makes CCR2 an attractive drug target 
for the pharmaceutical industry. As a consequence many CCR2 small molecule antagonists 
have been developed over the years, but unfortunately all clinical candidates tested so far 
appeared to lack efficacy in man. 
Most small molecule chemokine receptor antagonists bind at the main binding pocket 
in the upper half (exterior part) of the transmembrane (TM) helices, usually with one part 
in the so-called major binding pocket (surrounded by TM helices III, IV, V, VI and VII) and the 
other part in the minor binding pocket (surrounded by TM helices I, II, III and VII) [8]. Many 
small molecule antagonists contain a positively charged basic nitrogen that interacts with 
the conserved negatively charged glutamic acid residue (E2917.39) in TM-VII, which is directly 
located in between the major and minor binding pocket [9]. An example of such a CCR2 
antagonist is INCB3344 (Fig. 1), to which we refer as an orthosteric antagonist, since it was 
previously reported to inhibit CCR2 in a competitive manner with respect to the chemokine 
ligand CCL2 [10, 11]. Interestingly, other classes of antagonists were discovered to bind at 
a different binding site than INCB3344 [10]. It was shown that these antagonists, CCR2-RA-
[R] and JNJ-27141491 (Fig. 1), possess structural features different from the orthosteric 
antagonists and inhibit CCR2 in a noncompetitive manner with respect to CCL2. The current 
study took these findings as the starting point to resolve the location of the binding site for 
these allosteric CCR2 antagonists. For several other chemokine receptors the presence of an 
allosteric binding site has been reported [12, 13]. Some of these antagonists bind exclusively 
to the major or minor binding pocket [14] and their binding site can even be directed towards 
the extracellular loops, as illustrated in the CXCR4 crystal structure for the small molecule 
antagonist IT1t [15]. In addition, an allosteric binding site on the intracellular side of the 
receptor in the C-terminal domain has been suggested for the chemokine receptors CXCR2, 
CCR4 and CCR5 [16-18]. 
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In the present study we first showed that a previously described antagonist with a 
sulfonamide scaffold (SD-24) is also an allosteric antagonist (Fig. 1) [19]. Subsequently, we used 
a CCR2/CCR5 chimeric approach to get insight into the binding site of allosteric antagonists 
for CCR2 and made single point mutations in CCR2 to further map this binding pocket. We 
discovered the existence of an intracellular binding site in CCR2 that is recognized by (at 
least) three chemically different classes of antagonists. Finally, we discuss the compounds’ 
mechanism of action and the implications for targeting CCR2 in disease states.
Fig. 1. Chemical structures of the orthosteric CCR2 antagonist INCB3344 and the allosteric CCR2 
antagonists CCR2-RA-[R], JNJ-27141491 and SD-24.
Materials and Methods
Chemicals and reagents. CCL2 was purchased from PeproTech (Rocky Hill, NJ). INCB3344, JNJ-
27141491 and CCR2-RA-[R] were synthesized according to published methods [47-50]. SD-24 
(sulfonamide derivative #24 from the Peace et al. paper) was synthesized in-house, according 
to procedures described previously [19]. [3H]-INCB3344 (specific activity 32 Ci mmol−1) and 
[3H]-CCR2-RA (specific activity 63 Ci mmol−1) were custom-labeled by Vitrax (Placentia, CA). 
125I-CCL2 (2200 Ci/mmol), 125I-CCL3 (2200 Ci/mmol), [35S]GTPγS (1250 Ci/mmol) and myo-[3H]
inositol (PT6-271) (94.5 Ci/mmol) were purchased from Perkin-Elmer (Waltham, MA, USA). 
Bovine serum albumin (BSA, fraction V) was purchased from Sigma (St. Louis, MO, USA). 
Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from Pierce Chemical 
Company (Rockford, IL, USA). Polyethyleneimine (PEI) was obtained from Polysciences Inc. 
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(Warrington, PA, USA). Wild-type (WT) FLAG-tagged CCR5 was cloned in-house from a 
leukocyte cDNA library, while WT FLAG-tagged CCR2 cDNA was kindly provided by Dr Tim 
Wells (GlaxoSmithKline, UK). The chimeric receptor CCR5-CCR2all, was previously described 
[20], whereas CCR2-CCR5C-term and CCR5-CCR2C-term were designed in-house and cloned using 
PCR overlap extension technique (Piscataway, NJ). pcDNA3.1+ plasmid containing the WT 
CCR2 with a 3x hemagglutinin (HA) epitope tag at the N-terminus was kindly provided by 
James Pease (Imperial College London, UK). The promiscuous G protein GαΔ6qi4myr (Gqi4myr) was 
kindly provided by Evi Kostenis (University of Bonn, Germany). Tango CCR2-bla U2OS cells 
stably expressing human CCR2 (U2OS-CCR2) were obtained from Invitrogen (Carlsbad, CA). 
CHO (Chinese hamster ovary) cells were obtained from Hans den Dulk (Leiden University, 
the Netherlands) and COS-7 cells were obtained from ATCC (Rockville, MD). The monoclonal 
rabbit anti-HA-tag antibody and the HRP-conjugated goat anti-rabbit antibody were obtained 
from Novus Biologicals (Cambridge UK). The monoclonal mouse anti-FLAG M1 antibody was 
obtained from Sigma (St. Louis, MO) and the HRP-conjugated goat anti-mouse antibody was 
obtained from Pierce (Rockford, IL). AG 1-X8 anion exchange resin was obtained from Bio-Rad 
(Hercules, CA). All other chemicals were obtained from standard commercial sources. 
Site-directed mutagenesis. pcDNA3.1+ plasmids containing the human CCR2 mutants 
I208A5.45 and E291A7.39 (superscript indicates the Ballesteros Weinstein numbering system 
[21], in which transmembrane residues are assigned two numbers that belong to the helix 
number and the residue number relative to the most conserved residue in this helix, which is 
assigned 50) with a 3x hemagglutinin (HA) epitope tag at the N-terminus were kindly provided 
by James Pease (Hall et al., 2009). All other point mutations were generated by site-directed 
mutagenesis, using WT HA-tagged CCR2 plasmid DNA as a template for the generation of 
mutant plasmids by polymerase chain reaction (PCR) using the QuickChange® II Site-directed 
mutagenesis kit (Stratagene, the Netherlands) and the appropriate oligonucleotide primers 
(Eurogentec, the Netherlands), under conditions recommended by the manufacturer. 
All mutants were verified by DNA sequencing before use (LGTC, Leiden University, the 
Netherlands). 
Cell culture. COS-7 cells and U2OS-CCR2 cells were cultured as described before [10, 20]. 
Chinese hamster ovary (CHO) cells were cultured in Ham’s F12 culture medium supplemented 
with 10% (v/v) newborn calf serum, penicillin (50 IU/mL) and streptomycin (50µg/mL) at 37°C 
and 5% CO2. Cells were subcultured twice weekly at a ratio of 1:20 by trypsinization on 10-cm 
ø plates.
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Transfections. Transfections of COS-7 cells with FLAG-tagged CCR2, CCR5 or chimeric receptor 
were performed by the calcium phosphate precipitation method as described before [22]. 
Transfections of CHO cells with FLAG-tagged CCR2, CCR5 or chimeric receptor, as well as HA-
tagged WT or mutant CCR2, were performed with polyethyleneimine (PEI). For this purpose, 
CHO cells were grown to 50-60% confluence on 15-cm ø plates and transfected with 10 µg of 
plasmid DNA per 15-cm ø plate. Briefly, 10 µg of plasmid DNA was diluted in a sterile 150 mM 
NaCl solution and subsequently mixed with PEI solution (1mg/mL) to obtain a DNA:PEI mass 
ratio of 1:6. The mixture was incubated for 20 min at room temperature before transfection. 
The culture medium of the cells was refreshed and 1 mL of DNA/PEI mixture was added to 
cells and incubated for 48 hrs at 37°C and 5% CO2. 
Cell membrane preparation. Membranes were prepared as described before [10]. Briefly, 
cells were scraped from 15-cm ø plates upon which the membranes and cytosolic fractions 
were separated during several centrifugation steps. Finally, the membrane pellet was 
resuspended in ice-cold 50 mM Tris-HCl buffer containing 5 mM MgCl2, pH 7.4, and aliquots 
were stored at −80 °C. Membrane protein concentrations were measured using a BCA protein 
determination with BSA as a standard [23].
Cell surface expression by Enzyme-Linked Immunosorbent Assay (ELISA). For transfections 
with WT and mutant CCR2 receptors containing a HA-tag, CHO cells were plated 24 hrs after 
transfection at a density of 1x106 cells per well in a 96-well plate and incubated at 37 ºC and 
5% CO2 for 24 hrs. Cells were washed with PBS and incubated with rabbit anti-HA primary 
antibody (dilution 1:5000 in DMEM) for 30 min at RT. After a subsequent wash with DMEM/
HEPES (25 mM), cells were incubated with HRP-conjugated goat anti-rabbit secondary 
antibody (dilution 1:5000 in DMEM) for 30 min at RT. The cells were washed twice with pre-
warmed PBS, after which tetramethyl benzene (TMB) was added for 5 min in the dark at 
RT. The reaction was stopped by addition of 1 M H3PO4 and after 5 min absorbance was 
measured at 450 nm with a Victor2V plate reader (Perkin Elmer, Waltham, MA, USA). 
125I-CCL2 binding assays. 125I-CCL2 and 125I-CCL3 whole cell binding assays on COS-7 cells 
transfected with WT FLAG-tagged CCR2, CCR5 or chimeric receptor were performed as 
described before [20]. In these assays 125I-CCL2 was used for CCR2 and the two chimers 
CCR5-CCR2(all) and CCR2-CCR5(C-term), whereas 125I-CCL3 was used for CCR5 and the 
chimer CCR5-CCR2(C-term). 125I-CCL2 binding assays on U2OS-CCR2 cell membranes were 
performed as described before [10]. Briefly, the assay was performed in a 100 µL reaction 
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volume containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% 3-((3-cholamidopropyl)-
dimethylammonio)-1-propanesulfonate (CHAPS) and 15 μg of U2OS-CCR2 cell membrane 
protein at 37 °C. Displacement assays were performed with 0.1 nM 125I-CCL2 using six 
concentrations of competing ligand for 150 min of incubation. At this concentration, total 
radioligand binding did not exceed 10% of the amount added to prevent ligand depletion. 
Non-specific binding was determined with 10 μM INCB3344. Reactions were terminated as 
described before.
[3H]-INCB3344 binding assays. [3H]-INCB3344 membrane binding assays were performed 
as described before [10]. For the FLAG-tagged CCR2, CCR5 and the chimera’s expressed in 
CHO cells, homologous displacement studies were carried out with 2.1 nM and 5.0 nM [3H]-
INCB3344 to be able to determine the equilibrium dissociation constant KD. Studies with HA-
tagged WT and mutant receptors of CCR2 were carried out with a single concentration of 5.7 
nM [3H]-INCB3344. In all cases, eight concentrations of competing ligand were incubated for 
120 min at 25 °C. Non-specific binding for mutant and WT CCR2 receptors was determined 
in the presence of 10 μM INCB3344. For the WT receptor the measured non-specific binding 
was equal to the experiments in which 10 μM BMS22 was used, as described in our previous 
study [10]. In all experiments, total radioligand binding did not exceed 10% of the amount 
added to prevent ligand depletion.
[3H]-CCR2-RA binding assays. [3H]-CCR2-RA membrane binding assay conditions were similar 
as those for [3H]-INCB3344 binding assays as described before [10]. For the FLAG-tagged 
CCR2, CCR5 and the chimera’s expressed in CHO cells, homologous displacement studies were 
carried out with 4.5 nM and 7.9 nM [3H]-CCR2-RA to be able to determine the equilibrium 
dissociation constant KD. Displacement assays with HA-tagged WT and mutant receptors of 
CCR2 were carried out with a single concentration of 7.9 nM [3H]-CCR2-RA. In all cases, eight 
concentrations of competing ligand were incubated for 120 min at 25ºC. Non-specific binding 
was determined in the presence of 10 μM CCR2-RA-[R]. For the WT receptor the measured 
non-specific binding was equal to the experiments in which 10 μM JNJ-27141491 was used, 
as described in our previous study [10]. In all experiments, total radioligand binding did not 
exceed 10% of the amount added to prevent ligand depletion. 
Inositol Phosphate turnover (IP Turnover) assay. IP turnover was measured in COS-7 cells 
co-transfected with WT FLAG-tagged CCR2, CCR5 or chimeric receptor and the promiscuous 
G protein Gqi4myr, as described before [20]. 
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[35S]GTPγS binding assay. The [35S]GTPγS assay was performed as described before [10]. 
To determine G protein activation of the wild-type and mutant CCR2 receptors, 10 µg of 
CHO cell membranes were pre-incubated with 100 nM CCL2 (single point) or six increasing 
concentrations of CCL2 for 30 min at 25 °C. Then [35S]GTPγS (0.3 nM) was added, after which 
the mixture was incubated for 90 min and samples were harvested as described before. 
Data analysis. All experiments were analyzed using the non-linear regression curve fitting 
program Prism 5 (GraphPad, San Diego, CA, U.S.A.). pKD values for the FLAG-tagged CCR2, 
CCR5 and chimeric receptors were calculated using the homologous competitive binding 
curve fit. The pIC50 values for WT and mutant CCR2 of INCB3344, CCR2-RA-[R], JNJ-27141491 
and SD-24 were obtained by non-linear regression analysis of the displacement curves. 
Statistical analysis was performed with a two-tailed unpaired Student’s t-test. All values 
obtained are means of at least three independent experiments performed in duplicate, 
unless stated otherwise.
Antagonist superposition, homology modeling and ligand docking. To best superimpose the 
three different antagonists, multiple ligand conformations of each individual compound were 
generated using MacroModel version 10.1 [24], with mixed torsional/low-mode sampling 
and default settings. Subsequently the different ligand conformations were aligned using the 
flexible ligand alignment method within Maestro [25] and selected based on their pose and 
shape similarity. A homology model of the chemokine CCR2 receptor was constructed using 
the homology modeling tool within Maestro [25-27]. This model was based on the structure 
of the chemokine CCR5 receptor co-crystalized with maraviroc (Protein Data Bank: 4MBS). 
The best model was selected based on the energy-based scoring function, while the sequence 
alignment between CCR2 and CCR5 was performed using ClustalW as implemented within 
Maestro. CCR2-RA-[R] was docked into the receptor homology model using the induced fit 
docking protocol [28, 29]. The grid center was placed based on residues D782.40, Y3057.53, 
K3118.49 and F3128.50 with an automatic box size. Visualizations were created using PyMOL 
version 1.5.0.4. [30].
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Results
Effect of sulfonamide SD-24 on CCR2 radioligand binding. The sulfonamide derivative SD-24 
partially inhibited binding of 125I-CCL2 to CCR2-expressing U2OS cell membranes to 27 ± 6 % 
at 10 µM, with a pIC50 of 7.2 ± 0.2 (Fig. 2). [
3H]-CCR2-RA was fully displaced with a pKi value of 
9.0 ± 0.1. On the contrary, SD-24 slightly increased [3H]-INCB3344 binding to a maximum of 
120 % at 1 µM SD-24, indicating it binds at a site different from the previously described [10, 
11] orthosteric binding pocket of INCB3344 (Fig. 2).
Fig. 2. Modulation of 125I-CCL2, [3H]-INCB3344 and [3H]-CCR2-RA binding to U2OS cell membranes stably 
expressing CCR2 by increasing concentrations of the CCR2 antagonist SD-24. Results are presented 
as percentage of bound radioligand for one representative experiment performed in duplicate. SD-
24 inhibited binding of 125I-CCL2 with a pIC50 of 7.2 ± 0.2 and [
3H]-CCR2-RA with a pKi of 9.0 ± 0.1. For 
125I-CCL2, 27 ± 6 % radioligand remained bound in the presence of 10 µM SD-24. 
Comparison of CCR2 and CCR5. In order to identify regions that are responsible for binding 
of SD-24 and the other allosteric antagonists we compared the affinity of CCR2-RA-[R], JNJ-
27141491 and SD-24 for CCR2 and its close homolog CCR5 (Fig. 3A) in whole cell radioligand 
binding assays using 125I-CCL2 and 125I-CCL3, respectively. CCR2-RA-[R] and JNJ-27141491 
displaced 125I-CCL2 from CCR2 with pIC50 values of 6.1 ± 0.1 and 6.6 ± 0.1, respectively (Table 
1). In addition, JNJ-27141491 inhibited 125I-CCL3 from binding to CCR5 with a pIC50 value of 
5.4 ± 0.1, whereas CCR2-RA-[R] did not sufficiently displace 125I-CCL3 from CCR5 to be able to 
determine its affinity for CCR5. The affinity of SD-24 for CCR2 could not be measured in this 
whole cell binding assay, and neither was any displacement of 125I-CCL3 from CCR5 observed 
in the presence of SD-24 (Table 1). Differently, in the functional IP turnover assay the pIC50 
values for CCR2 and CCR5 inhibition could be determined for all antagonists (Table 2). In this 
assay CCR2-RA-[R], JNJ-27141491 and SD-24 showed a 7-fold, 14-fold and 22-fold reduced 
potency to inhibit CCR5 compared to CCR2, respectively.






















































Fig. 3. (A) Sequence alignment with ClustalW2 of CCR2 and CCR5, for which the transmembrane 
regions as well as the intracellular and extracellular loops are indicated (bottom). Differing residues are 
indicated with an asterisk, and CCR2 residues mutated in this study are indicated in black. The arrow 
presents the location where the C-termini were swapped. The locations where the extracellular loops of 
CCR2 were inserted into CCR5 can be found in Thiele et al. 2011. (B) Schematic representation of CCR5 
and the chimeric receptors CCR5-CCR2(all), CCR2-CCR5(C-term) and CCR5-CCR2(C-term). (C) Schematic 
representation of CCR2. The approximate location of the residues K2.34, D2.40, I5.45, V6.36, E7.39, Y7.53, K8.49 
and F8.50 is indicated.
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The orthosteric antagonist INCB3344 displaced the radioligands 125I-CCL2 and 125I-CCL3 from 
CCR2 and CCR5, respectively, with a pIC50 of 7.8 ± 0.2 and 5.3 ± 0.2 (Table 1). Its pIC50 to inhibit 
IP turnover was 8.0 ± 0.01 for CCR2 and 5.3 ± 0.01 for CCR5 (Table 2). In comparison to the 
allosteric antagonists, INCB3344 showed a much lower affinity (280-fold) and potency (460-
fold) for CCR5 compared to CCR2.
To better determine the affinity of INCB3344 and CCR2-RA-[R] for CCR2 and CCR5 
we performed homologous displacement assays on membrane preparations of CHO cells 
transfected with CCR2 and CCR5. The pKD of INCB3344 for CCR2 was 8.1 ± 0.1, whereas 
binding to CCR5 could not be detected at nanomolar concentrations of [3H]-INCB3344. The 
pKD of CCR2-RA-[R] for CCR2 and CCR5 was 8.8 ± 0.1 and 7.0 ± 0.1, respectively (Table 3). All 
these data together suggest that the orthosteric binding site is more divergent between CCR2 
and CCR5 than the allosteric binding pocket.
Table 3. Displacement of [3H]-INCB3344 binding and [3H]-CCR2-RA binding from CHO membranes 
expressing FLAG-tagged CCR2, CCR5 and CCR2-CCR5(C-term) receptors.
[3H]-INCB3344 [3H]-CCR2-RA
Construct pKD ± S.E.M. and (KD (nM))
CCR2 8.1 ± 0.1 (8.3) 8.8 ± 0.1  (1.7)
CCR5 no binding 7.0 ± 0.1 (100)
CCR2-CCR5(C-term) 8.6 ± 0.1 (2.3) 8.7 ± 0.1  (2.0)
Data are presented as mean pKD ± S.E.M. or mean KD (nM) of at least three experiments performed in 
duplicate.
CCR2-CCR5 chimeric approach. Given the high structural similarity between CCR2 and 
CCR5, we took CCR5 as a template structure to further elucidate the allosteric binding site 
in CCR2. Therefore we decided to use a chimeric approach to investigate the role of the 
extracellular loops and intracellular region of the receptor in binding of the antagonists (Fig. 
3B). The chimera CCR5-CCR2(all), which consisted of CCR2’s extracellular receptor regions, 
and CCR5 for the remainder of the construct, was used to study the role of the extracellular 
loops for small molecule binding. In order to study the role of the C-terminus in binding 
of the antagonists, two novel chimera’s were constructed; CCR5-CCR2(C-term) and CCR2-
CCR5(C-term), consisting of CCR5 with CCR2 C-terminus, and CCR2 with CCR5 C-terminus, 
respectively. We confined ourselves to the C-terminus, as the intracellular loops are highly 
similar in sequence between CCR2 and CCR5 (Fig. 3A). 
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For the two allosteric antagonists CCR2-RA-[R] and JNJ-27141491, the ability to inhibit 
binding of 125I-CCL2 to CCR2 as well as the potency to inhibit IP3 formation by CCL2 was not 
affected when the C-terminal part of CCR5 was introduced in CCR2 (CCR2-CCR5(C-term)) 
(Tables 1 and 2). In addition, for CCR2-RA-[R] and JNJ-27141491 no difference was observed 
in their potency to inhibit IP3 formation by CCL3 between CCR5 and CCR5-CCR2(C-term) 
(Table 2). The displacement of 125I-CCL3 from CCR5-CCR2(C-term) by CCR2-RA-[R], JNJ-
27141491 and SD-24 could not be compared to CCR5, since their affinities were too low in a 
number of cases (Table 1). Similarly, SD-24 did not displace 125I-CCL2 binding from CCR2 and 
CCR2-CCR5(C-term) (Table 1). However, the pIC50 value of SD-24 to inhibit IP3 formation via 
CCR5-CCR2(C-term) was with 5.6 ± 0.1 slightly higher than the pIC50 of 5.3 ± 0.1 for CCR5. 
All together, the data of the IP turnover assay suggest that non-conserved residues in the 
C-terminus of CCR2 compared to CCR5 are not involved in binding of the allosteric antagonists 
CCR2-RA-[R] and JNJ-27141491. For SD-24, a 2-fold increase in potency was observed upon 
introduction of the CCR2 C-terminus in CCR5, whereas introduction of the CCR5 C-terminus 
in CCR2 did not result in any changes. 
Upon introduction of the extracellular loops of CCR2 in CCR5 (chimer CCR5-CCR2(all)), 
a significant decrease in potency to inhibit IP turnover was observed for CCR2-RA-[R] as its 
pIC50 value was 5.2 ± 0.2 for CCR5-CCR2(all) compared to 6.2 ± 0.1 in case of CCR5 (Table 
2). In the binding assays the affinities of CCR2-RA-[R] and SD-24 for CCR5-CCR2(all) were 
negligible (Table 1). Differently, a slight decrease in affinity of JNJ-27141491 was observed, 
since its pIC50 value was 5.0 ± 0.1 for CCR5-CCR2(all) compared to 5.4 ± 0.1 for CCR5 (Table 
1). It should be noted that we compared binding and activation of CCR5 by 125I-CCL3/CCL3 
with binding and activation of CCR5-CCR2(all) by 125I-CCL2/CCL2. It can thus not be excluded 
that activation of these receptors in a molecularly different way could be responsible for the 
observations.
In contrast to the allosteric antagonists, the inhibitory potency and affinity of the 
orthosteric antagonist INCB3344 was increased for CCR5 when the extracellular loops of 
CCR2 were introduced. INCB3344 inhibited 125I-CCL3 binding to CCR5 and 125I-CCL2 binding 
to CCR5-CCR2(all) with a pIC50 of 5.3 ± 0.2 and 6.3 ± 0.1, respectively (Table 1). In addition, 
the potency of INCB3344 to inhibit CCL2-induced CCR5-CCR2(all) activity in the functional 
assay was increased 45-fold compared to its potency to inhibit CCL3-induced CCR5 activity 
(Table 2). Next we measured the effect of the C-terminus swap on the affinity and potency 
of INCB3344. For CCR2-CCR5(C-term) the affinity of INCB3344 and its potency to inhibit IP 
turnover were not significantly altered compared to CCR2. Exchange of the CCR5 C-terminus 
with that of CCR2 made INCB3344 unable to displace 125I-CCL3 from CCR5-CCR2(C-term), 
84  |  Chapter 4
whereas the potency to inhibit IP turnover was similar for CCR5-CCR2(C-term) compared to 
CCR5. 
The small molecule radioligands [3H]-INCB3344 and [3H]-CCR2-RA were only able to bind 
to CCR2-CCR5(C-term) of all three chimers, with a pKD of 8.6 ± 0.1 and 8.7 ± 0.1, respectively 
(Table 3). Thus no significant change compared to the WT CCR2 pKD of 8.8 ± 0.1 was observed 
for [3H]-CCR2-RA, in agreement with the chemokine-displacement assays (Table 1 and 3). 
[3H]-INCB3344 was found to bind slightly better to CCR2-CCR5(C-term) compared to CCR2 
(pKD = 8.1 ± 0.1), somewhat different than observed in the chemokine-displacement assays 
(Table 1 and 3). 
Identification of intracellular residues involved in CCR2-RA-[R] binding. To further investigate 
the possibility of an intracellular binding pocket, we applied a site-directed mutagenesis 
approach. We initially constructed four mutations in CCR2, K72A2.34, D78N2.40, Y305A7.53 and 
K311A8.49 (Fig 3A+C). K722.34 in ICL1 is one of the few differential residues in the intracellular 
loops of CCR2 compared to CCR5 (Fig. 3A). Y3057.53 is very conserved among G protein-coupled 
receptors, whereas D782.40 and K3118.49 are typical residues among chemokine receptors (see 
also Discussion). As a control we included I208A5.45, which was previously not predicted in 
any binding site, and E291A7.39, which is the highly conserved acidic residue in the orthosteric 
binding pocket of chemokine receptors. All six mutant receptors were expressed at the cell 
surface, as determined by whole cell ELISA (Fig 4). 
Mutation of Y3057.53 into an alanine residue (Y305A) completely abolished [3H]-CCR2-
RA binding, whereas the affinity of [3H]-INCB3344 was not affected (Table 4). The affinity of 
CCR2-RA-[R] for the K311A8.49 mutant receptor was 10-fold decreased compared to WT CCR2, 
whereas the K72A2.34 and D78N2.40 mutations did not affect binding. The affinity of INCB3344 
was not affected by any of these mutations at the intracellular region (Table 4). In contrast, 
the affinity of INCB3344 was 8-fold decreased for the E291A7.39 mutant receptor compared 
to WT CCR2, whereas the affinity of CCR2-RA-[R] was not affected by this mutation located 
in the upper half of the receptor. These results reveal that the two residues Y3057.53 and 
K3118.49, both located at the transmembrane/intracellular side of the receptor, are involved in 
binding of the allosteric antagonist CCR2-RA-[R], whereas E2917.39 in the orthosteric binding 
pocket is only important for binding of INCB3344 to CCR2. 
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Fig. 4. Surface expression of the HA-tagged WT and mutant CCR2 receptors in CHO cells as measured by 
ELISA. Data was normalized for WT CCR2 expression (100%) and is presented as mean ± SD of at least 
two experiments performed in quadruplicate. 
Table 4. Displacement of [3H]-INCB3344 binding and [3H]-CCR2-RA binding from CHO membranes 










Construct pIC50 ± S.E.M. and IC50 (nM)
WT CCR2 7.8 ± 0.03 (16) 7.8 ± 0.05 (16) 7.6 ± 0.1 (24) 7.8 ± 0.1 (16)
K72A2.34 7.8 ± 0.01 (15) 7.7 ± 0.1 (21) 7.3 ± 0.1* (45) 7.6 ± 0.1 (24)
D78N2.40 7.8 ± 0.1 (16) 7.7 ± 0.1 (21) 7.4 ± 0.1* (43) 7.5 ± 0.1* (33)
I208A5.45 7.8 ± 0.1 (17) 7.7 ± 0.1 (19) 7.8 ± 0.1 (17) 7.9 ± 0.02 (12)
V244A6.36 8.1 ± 0.03** (7.5) no binding ND ND
E291A7.39 6.9 ± 0.1** (126) 7.7 ± 0.1 (21) 7.7 ± 0.1 (22) 7.7 ± 0.05 (20)
Y305A7.53 7.7 ± 0.03 (19) no binding ND ND
K311A8.49 7.7 ± 0.03 (18) 6.8 ± 0.1** (169) 7.5 ± 0.1 (30) 7.1 ± 0.1** (74)
F312A8.50 8.0 ± 0.1** (9.2) no binding ND ND
Data are presented as mean pIC50 ± S.E.M. and mean IC50 (nM) of at least three experiments performed 
in duplicate. 
ND, not determined
* p< 0.05 vs. WT CCR2, Student’s t-test.
** p< 0.005 vs. WT CCR2, Student’s t-test.
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Docking of CCR2-RA-[R] in a CCR2 homology model. To obtain further insight in the binding 
pose of CCR2-RA-[R], we constructed a CCR2 homology model using the crystal structure 
of CCR5 (PDB: 4MBS) and docked the antagonist CCR2-RA-[R] in the model. When standard 
docking was used, only low scoring poses were found. Therefore we employed induced-fit 
docking to account for the flexibility of the intracellular pocket. Final poses were selected based 
on both the score and consistency with experimental results. In Figure 5 the interactions of 
CCR2-RA-[R] with V2446.36, K3118.49, Y3057.53 and F3128.50 are visualized. The pocket is shielded 
by Y3057.53 at the top and F3128.50 at the side, both enabling hydrophobic interactions with 
CCR2-RA-[R]. K3118.49 is turned towards the bottom of the binding pocket and interacts with 
one of the carbonyl oxygens in CCR2-RA-[R]. At the side of the binding pocket, V2446.36 was 
found to interact with the hexyl-ring of CCR2-RA-[R]. The residues K72A2.34 and D782.40 were 
not in close proximity to CCR2-RA-[R] (Fig. 5A), which was in agreement with their lack of 










Fig. 5. (A) Induced fit docking of CCR2-RA-[R] in a homology model of CCR2 based on the crystal 
structure of CCR5. The pocket is shielded by Y3057.53 at the top and F3128.50 at the side, K3118.49 is turned 
towards the bottom of the binding pocket and V2446.36 interacts at the side with the hexyl-ring. D782.40 
and K722.34 are represented in yellow, as these residues are not predicted to interact with CCR2-RA-[R]. 
(B) Interaction map of CCR2-RA-[R] with surrounding residues upon induced fit docking. 
Experimental evidence for the docking pose of CCR2-RA-[R]. We determined the effect of 
mutagenesis of V2446.36 in TM-VI and F3128.50 in helix-VIII on binding of [3H]-CCR2-RA, since 
these residues were predicted to be important for binding of CCR2-RA-[R] in the homology 
model. Both mutant receptors V244A6.36 and F312A8.50 were expressed at the cell surface, as 
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determined by whole cell ELISA (Fig. 4). Similar to Y305A7.53, the binding of [3H]-CCR2-RA was 
completely abolished for V244A6.36 and F312A8.50, while [3H]-INCB3344 was able to bind with 
a slightly increased affinity to both mutant receptors in comparison to WT CCR2 (Table 4). 
Binding site of JNJ-27141491 and SD-24. On the assumption that the small molecule 
antagonists JNJ-27141491 and SD-24 share the same binding site as CCR2-RA-[R], we 
subjected these two compounds to displacement studies with radiolabeled [3H]-CCR2-RA 
on the series of CCR2 single point mutations (Table 4). JNJ-27141491 showed a small but 
significant affinity decrease in displacing [3H]-CCR2-RA compared to wild-type CCR2 for the 
K72A2.34 and D78N2.40 mutant receptors of 1.8-fold in both cases. The affinity of SD-24 was 
2-fold and 4.4-fold decreased for the D78N2.40 and K311A8.49 mutant receptors. Due to a lack of 
[3H]-CCR2-RA binding to V244A6.36, Y305A7.53 and F312A8.50, we could not use these mutants in 
the heterologous displacement assays. Neither I208A5.45 nor E291A7.39 affected the binding of 
the antagonists. These data confirm that JNJ-27141491 and SD-24 bind in the same region as 
CCR2-RA-[R], albeit with a different orientation, since K722.34, D782.40 and K3118.49 differently 
affected the binding of the three allosteric antagonists. In agreement with these different 
binding poses, the best possible alignment of the three antagonists illustrated that these 
structures cannot be fully superimposed (Fig. 6). The substituted aromatic ring of CCR2-RA-
[R] is overlaid with the aromatic ring structures of JNJ-27141491 and SD-24. However, at the 
position of the middle pyrroline ring structure of CCR2-RA-[R], SD-24 contains an aromatic 
ring whereas JNJ-27141491 extends further with its isoxazole ring. 
Figure 6
Fig. 6. Superimposition of CCR2-RA-[R] (lilac), JNJ-27141491 (green) and SD-24 (magenta). At the 
bottom right the different properties of the antagonists are illustrated: JNJ-27141491 is extended at 
this side with an isoxazole ring structure, and the aromatic ring structure of SD-24 is superimposed with 
the pyrroline ring structure of CCR2-RA-[R].
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Effect of CCR2 mutations on receptor activation. The effects of the mutations on receptor 
activation were determined in a [35S]GTPγS assay. [35S]GTPγS binding was equal for mock 
transfected CHO cell membranes as for WT CCR2 CHO cell membranes (data not shown), and 
therefore no basal activity is reported in Figure 7. The mutations K72A2.34, V2446.36, E291A7.39, 
Y305A7.53, K311A8.49 and F312A8.50 distorted receptor activation as no [35S]GTPγS binding 
window was observed upon addition of 100 nM CCL2 (Fig 5A). CCL2 was found to induce G 
protein-activation for WT CCR2 with a pEC50 value of 7.6 ± 0.2 (Fig. 7B). D78N
2.40 was the only 
mutant receptor that allowed significant G protein-activation by CCL2, which yielded a pEC50 
value of 7.8 ± 0.1 (Fig. 7B). 
Fig. 7. (A) G protein-activation by CCL2 measured in a [35S]GTPγS binding assay on CHO cell membranes 
expressing WT and mutant CCR2 receptors. (B) Concentration-effect curves of CCL2 on WT and 
D78N2.40 CCR2 resulting in a pEC50 of 7.6 ± 0.2 and 7.8 ± 0.1, respectively. A representative graph of one 
experiment performed in duplicate is shown. 
Discussion
Since the early days of GPCR research, our understanding of ligands that activate or inhibit 
these receptors has increased dramatically [31, 32]. We can now distinguish GPCR ligands 
with a broad spectrum of activities and mechanisms of action, which implies the presence 
of multiple binding sites, including so-called allosteric binding sites [33]. In the present study 
we provided evidence for the presence of an allosteric intracellular binding site for small 
molecule antagonists of the chemokine receptor CCR2. 
Without knowing their location on the receptor we have previously reported on multiple 
binding sites for small molecule CCR2 ligands, and classified CCR2-RA-[R] and JNJ-27141491 
as allosteric antagonists based on radioligand binding studies [10]. Besides these, we now 
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identified SD-24 to bind at the same allosteric binding pocket at CCR2 (Fig. 2). Structurally 
related ligands with a pyrazinyl-sulfonamide scaffold have been reported to bind at the 
intracellular side of CCR4 [16]. Although the precise location of this binding site was not 
identified, interactions of these antagonists with the C-terminus of CCR4 were reported. 
In order to elucidate the location of the CCR2 binding site for CCR2-RA-[R], JNJ-27141491 
and SD-24, we constructed several CCR2-CCR5 chimeric receptors to identify regions 
responsible for binding. CCR2 and CCR5 bear a high sequence similarity of approximately 
70%, which makes them perfect candidates for the construction of chimeric receptors [34, 
35]. Besides the suggested intracellular binding site for CCR4, other allosteric ligands for 
chemokine receptors have been reported to interact with the extracellular loops (ECLs). ECL2 
contributes to the CXCR4 binding site of the co-crystallized ligand It1 [15], and interactions 
with ECL2 were reported for the CCR5 antagonists AK530 [36], aplaviroc [20] and small 
molecule ligands targeting CCR1 and CCR8 [37].
We constructed CCR2-CCR5 chimeras in which either these extracellular regions or the 
C-terminus were swapped. Binding of the orthosteric CCR2 antagonist INCB3344 was not 
affected after exchange of the C-terminus in the chemokine-displacement assays, but the 
binding to CCR5 was increased when extracellular loops of CCR2 were introduced. This fits 
very well with an orthosteric binding mode, since other small molecule chemokine receptor 
ligands that bind to the major binding pocket have been found to also interact with ECL2 [20, 
36, 37]. However, CCR5 binding of the allosteric antagonists CCR2-RA-[R], JNJ-27141491 and 
SD-24 was not improved after introduction of the ECLs of CCR2. The affinity and potency of 
CCR2-RA-[R] and JNJ-27141491 did not change after swapping the C-terminus between CCR2 
and CCR5, while for SD-24 a small but significant increase in potency was measured upon 
introduction of the CCR2 C-terminus in CCR5. It should be noted that intracellular antagonists 
need to pass the cell membrane before they can exert receptor inhibition in case of the 
whole cell binding assays and functional assays. In these studies, the allosteric antagonists 
remarkably displayed up to 10-fold higher potency in the whole cell IP3 assay performed 
at 37 ºC compared to their IC50 in the whole cell binding assay performed at 4 ºC, whereas 
INCB3344 behaved similarly in both assays. In addition, the binding of the allosteric ligands to 
CCR2 in the whole cell assays at 4 ºC were much higher than the corresponding values in the 
membrane assays at 37 ºC (Table 1 and Fig. 2) [10]. Although different cellular systems were 
used in these distinct assays, the antagonist binding to the intracellular binding pocket could 
also explain the decreased affinities in whole cell assays at 4ºC due to putative difficulties to 
enter the cell at such a low temperature. 
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To explore the possibility of an intracellular binding site, we focused on three conserved 
residues among chemokine receptors that were previously reported to be involved in small 
molecule binding at CXCR2, being D782.40, Y3057.53 and K3118.49 [18]. The binding of [3H]-CCR2-
RA was completely abolished for Y305A7.53, and a 10-fold decreased affinity was observed 
for K311A8.49. Upon considering the important GPCR motifs in this intracellular region and 
subsequent induced fit docking in a CCR2 homology model we identified F3128.50 and V2446.36 
as part of the intracellular pocket, and mutagenesis of these residues into alanine completely 
prevented [3H]-CCR2-RA from binding. This data is in line with the unaffected affinity of the 
allosteric antagonists for the chimera’s in which the C-terminus was swapped, since K8.49 and 
F8.50 are present in both CCR2 and CCR5. 
Y3057.53 is the highly conserved tyrosine in the NPxxY motif found in 92% of class A 
GPCRs and this motif has been shown to be important for receptor internalization, receptor 
signalling and activation [38-40]. For CCR2 we confirmed its critical role in signalling, since 
a loss of G protein-activation was observed for Y305A7.53 (Fig. 7). The increasing number 
of GPCR crystal structures show that Y3057.53 can interchange between multiple different 
states [41], which emphasizes the flexibility of this residue and therefore also its potential to 
contribute to the creation of an intracellular small molecule binding pocket. 
Together with F3128.50 which is conserved in 68% of class A GPCRs, Y3057.53 forms the 
NPxxYx5,6F motif [38]. The π-stacking interaction between F312
8.50 and Y3057.53 directly links 
TM-VII and helix-VIII and keeps the receptor in an inactive state [40], as observed in multiple 
crystal structures including the recent CCR5 structure [42]. Upon activation, the aromatic 
stacking interaction is disrupted which allows Y3057.53 to rotate into the helical TM core to 
permit receptor signalling [41]. In induced-fit docking with CCR2-RA-[R] we observed that 
Y3057.53 likely shields the top of the binding pocket, whereas F3128.50 is positioned between 
TM-VII and TM-I and may therefore contribute to hydrophobic interactions with the space-
filling chlorine substituent on the phenyl ring of CCR2-RA-[R] (Fig. 5).
Besides Y3057.53 and F3128.50, the residues V2446.36 and K3118.49 were found important 
for binding of CCR2-RA-[R]. K3118.49 is a basic, positively charged residue and therefore a likely 
partner to interact with the partially negative charge on the oxygen present in CCR2-RA-
[R] (Fig. 1 and 5). This interaction was visualized in the docking pose, in which K3118.49 was 
found to shield the bottom of the binding pocket. K8.49 is highly conserved among chemokine 
receptors (68.4%), but otherwise not prevalent among class A GPCRs (5.7%). Besides in 
CCR2, this residue was also found to be important in CXCR2 for interaction with the acidic 
Pteridone-1, Sch527123 and SB265610 antagonists [17, 18]. It would be interesting to study 
whether such a basic residue at this position is facilitating the presence of a small molecule 
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binding pocket, in view of the prevalence of intracellular antagonists among the chemokine 
receptor family so far.
The loss of [3H]-CCR2-RA binding upon the mutation of V2446.36 into alanine confirms 
that TM-VI is involved in the creation of the intracellular small molecule binding pocket. 
Notably, it is TM-VI that moves outward on activation of GPCRs as has become evident from a 
comparison between active and inactive state crystal structures [43]. Besides steric hindrance 
by the antagonist for G protein binding, the fixation of TM-VI in an inactive state might be 
another mechanism by which these antagonists exert their inhibitory effect. Interestingly this 
valine residue is among the few differential intracellular residues between CCR2 and CCR5, 
since a leucine is present on this position in CCR5 (Fig. 3A). Clearly the presence of a valine is 
very important for high affinity binding of CCR2-RA-[R], and the extended alkyl chain of the 
leucine in CCR5 may cause steric hindrance preventing high affinity binding of CCR2-RA-[R]. 
JNJ-27141491 and SD-24 share the intracellular binding pocket of CCR2-RA-[R], but 
were found to interact differently with surrounding residues. K311A8.49 showed a significant 
reduction in affinity for SD-24 (4-fold), whereas no change was observed for JNJ-27141491. 
A 2-fold change in affinity was observed for D78N2.40 for both JNJ-27141491 and SD-24, and 
K72A2.34 only affected JNJ-27141491. These two residues were not important for binding of 
CCR2-RA-[R], but do surround its binding pocket and therefore serve as likely interaction 
partners for structurally different antagonists like JNJ-27141491 and SD-24 (Fig. 5 and 6).
Importantly, the affinity of the orthosteric antagonist INCB3344 was not affected for 
any of the mutations at the intracellular interface. Instead a significantly reduced affinity 
of INCB3344 was observed for the E291A7.39 mutation (8-fold), as was published before for 
other orthosteric antagonists [44, 45]. Of note, this is the first study with experimental data 
that confirms the interaction of INCB3344 with E2917.39 of CCR2 – a residue that is known 
to function as an anchor point for many positively charged CC-chemokine receptor small 
molecules [9, 45]. Interestingly a slight increase in INCB3344 affinity was observed for the 
F312A8.50 and V244A6.36 mutant receptors. This could imply that these mutants induce an 
inactive conformation of the receptor, in agreement with their lack of G protein-activation in 
the [35S]GTPγS assay, and thereby enhance binding of INCB3344. 
Intracellular binding sites have become subject of study over the past few years. The 
cytoplasmic tails of CCR4, CCR5 and CXCR1 have been implicated in the binding of antagonists, 
as were several specific intracellular residues for antagonists of CXCR2, including equivalent 
residues we studied [16-18]. In addition, an allosteric modulator of the PAR1 receptor was 
found to act through helix-VIII [46]. In the current study we largely identified the location of 
this intracellular binding pocket for CCR2. Notably, we were for the first time able to visualize 
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such an intracellular binding pocket upon induced-fit docking of CCR2-RA-[R] in a CCR2 
homology model that was constructed based on the recent crystal structure of CCR5 [42]. 
Previous attempts to predict the location of intracellular binding pockets in homology models 
most likely failed due to the lack of a closely related crystal structure [18]. 
In summary, the evidence for intracellular binding pockets at (chemokine) GPCRs is 
accumulating. The results of our mutagenesis and docking studies provide evidence for such 
an allosteric binding site on CCR2 at a defined location and may facilitate the design of novel 
intracellular antagonists for this and other chemokine receptors, and, hopefully, for GPCRs 
in general. 
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Abstract 
The chemokine receptor CCR2 is a G protein-coupled receptor (GPCR) that is expressed on 
immune cells and involved in many diseases characterized by inflammation. Previously two 
distinct binding pockets were reported for small molecules targeting this receptor. In the 
present study, we revealed yet another binding pocket via which amiloride analogues and 
sodium ions were discovered to modulate CCR2.
In radioligand binding studies the amiloride analogue HMA allosterically inhibited 
binding of the agonist 125I-CCL2, the orthosteric antagonist [3H]-INCB3344 and the intracellular 
antagonist [3H]-CCR2-RA-[R]. Differently, sodium ions only allosterically inhibited 125I-CCL2 
binding, while they enhanced binding of [3H]-CCR2-RA-[R]. Three residues located in the core 
of the transmembrane domain, D882.50, W2566.48 and H2977.45, turned out to be important 
for modulation of the antagonist radioligands, since mutation of these residues abolished or 
diminished the allosteric effects induced by HMA and sodium ions. Upon induced-fit docking 
of HMA in a homology model of CCR2, we visualized its interaction with D882.50, W2566.48 and 
H2977.45 and predicted additional surrounding residues of this binding pocket. 
With this work we identified a third binding pocket for small molecules at CCR2, which 
is located in the core domain of the receptor. By means of the intracellular radioligand [3H]-
CCR2-RA-[R] we were able to demonstrate allosteric modulation of the intracellular CCR2 
domain by HMA and sodium ions, which has not yet been reported for other GPCRs. This 
work contributes to our knowledge of allosteric modulation of GPCRs, and offers novel 
opportunities for targeting CCR2.
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Introduction
G protein-coupled receptors (GPCRs) comprise the largest family of cell-surface signal-
transduction proteins in mammalian cells [1]. They transfer signals into the cell upon binding 
of their endogenous ligand at the extracellular face of the receptor. However, during the 
last decades many small molecule ligands and endogenous chemical entities have been 
discovered to bind at sites different from where the endogenous ligand binds, so-called 
allosteric sites [2]. Via these sites they can activate, inhibit or modulate the response of the 
GPCR. In this study we reveal a novel allosteric binding site in the chemokine receptor CCR2 
that allows amiloride analogues and sodium ions to modulate the receptor. 
CCR2 is a member of the CC-chemokine receptors which belong to the family of class A 
GPCRs. It is mainly expressed on monocytes, dendritic cells and lymphocytes, and therefore 
this receptor is important for correct functioning of the immune system [3, 4]. However, 
CCR2 is also involved in a variety of diseases including atherosclerosis, rheumatoid arthritis 
and chronic pain, which makes it an attractive target for the pharmaceutical industry [5]. 
Many CCR2 small molecule antagonists have been developed, but unfortunately without any 
clinical success so far. Development of allosteric drugs might offer therapeutic benefits for 
targeting this receptor [6]. 
CCR2 is mainly activated by its endogenous chemokine ligand CCL2, which is a peptide 
of 76 amino acids that binds to the extracellular loops (ECLs) and the TM domain of CCR2 [7]. 
The numerous small molecule antagonists that have been synthesized so far are chemically 
divergent, and were recently discovered to bind to two distinct binding sites at CCR2 [8]. One 
class of antagonists binds in the main binding pocket, located at the upper half of the TM 
domain of the receptor (orthosteric site), while the other class binds at the intracellular side of 
the receptor (allosteric site) (Chapter 4). The presence of these multiple binding sites alerted 
us to investigate whether CCR2 is also prone to modulation by typical GPCR modulators such 
as amiloride analogues and sodium ions, and if so, via which binding site this is manifested. 
Amiloride analogues and sodium ions have been found to modulate several class A GPCRs, 
including adenosine, dopamine and opioid receptors [9-11]. The binding pocket for these 
ligands is located in the core of the TM-domain, surrounded by the highly conserved residues 
D2.50 and W6.48. The position of the sodium ion within this pocket has been revealed in high 
resolution crystal structures of the inactive A2A adenosine receptor (A2AAR) [12], the inactive 
protease-activated receptor 1 (PAR1) [13], and the inactive δ-opioid receptor (δ-OR) [11]. In 
addition, several biochemical studies provided proof that amiloride analogues bind to this 
same binding pocket in e.g., the α2-adrenergic receptor [36] and the A2AAR [10, 14].
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Up to date there is no evidence of the presence of such a sodium binding pocket for 
chemokine receptors, and neither has modulation of this receptor family by amiloride 
analogues been researched. In the present study, we took advantage of the availability of 
two different tool compounds, the orthosteric antagonist radioligand [3H]-INCB3344 and 
the intracellular antagonist radioligand [3H]-CCR2-RA-[R], to study CCR2 modulation by 
the sodium ions and amiloride analogues. We unmasked a third binding pocket for small 
molecules at CCR2, and thereby revealed that this receptor bears small molecule binding 
pockets throughout the entire transmembrane region. Therefore, this study offers novel 
opportunities for targeting CCR2.
Materials and methods
Chemicals and reagents. INCB3344 and CCR2-RA-[R] were synthesized according to published 
methods [15-17]. [3H]-INCB3344 (specific activity 32 Ci mmol−1) and [3H]-CCR2-RA-[R] (specific 
activity 60 Ci mmol−1) were custom-labeled by Vitrax (Placentia, CA). Bovine serum albumin 
(BSA, fraction V) was purchased from Sigma (St. Louis, MO, USA). Bicinchoninic acid (BCA) 
and BCA protein assay reagent were obtained from Pierce Chemical Company (Rockford, 
IL, USA). Tango CCR2-bla U2OS cells stably expressing human CCR2 (U2OS-CCR2) were 
obtained from Invitrogen (Carlsbad, CA). Chinese hamster ovary (CHO) cells were obtained 
from Hans den Dulk (Leiden University, the Netherlands). pcDNA3.1+ plasmid containing 
wild-type (WT) CCR2 with a 3x hemagglutinin (HA) epitope tag at the N-terminus was kindly 
provided by James Pease (Imperial College London, UK) [18]. The monoclonal rabbit anti-HA-
tag antibody and the HRP-conjugated goat anti-rabbit antibody were obtained from Novus 
Biologicals (Cambridge UK). LiCl was obtained from Merck KGaA (Darmstadt, Germany). KCl, 
NaCl, amiloride (3,5-diamino-6-chloro-N-[diaminomethylene]pyrazine-2-carboxamide) and 
HMA (5-[N,N-hexamethylene]amiloride) were purchased from Sigma Aldrich (Zwijndrecht, 
the Netherlands). MGCMA (5-[N-methyl-N-guanodinocarbonyl-methyl]amiloride), benzamil 
(3,5-diamino-N-[(1E)-amino-(benzylamino)methylidene]-6-chloropyrazine-2-carboxamide), 
MIBA (5-[N-methyl-N-isobutyl]amiloride) and phenamil (3,5-diamino-N-[imino(phenylamino)
methyl]pyrazinecarboxamide) were obtained from Dr E. J. Cragoe (Lansdale, USA) and were 
synthesized as described before [19]. Sodium butyrate was obtained from Fisher Scientific 
(Landsmeer, NL). Polyethylenimine (PEI) was obtained from Polysciences Inc (Eppelheim, 
Germany). All other chemicals were obtained from standard commercial sources.
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Cell culture. U2OS-CCR2 cells were cultured as described before [8]. CHO cells were cultured 
in DMEM/Ham’s F12 medium supplemented with 10% fetal calf serum, 50 IU/ml penicillin, 
and 50 µg/ml streptomycin, in a humidified atmosphere at 37 °C and 5% CO2. Cells were 
subcultured twice a week at a ratio of 1:20 on 10 cm ø or 15 cm ø plates by trypsinization.
Site-directed mutagenesis. D88A2.50, W256A6.48 and H297A7.45 mutations (superscript indicates 
the Ballesteros Weinstein numbering system [20], in which transmembrane residues are 
assigned two numbers that belong to the helix number and the residue number relative to the 
most conserved residue in this helix, which is assigned 50) were generated by site-directed 
mutagenesis using WT HA-tagged CCR2 plasmid DNA as a template for the generation of 
mutant plasmids by polymerase chain reaction (PCR) using the QuickChange®II site-directed 
mutagenesis kit (Stratagene, the Netherlands) and the appropriate oligonucleotide primers 
(Eurogentec, the Netherlands), under conditions recommended by the manufacturer. All 
mutants were verified by DNA sequencing before use (LGTC, The Netherlands).
PEI transfections. WT and mutant CCR2 receptors were transiently transfected into CHO cells 
using PEI. One day prior to transfection CHO cells were split in a ratio of 1:9 on 15 cm ø 
plates, to reach 50-60% confluence. 10 µg of plasmid DNA was diluted in a sterile 150 mM 
NaCl solution and subsequently mixed with PEI solution (1 mg/mL) to obtain a DNA:PEI mass 
ratio of 1:6. The mixture was incubated for 20 min at room temperature before transfection. 
The culture medium of the cells was refreshed and 1 mL of DNA/PEI mixture was added to 
cells and incubated for 48 hrs at 37 °C and 5% CO2. In case of transfections with mutant CCR2 
receptors, 500 μl sodium butyrate (final concentration of 5 mM) was added to each plate 
after 24 hrs in order to increase the receptor expression [21].
Cell surface expression by Enzyme-Linked Immunosorbent Assay (ELISA). Cell surface 
expression of WT and mutant CCR2 constructs, all containing a HA-tag, was measured by 
enzyme linked immunosorbent assay (ELISA). In a 96-well plate, 1x106 cells per well were 
plated 24 hrs after transfection and incubated at 37 °C, 5% CO2. 48 hrs after transfection cells 
were fixed with 3.7% formaldehyde. The cells were washed with DMEM and the primary 
antibody (monoclonal rabbit anti-HA-tag 1:5000 in DMEM) was incubated for 30 min at RT. 
After removal of the primary antibody, the cells were washed with DMEM/25 mM HEPES and 
dried for 10 min. Subsequently, a mixture of the secondary antibody (HRP-conjugated goat 
anti-rabbit 1:5000 in DMEM) was incubated for 30 min. The cells were washed twice with PBS 
(37 °C) and left to dry for 10 min at RT. 100 μl tetramethylbenzene (TMB) was added in the 
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dark and incubated for 5 min. The reaction was stopped after addition of 100 μl 1 M H3PO4. 
After 5 min, absorbance was measured at 450 nm with a Victor2V plate reader (Perkin Elmer, 
Waltham, MA, USA).
Cell membrane preparation. Preparation of membranes was performed as described before 
[8]. Briefly, cells were scraped from 15 cm ø plates upon which the membranes and cytosolic 
fractions were separated during several centrifugation steps. Finally, the membrane pellet 
was resuspended in ice-cold 50 mM Tris-HCl buffer containing 5 mM MgCl2, pH 7.4, and 
aliquots were stored at −80 °C. Membrane protein concentrations were measured using a 
BCA protein determination with BSA as a standard [22]. 
[3H]-INCB3344 binding assays. Binding assays were performed in a 100 µL reaction volume 
containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% CHAPS and 7.5 µg of membrane 
protein for WT CCR2 membranes and 20-40 µg for mutant receptors, at 25 °C. Saturation 
experiments were performed using 12 different concentrations of radioligand from 0.5 to 20 
nM for 120 min of incubation. Non-specific binding was determined at three concentrations 
of radioligand with 10 μM BMS22. Displacement assays were carried out with 3.5 nM 
[3H]-INCB3344 using 10 concentrations of competing ligand for 120 min of incubation. In 
dissociation experiments the membranes were first incubated with 3.5 nM [3H]-INCB3344 for 
90 min. Dissociation was initiated by addition of 10 µM BMS22 in the absence or presence 
of modulator at different time points during 180 min. Homologous competition experiments 
with mutant receptors were performed with 3.5 nM [3H]-INCB3344 and increasing 
concentrations of unlabeled INCB3344 for an incubation time of 120 min. For assays with 
the mutant receptors and NaCl or HMA, a radioligand concentration of 6.0 nM was used. The 
assays were terminated as described before [8]. In all experiments, total radioligand binding 
did not exceed 10% of the amount added to prevent ligand depletion. 
[3H]-CCR2-RA-[R] binding assays. Assay conditions were similar as described for [3H]-
INCB3344 binding assays, unless otherwise stated. Saturation experiments were carried out 
using 12 different concentrations of radioligand from 0.1 to 75 nM for 120 min of incubation. 
Non-specific binding was determined at three concentrations of radioligand with 10 μM 
JNJ-27141491. Displacement assays were carried out with 7.0 nM [3H]-CCR2-RA-[R] using 
10 concentrations of competing ligand for 120 min of incubation. Kinetic experiments were 
performed at 15 °C. For dissociation experiments the membranes were first incubated with 
7.0 nM [3H]-CCR2-RA-[R] for 90 min. Dissociation was initiated upon addition of 10 µM of JNJ-
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27141491 in the absence or presence of modulator at different time points during 180 min. 
For displacement and dissociation assays non-specific binding was determined with 10 μM 
JNJ-27141491. Homologous competition experiments with mutant receptors were performed 
with 20 nM [3H]-CCR2-RA-[R] and increasing concentrations of unlabeled CCR2-RA-[R] for an 
incubation time of 120 min. Non-specific binding was determined with 10 μM CCR2-RA-[R]. 
For assays with the mutant receptors and NaCl or HMA, a radioligand concentration of 20 
nM was used. For measurements with HMA, nonspecific binding was determined for every 
data point with a combination of 10 µM CCR2-RA-[R] and 0.1 mM HMA. The assays were 
terminated as described before [8]. In all experiments, total radioligand binding did not 
exceed 10% of the amount added to prevent ligand depletion. 
125I-CCL2 dissociation assay. The assay was performed in a 100 µL reaction volume 
containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2 and 0.1% 3-((3-cholamidopropyl)-
dimethylammonio)-1-propanesulfonate (CHAPS). 15 μg of U2OS-CCR2 membrane protein 
was incubated with 0.1 nM 125I-CCL2 for 2 hrs at 37ºC. Subsequently, dissociation was initiated 
upon addition of 50 nM CCL2 in the absence or presence of modulator at different time points. 
Non-specific binding was determined with 10 μM INCB3344. The assay was terminated as 
described before [8]. Total radioligand binding did not exceed 10% of the amount added to 
prevent ligand depletion. 
Homology modeling and docking. A homology model of the chemokine CCR2 receptor was 
constructed using the homology modeling tool within Maestro [23-25]. This model was based 
on the structure of the chemokine CCR5 receptor co-crystalized with maraviroc (Protein Data 
Bank: 4MBS). The best model was selected based on the energy-based scoring function, the 
alignment between CCR2 and CCR5 was performed using ClustalW as implemented within 
Maestro. HMA was docked using the induced fit docking protocol [26, 27]. The grid center 
was placed based on residues D882.50, W2566.48 and H2977.45 with an automatic box size. 
Visualizations were created using PyMOL version 1.6.0.0. [28].
Data analysis. All experiments were analyzed using the non-linear regression curve fitting 
program Prism 5 (GraphPad, San Diego, CA, U.S.A.). The pIC50 values of HMA and MIBA were 
obtained by non-linear regression analysis of the displacement curves. The pKD, defined as –
log10KD, and Bmax values of [
3H]-INCB3344 and [3H]-CCR2-RA-[R] for WT CCR2 were obtained by 
computer analysis of saturation curves according to the equation bound = (Bmax*[L])/([L]+Kd) 
where Bmax is the maximal number of binding sites (pmol/mg) and KD is the concentration 
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of radioligand required to reach half-maximal binding. The pKD values of [
3H]-INCB3344 
and [3H]-CCR2-RA-[R] for mutant CCR2 receptors were calculated from homologous 
competition experiments using the Cheng-Prusoff equation, assuming that unlabeled and 
labeled INCB3344 had identical affinities, and the same for unlabeled and labeled CCR2-
RA-[R] [29]. The dissociation rate constant (koff) was obtained by computer analysis of the 
exponential decay of radioligand binding to the receptor. [3H]-INCB3344 experiments were 
fitted according to monophasic equations. Dissociation of [3H]-CCR2-RA-[R] occurred in a 
biphasic manner. Binding data from 125I-CCL2 dissociation kinetic experiments were fitted 
assuming monophasic or biphasic dissociation curves. By the F-test, a significant better fit 
for biphasic dissociation was found for curves with addition of HMA and NaCl. Data shown 
are the mean ± S.E.M. of at least 3 separate experiments performed in duplicate. Statistical 
analysis was performed with a two-tailed unpaired Student’s t-test.
Results
Antagonist equilibrium binding assays. To determine if CCR2 was susceptible to modulation 
by amiloride analogues (Fig. 1) and sodium ions, we performed equilibrium binding studies 
with the radiolabeled orthosteric antagonist [3H]-INCB3344 and allosteric antagonist [3H]-
CCR2-RA-[R]. 
Addition of 0.1 mM amiloride, benzamil, phenamil or MGCMA did not result in any 
radioligand displacement (data not shown). Differently, [3H]-INCB3344 was displaced by 
HMA and MIBA with a pIC50 of 4.1 ± 0.1 and 3.8 ± 0.0, respectively (Fig. 2A+B). The allosteric 
radioligand [3H]-CCR2-RA-[R] was also displaced by both HMA and MIBA with a pIC50 of 4.1 
± 0.1 and 3.9 ± 0.0 (Fig. 2A+B). These data indicate that CCR2 possesses a binding pocket 
for amiloride analogues, among which HMA binds with the highest affinity. In addition, the 
hill slopes of the curves deviated from unity, being -1.9 ± 0.1 (HMA) and -1.9 ± 0.5 (MIBA) for 
displacement of [3H]-INCB3344, and -2.1 ± 0.1 (HMA) and -2.0 ± 0.3 (MIBA) for displacement 
of [3H]-CCR2-RA-[R] (Table 1). This suggests that HMA and MIBA bind to CCR2 in an allosteric 
manner with respect to both antagonist radioligands. 
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Fig. 1. Chemical structures of amiloride and the amiloride analogues HMA, MIBA, benzamil, phenamil 
and MGCMA.
Fig. 2. Displacement of the orthosteric antagonist [3H]-INCB3344 and the allosteric antagonist [3H]-
CCR2-RA-[R] from CHO cell membranes transiently expressing CCR2, upon addition of increasing 
concentrations of the amiloride analogues HMA (A) or MIBA (B). Results are presented as percentage of 
bound radioligand for one representative experiment performed in duplicate.
Table 1. Displacement of [3H]-INCB3344 and [3H]-CCR2-RA-[R] by HMA and MIBA from CHO cell 
membranes transiently expressing CCR2.
orthosteric [3H]-INCB3344 allosteric [3H]-CCR2-RA-[R]
amiloride analogue HMA MIBA HMA MIBA
pIC50 ± S.E.M. 4.1 ± 0.1 3.8 ± 0.0 4.1 ± 0.1 3.9 ± 0.0
hill slope -1.9 ± 0.1 -1.9 ± 0.5 -2.1 ± 0.1 -2.0 ± 0.3
Data presented as pIC50 (mean ± S.E.M.) of three independent experiments performed in duplicate.
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Besides the amiloride analogues, we also included sodium ions in the antagonist 
radioligand binding studies. Interestingly, high concentrations of NaCl significantly enhanced 
binding of the allosteric antagonist [3H]-CCR2-RA-[R] up to 131 ± 7 % at 1 M, whereas binding 
of the orthosteric antagonist [3H]-INCB3344 was not affected (Fig. 3A). To further investigate 
if the enhanced binding of [3H]-CCR2-RA-[R] was the result of CCR2 modulation by the 
sodium cation or rather the chloride anion, we performed similar binding experiments in the 
presence of 1 M LiCl or KCl. LiCl significantly enhanced binding of [3H]-CCR2-RA-[R] up to 169 
± 16 %, whereas [3H]-CCR2-RA-[R] binding in the presence of 1 M KCl was not affected (Fig. 
3B). 
Fig. 3. (A) Modulation of binding of the orthosteric antagonist [3H]-INCB3344 and the allosteric antagonist 
[3H]-CCR2-RA-[R] to CHO cell membranes transiently expressing CCR2 by increasing concentrations of 
NaCl. Results are presented as percentage of bound radioligand for one representative experiment 
performed in duplicate. (B) Modulation of binding of the allosteric antagonist [3H]-CCR2-RA-[R] by 1 M 
LiCl, NaCl or KCl. Results are presented as mean ± S.E.M. for at least three independent experiments 
performed in triplicate. * p < 0.05 vs. control, ** p < 0.005 vs. control, Student’s t-test.
Antagonist radioligand dissociation assays. Since the equilibrium binding studies indicated 
allosteric interactions of the amiloride analogues and sodium ions with respect to one or both 
of the antagonist radioligands, we continued with kinetic binding studies to further explore 
their mode of action. For both radioligands [3H]-INCB3344 and [3H]-CCR2-RA-[R], dissociation 
was initiated by the addition of excess competing unlabeled ligand in the presence and 
absence of the most potent amiloride analogue HMA and a physiological concentration (150 
mM) of sodium ions. In the presence of 0.1 mM HMA the dissociation rate of the orthosteric 
antagonist [3H]-INCB3344 was 0.030 ± 0.001 min-1, which was significantly faster than 0.024 
± 0.002 min-1 in the control situation (Fig. 4A, Table 2). [3H]-CCR2-RA-[R] dissociated in a 
biphasic manner from the receptor, with the fast phase accounting for 48% of the dissociation 
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(Table 2). In the presence of 0.1 mM HMA we observed an increased, albeit not significant (p 
= 0.13), fast phase dissociation rate of 0.27 ± 0.09 min-1 compared to 0.10 ± 0.03 min-1 in the 
control situation (Fig. 4B, Table 2). The percentage of fast phase dissociation was not affected 
in the presence of HMA, nor was kslow. These data suggest noncompetitive interactions of 
HMA with respect to both radioligands. On the other hand, addition of 150 mM NaCl did not 
significantly affect the dissociation rate of either one of the antagonist radioligands (Fig. 4, 
Table 2).
Fig. 4. Dissociation of the antagonist radioligands from CHO cell membranes transiently expressing 
CCR2. (A) Dissociation of [3H]-INCB3344 was initiated upon addition of 10 μM competing ligand BMS22 
in the presence and absence of 0.1 mM HMA or 150 mM NaCl at various time points. (B) Dissociation 
of [3H]-CCR2-RA-[R] was initiated upon addition of 10 μM competing ligand JNJ-27141491 in the 
presence and absence of 0.1 mM HMA or 150 mM NaCl at various time points. Results are presented as 
percentage of bound radioligand for one representative experiment performed in duplicate.
Table 2. Dissociation rate of [3H]-INCB3344 and [3H]-CCR2-RA-[R] from CHO cell membranes transiently 
expressing CCR2 in the presence and absence of NaCl and HMA.
orthosteric [3H]-INCB3344 allosteric [3H]-CCR2-RA-[R]
control
+ 150 mM 
NaCl
+ 0.1 mM 
HMA
control
+ 150 mM 
NaCl
+ 0.1 mM 
HMA
kfast (min
-1) 0.024 ± 0.002 0.025 ± 0.001 0.030 ± 0.001* 0.10 ± 0.03 0.16 ± 0.07 0.27 ± 0.09
kslow (min
-1) n.a. n.a. n.a. 0.022 ± 0.005 0.030 ± 0.005 0.030 ± 0.009
% fast 100 100 100 48 ± 6 43 ± 9 50 ± 12
Data presented as mean ± S.E.M. of three independent experiments performed in duplicate.
n.a., not applicable
* p< 0.05 vs. control, Student’s t-test.
Antagonist saturation binding assays. To confirm the observed noncompetitive effects 
of HMA in the dissociation studies, we performed saturation binding experiments of [3H]-
INCB3344 and [3H]-CCR2-RA-[R] in the presence and absence of 80 µM HMA. As a control 
we added unlabeled INCB3344 or CCR2-RA-[R]. Addition of HMA significantly decreased 
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the Bmax of the orthosteric antagonist [
3H]-INCB3344, from 11 ± 1 pmol/mg in the control 
situation to 7.9 ± 0.6 pmol/mg in the presence of HMA (Fig. 5A and Table 3). The pKD of 8.7 
± 0.0 was decreased to 8.5 ± 0.1 in the presence of HMA. The decrease in Bmax suggests a 
noncompetitive interaction of HMA and INCB3344, whereas the small but significant decrease 
in the affinity of [3H]-INCB3344 would reflect a competitive interaction. Differently, the Bmax of 
[3H]-INCB3344 was not affected in the presence of INCB3344, whereas its pKD was decreased 
to 8.3 ± 0.0 (Fig. 5A and Table 3), both in agreement with a competitive mode of interaction.
The Bmax for [
3H]-CCR2-RA-[R] of 10 ± 0.4 pmol/mg was decreased to 7.8 ± 0.9 pmol/mg in 
the presence of HMA (Fig. 5B, Table 3). In addition, the pKD of 8.1 ± 0.1 of [
3H]-CCR2-RA-[R] 
was not significantly changed by HMA, which suggests a purely noncompetitive mode of 
interaction. In the presence of CCR2-RA-[R] the Bmax of [
3H]-CCR2-RA-[R] was not affected, 
whereas its pKD was decreased to 7.6 ± 0.1 (Fig. 5B and Table 3). These data are in agreement 
with a competitive mode of interaction.
Fig. 5. Saturation binding of the antagonist radioligands to CHO cell membranes transiently expressing 
CCR2. (A) Binding of the orthosteric antagonist [3H]-INCB3344 in the presence and absence of 6.0 nM 
INCB3344 or 80 µM HMA. (B) Binding of allosteric antagonist [3H]-CCR2-RA-[R] from CHO membranes 
transiently expressing CCR2 in the presence and absence of 6.0 nM CCR2-RA-[R] or 80 µM HMA. Results 
are presented as amount of bound radioligand in pmol/mg protein of one representative experiment 
performed in duplicate.
Table 3. Saturation binding of [3H]-INCB3344 and [3H]-CCR2-RA-[R] to CHO cell membranes transiently 
expressing CCR2 in the presence and absence of HMA or competing unlabeled ligand.
orthosteric [3H]-INCB3344 allosteric [3H]-CCR2-RA-[R]
control + 6.0 nM INCB3344
+ 80 µM 
HMA control
+ 18 nM CCR2-
RA-[R]
+ 80 µM 
HMA
B
max (pmol/mg) 11 ± 0.7 11 ± 0.8 7.9 ± 0.6* 10 ± 0.4 11 ± 0.7 7.8 ± 0.9*
pKD 8.7 ± 0.0 8.3 ± 0.0** 8.5 ± 0.1* 8.1 ± 0.1 7.6 ± 0.1* 7.8 ± 0.2
Data presented as mean ± S.E.M. of three independent experiments performed in duplicate.
* p< 0.05 vs. control, Student’s t-test.
** p< 0.005 vs. control, Student’s t-test.
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Agonist modulation by HMA and NaCl. Besides the modulation of antagonist binding, we 
also determined the effect of HMA and NaCl on the dissociation of the agonist radioligand 
125I-CCL2. These assays were performed with membrane preparations of U2OS cells stably 
expressing CCR2, since the non-specific binding of 125I-CCL2 to these membranes was 
substantially lower compared to that for membranes of CHO cells transfected with CCR2. 
Dissociation of 125I-CCL2 was initiated by an excess of CCL2 in the presence and absence of 
0.1 mM HMA or 150 mM NaCl. The dissociation in the control situation was monophasic with 
a rate of 0.030 ± 0.002 min-1, whereas in the presence of HMA or NaCl a biphasic dissociation 
pattern was observed (Fig. 6 and Table 4). Although the dissociation rates could therefore not 
be directly compared, enhanced 125I-CCL2 dissociation was observed in both cases compared 
to the control situation (Fig. 6 and Table 4). These data show that the endogenous chemokine 
ligand is allosterically modulated by HMA and NaCl. Notably, physiological NaCl concentrations 
apparently increased the dissociation rate of 125I-CCL2, whereas the dissociation rate of the 
antagonist radioligands at this concentration of NaCl was not affected. 
Fig. 6. Dissociation of agonist radioligand 125I-CCL2 from U2OS membranes stably expressing CCR2. 
Dissociation was initiated upon addition of 50 nM CCL2 in the presence or absence of 0.1 mM HMA or 
150 mM NaCl at different time points. Results are presented as percentage of bound radioligand for one 
representative experiment performed in duplicate.
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Table 4. Dissociation rates of 125I-CCL2 from U2OS cell membranes stably expressing CCR2 in the 
presence and absence of NaCl and HMA.
control + 150 mM NaCl + 0.1 mM HMA
kfast (min
-1) 0.030 ± 0.002 0.21 ± 0.01 0.29 ± 0.03
kslow (min
-1) n.a. 0.025 ± 0.001 0.010 ± 0.003
% fast 100 46 ± 7 86 ± 2
Data presented as mean ± S.E.M. of three independent experiments performed in duplicate.
n.a., not applicable
The effect of mutations in the core TM domain on antagonist binding. In the radioligand 
binding studies presented above we observed allosteric modulation of 125I-CCL2, [3H]-
INCB3344 and [3H]-CCR2-RA-[R] by HMA, and allosteric modulation of 125I-CCL2 and [3H]-
CCR2-RA-[R] by sodium ions. This suggests that HMA and sodium ions bind to a site other 
than the orthosteric binding site in the TM domain and distinct from the allosteric binding 
site at the intracellular side of the receptor. To elucidate the location of this additional binding 
site, we mutated three residues in the core region of the TM domain, D882.50, W2566.48 and 
H2977.45. 
By means of whole cell ELISA we measured the expression of the mutant receptors. Cell 
surface expression of D88A2.50, W256A6.48 and H297A7.45 was 46 %, 19 % and 14 % compared 
to wild type CCR2 (Fig. 7), suggesting that mutations in the core domain affected the stability 
of the receptor and/or its transport to the cell membrane. Nevertheless, with sufficient 
amounts of membrane protein and radioligand we were able to measure the affinity of 
[3H]-INCB3344 and [3H]-CCR2-RA-[R] in homologous displacement assays. Binding of [3H]-
INCB3344 to W256A6.48 could not be detected, whereas the pKD for D88A
2.50 and H297A7.45 was 
8.5 ± 0.3 and 8.6 ± 0.1 with a Bmax of 1.8 ± 0.7 pmol/mg and 0.49 ± 0.17 pmol/mg, respectively 
(Table 5). The affinity of [3H]-INCB3344 for these two mutant receptors was therefore similar 
to the pKD of 8.7 ± 0.0 for WT CCR2. The intracellular antagonist [
3H]-CCR2-RA-[R] was able 
to bind to all mutant receptors, with a pKD of 7.3 ± 0.2, 6.7 ± 0.1 and 6.8 ± 0.1 for D88A
2.50, 
W256A6.48 and H297A7.45 (Table 5). Compared to the pKD of 8.1 ± 0.1 for WT CCR2, the affinity 
of [3H]-CCR2-RA-[R] for all three mutant receptors was substantially decreased. The Bmax of 
[3H]-CCR2-RA-[R] for the D88A2.50, W256A6.48 and H297A7.45 mutant receptors was 2.0 ± 0.6 
pmol/mg, 2.8 ± 0.5 pmol/mg and 3.1 ± 0.5 pmol/mg, respectively (Table 5).
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Fig. 7. Surface expression of the HA-tagged WT and mutant CCR2 receptors in CHO cells as measured by 
ELISA. Data was normalized for WT CCR2 expression (100%) and is presented as mean ± SD of at least 
two experiments performed in quadruplicate. 
Table 5. The affinity (pKD) and maximum number of binding sites (Bmax) of [
3H]-INCB3344 and [3H]-CCR2-
RA-[R] for three mutant CCR2 receptors that were transiently expressed on CHO cell membranes. Values 
were determined from homologous competition experiments with the unlabeled ligands INCB3344 and 
CCR2-RA-[R], respectively. 
orthosteric [3H]-INCB3344 allosteric [3H]-CCR2-RA-[R]
construct pKD Bmax (pmol/mg) pKD Bmax (pmol/mg)
D88A2.50 8.5 ± 0.3 1.8 ± 0.7 7.3 ± 0.2 2.0 ± 0.6
W256A6.48 no binding 6.7 ± 0.1 2.8 ± 0.5
H297A7.45 8.6 ± 0.1 0.49 ± 0.17 6.8 ± 0.1 3.1 ± 0.5
Data presented as mean ± S.E.M. of three independent experiments performed in duplicate.
The effect of mutations in the core TM domain on modulation by HMA and sodium ions. 
Antagonist radioligand binding was measured for WT CCR2 as well as for the mutant receptors 
D88A2.50, W256A6.48 and H297A7.45 upon addition of 1 M NaCl or 0.1 mM HMA. The results of 
these experiments will be discussed per mutant in this section. 
For D88A2.50, the percentage of [3H]-INCB3344 binding in the presence of 0.1 mM HMA 
increased to 34 ± 6 % compared to 20 ± 2 % for WT CCR2 (Fig. 8A). Similarly, the percentage 
of [3H]-CCR2-RA-[R] binding to D88A2.50 in presence of 0.1 mM HMA increased to 62 ± 5 % 
compared to 18 ± 2 % for WT CCR2 (Fig. 8B), indicating that the ability of HMA to displace 
both antagonists decreased upon mutation of D882.50. Addition of 1 M NaCl did not affect 
[3H]-INCB3344 binding to WT CCR2, neither was a significant change observed for D88A2.50 
(Fig. 8A). However, enhanced binding of [3H]-CCR2-RA-[R] was observed for WT CCR2 in the 
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presence of 1 M NaCl, to a percentage of 133 ± 5, which was reduced to 96 ± 4 % upon 
introduction of D88A2.50 (Fig. 8B). These results indicate that D882.50 is involved in sodium ion 
binding in CCR2. 
For W256A6.48 we did not measure any binding of [3H]-INCB3344, and therefore we 
solely used [3H]-CCR2-RA-[R] to study the effects of NaCl and HMA. No displacement of [3H]-
CCR2-RA-[R] was observed upon addition of 0.1 mM HMA (Fig. 8B), revealing a crucial role for 
W2566.48 in CCR2 modulation by HMA. In the presence of 1 M NaCl, binding of [3H]-CCR2-RA-
[R] was increased to 117 ± 8 %, although not significant with respect to the control situation 
(p = 0.1) (Fig. 8B). This indicates that W256A6.48 is important for the allosteric enhancement 
by sodium ions that was observed for the WT receptor. 
For H297A7.45, the percentage of [3H]-INCB3344 and [3H]-CCR2-RA-[R] binding compared 
to WT in the presence of 0.1 mM HMA significantly increased to 30 ± 5 % and 82 ± 7 %, 
respectively (Fig. 8A+B). In addition, the ability of sodium ions to enhance [3H]-CCR2-RA-[R] 
binding was completely abolished since only 82 ± 6 % of radioligand binding was measured 
compared to 133 ± 5 % for the WT receptor (Fig. 8B). These data indicate that the ability of 
both HMA and sodium ions to modulate CCR2 decreased upon mutation of H2977.45.
Fig. 8. Equilibrium binding of the orthosteric antagonist [3H]-INCB3344 (A) and the allosteric antagonist 
[3H]-CCR2-RA-[R] (B) in the presence and absence of 1 M NaCl or 0.1 mM HMA. For these experiments 
CHO cell membranes transiently expressing WT or mutant CCR2 were used. Data are presented as mean 
± S.E.M of the percentage of bound radioligand of at least three independent experiments performed in 
triplicate. * p < 0.05 vs. WT, ** p < 0.01 vs. control, *** p < 0.01 vs. WT, Student’s t-test.
Docking of HMA in a CCR2 homology model. We constructed a CCR2 homology model 
using the crystal structure of CCR5 (PDB: 4MBS), and performed docking of HMA therein. 
The positively charged guanidinium group of HMA was docked towards the bottom of the 
binding pocket where it formed ionic interactions with the negatively charged D882.50 (Fig. 
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9A+B). For W2566.48, a hydrogen bonding interaction with the oxygen of HMA (Fig. 9A) as 
well as π-stacking interactions with the pyrimidine core (Fig. 9B) was predicted. Yet another 
interaction, between H2977.45 and the oxygen of HMA, is visualized in the docking pose as well 






Fig. 9. (A) Induced fit docking of HMA in a homology model of CCR2 based on the crystal structure of 
CCR5. An ionic interaction between D882.50 and the guanidinium group of HMA and between H2977.45 
and the oxygen of HMA is illustrated, as well as a hydrogen bonding interaction of W2566.48 and the 
oxygen of HMA. (B) The 2D interaction map that illustrates an additional π-stacking interaction between 
W2566.48 and the pyrimidine core of HMA, as well as all surrounding residues. 
Discussion
Modulation of GPCRs by sodium ions and amiloride analogues has been described for a 
number of class A GPCRs, including adrenergic receptors [30], adenosine receptors [10, 12], 
dopamine receptors [9] and opioid receptors [11]. This ubiquitous amount of data among 
various GPCRs suggests interactions with a very conserved site, providing evidence for 
a common allosteric mechanism [31]. With the present study we add the first chemokine 
receptor, CCR2, to the list of GPCRs that are modulated by amiloride analogues and sodium 
ions. For CCR2 two distinct small molecule binding pockets have previously been identified 
[8], of which one is located at the upper half of the TM domain, whereas as the other pocket 
resides at the intracellular side of the receptor (Chapter 4). Here we provide evidence for 
modulation of CCR2 by the amiloride analogue HMA and sodium ions via yet another site, 
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suggesting that CCR2 comprises three distinct small molecule binding pockets. Moreover, 
by means of the intracellular radioligand [3H]-CCR2-RA-[R] as a unique tool compound, we 
were able to study the influence at the intracellular side of the receptor induced by HMA and 
sodium ions.
In radioligand binding assays we observed allosteric modulation of 125I-CCL2 and [3H]-
CCR2-RA-[R] by sodium ions. We measured increased binding of the intracellular antagonist 
[3H]-CCR2-RA-[R] at a high concentration of 1 M NaCl. To address the question whether 
sodium or chloride ions are responsible for this effect, we also examined the effects of equal 
concentrations of LiCl and KCl. Their differential effects strongly pointed to the involvement 
of monovalent cations rather than (chloride) anions. Lithium ions, which have a smaller 
diameter than sodium ions, even further enhanced [3H]-CCR2-RA-[R] binding, while the 
larger potassium ions did not modulate antagonist binding at all. These data suggest that the 
size of the cations that are able to modulate CCR2 antagonist binding is restricted to the 116 
pm diameter of sodium. A physiologically relevant NaCl concentration of 150 mM did not 
affect binding of [3H]-CCR2-RA-[R], but increased the dissociation rate of 125I-CCL2. This latter 
finding is in line with data for other GPCRs indicating that sodium ions stabilize the inactive 
state of the receptor and decreases the affinity of agonists [12, 32-34]. While this is the 
first study to report the effect of sodium ions on an intracellular GPCR antagonist, allosteric 
enhancement of orthosteric antagonists by NaCl has previously been described for among 
others dopamine, adenosine and α2-adrenergic receptors [9, 10, 33, 34]. Interestingly, in 
our study the binding of the orthosteric antagonist INCB3344 was not modulated by NaCl. It 
should be noted that all orthosteric GPCR antagonists for which binding was previously found 
to be enhanced by NaCl, behaved as inverse agonists. Therefore enhancement by NaCl, which 
stabilizes the inactive state of the receptor, is compliant with their mechanism of action. For 
INCB3344 no such inverse agonism has been detected [8, 35], which could explain the lack 
of effect of NaCl. 
Previous studies have shown that amiloride and its analogues bind to the same binding 
pocket as sodium ions [12, 36]. They are known to decrease agonist binding, and in contrast 
to sodium ions, they also decrease antagonist binding [10, 34, 36]. For CCR2 we discovered 
that the amiloride analogues HMA and MIBA displaced the orthosteric antagonist [3H]-
INCB3344 as well as the intracellular antagonist [3H]-CCR2-RA-[R] with similar potencies. In 
kinetic experiments in the presence of HMA we observed increased dissociation rates for both 
antagonist radioligands as well as for the radiolabeled agonist 125I-CCL2. Saturation binding 
experiments in the presence of HMA revealed characteristics of a noncompetitive ligand with 
respect to the allosteric antagonist [3H]-CCR2-RA-[R] and mixed effects with respect to the 
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orthosteric antagonist [3H]-INCB3344. All these results together strongly indicate allosteric 
modulation of CCR2 by HMA, acting via yet another allosteric binding pocket for small 
molecules on CCR2. The mixed effect in the saturation binding assay with [3H]-INCB3344 could 
indicate that the binding site of HMA and INCB3344 are partially overlapping. Nevertheless, 
whereas INCB3344 enhanced binding of [3H]-CCR2-RA-[R] [8], HMA completely displaced 
this radioligand from CCR2. Although HMA and INCB3344 most likely bind in close proximity, 
these two ligands clearly induce distinct conformational changes of CCR2.
Several highly conserved amino acid residues in class A non-olfactory GPCRs have been 
reported to be involved in sodium ion and/or HMA binding, including D2.50 (92% conserved), 
W6.48 (78% conserved) and N7.45 (63% conserved) [11-14]. CCR2 contains the residues D882.50 
and W2566.48, but at position 7.45 a histidine is present instead of an asparagine. H7.45 is highly 
conserved among chemokine receptors (87%), but otherwise not prevalent in class A GPCRs 
(10%) (GMOS web interface. http://lmc.uab.cat/gmos/, accessed on 25-02-2014). In our 
studies, mutation of W256A6.48 completely prevented [3H]-INCB3344 from binding, whereas 
its affinity for D88A2.50 and H297A7.45 was only slightly decreased. Since W6.48 is located at the 
top of the sodium binding pocket [11, 12] (Fig. 9A) and was previously found to interact with 
the CCR5 antagonist maraviroc [37], this residue in CCR2 could be an interaction partner 
for INCB3344. Binding studies with the intracellular radioligand [3H]-CCR2-RA-[R] revealed 
dramatic conformational changes of the intracellular region of the receptor by mutations 
in the sodium binding pocket, since the affinity of CCR2-RA-[R] for all mutant receptors was 
drastically decreased compared to WT CCR2. D2.50 and W6.48 are known to be critical residues 
for the conformational changes at the intracellular side between inactive and active states of 
a GPCR. Both residues were predicted to participate in a water-mediated hydrogen-bonding 
network with other residues that include N7.49 and Y7.53 of the NPxxY motif at the bottom of 
TM-VII [38, 39]. 
Since we were able to measure binding of at least one of the antagonist radioligands 
for all three mutant receptors, we examined the effect of these residues on modulation of 
CCR2 by sodium ions and HMA. D882.50 revealed a critical role for modulation by sodium ions, 
as enhancement of the intracellular radioligand [3H]-CCR2-RA-[R] was completely abolished 
for the D88A2.50 mutant receptor. Recent high-resolution crystal structures of the δ-OR, A2AAR 
and PAR1 confirm the central role of D2.50 in the coordination of the sodium ion [11-13]. Our 
findings suggest that such a sodium ion binding site is present in CCR2 as well. Mutation 
of W2566.48 into alanine also partially reduced the enhanced [3H]-CCR2-RA-[R] binding upon 
addition of NaCl, indicating that W6.48 is involved in the formation of the sodium binding pocket 
of CCR2. In the crystal structures of the A2AAR and the δ-OR, hydrogen bonding interactions 
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between W6.48 and water molecules surrounding the sodium pocket were identified [11, 
12], but the exact role of W6.48 in antagonist modulation by sodium ions in these receptors 
remains to be deciphered. Additionally we found that H2977.45 was necessary for the sodium 
ion to enhance binding of [3H]-CCR2-RA-[R]. This residue is therefore likely to play a similar 
role as the conserved N7.45 in the majority of other GPCRs in the creation of the binding pocket 
for the sodium ion [11, 12]. 
Mutation of W2566.48 completely prevented CCR2 modulation by 0.1 mM HMA, whereas 
D88A2.50 and H297A7.45 still allowed HMA to displace both antagonist radioligands, although 
to a lesser extent as for WT CCR2. The important role of W6.48 is in agreement with a study 
of the A2AAR in which extensive steric interactions between W
6.48 and HMA were predicted 
upon induced fit docking [14]. However, the observed decrease in the potency of HMA to 
displace the CCR2 antagonists is opposite to a 4-fold increase in affinity that was previously 
found for the A3 adenosine receptor (A3AR) upon mutation of W
6.48 into alanine [34]. Although 
this binding pocket is highly conserved among class A GPCRs, small modifications due to a 
few differential residues might lead to distinct positioning of HMA in this pocket. From the 
15 conserved GPCR residues that are lining the sodium ion binding pocket in inactive GPCR 
crystal structures [14], 6 are different for CCR2, including S872.49, G1273.39, I1313.43, Y2526.44, 
H2977.45, C2987.46. Except for I1313.43, all these residues were predicted to be in close proximity 
of HMA in CCR2 (Fig. 9B), which could therefore be a reason for the observed differences in 
HMA and sodium ion modulation of CCR2 compared to other GPCRs. 
In agreement with radioligand binding studies, molecular docking of HMA in the 
homology model of CCR2 revealed direct ionic and hydrogen bonding interactions with 
D882.50 and H2977.45. In addition, hydrogen bonding as well as π-stacking interactions between 
HMA and W2566.48 were predicted. The lack of affinity that was observed in the radioligand 
binding assays for amiloride and its analogues phenamil, benzamil and MGCMA further 
supports this docking pose of HMA in our model. The phenyl ring of benzamil and phenamil 
that is attached to the guanidinium group would cause steric hindrance, and interference 
with the ionic interactions between HMA and D2.50. In addition, at the top of the binding 
pocket the hydrophobic hexamethylene group of HMA and the N-methyl-N-isobutyl group of 
MIBA seem to be involved in crucial hydrophobic interaction, since the lack of such a group 
in amiloride and the presence of a positively charged substituent in MGCMA prevented these 
ligands from binding. 
In summary we have revealed that CCR2 is modulated by amiloride analogues as well 
as sodium ions, which is mediated via a third small molecule binding pocket in the core of 
the TM domain. Due to its close proximity to the orthosteric binding pocket, this finding 
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could potentially lead to the development of bitopic ligands binding to both sites. These 
ligands might have distinct pharmacological properties since they target a domain that is so 
important for conformational rearrangements of the entire receptor. Our findings provide 
further understanding of sodium ion and HMA modulation, via a highly conserved site, and 
offer novel opportunities for targeting CCR2 and GPCRs in general.
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Abstract
Preclinical models of inflammatory diseases (e.g., neuropathic pain, rheumatoid arthritis, and 
multiple sclerosis) have pointed to a critical role of the chemokine receptor 2 (CCR2) and 
chemokine ligand 2 (CCL2). However, one of the biggest problems of high-affinity inhibitors 
of CCR2 is their lack of efficacy in clinical trials. We report a new approach for the design of 
high-affinity and long-residence-time CCR2 antagonists. We developed a new competition 
association assay for CCR2, which allows us to investigate the relation of the structure of 
the ligand and its receptor residence time (i.e., structure–kinetic relationship (SKR)) next to 
a traditional structure–affinity relationship (SAR). By applying combined knowledge of SAR 
and SKR, we were able to re-evaluate the hit-to-lead process of cyclopentylamines as CCR2 
antagonists. Affinity-based optimization yielded compound 1 with good binding (Ki = 6.8 nM) 
but very short residence time (2.4 min). However, when the optimization was also based 
on residence time, the hit-to-lead process yielded compound 22a, a new high-affinity CCR2 
antagonist (3.6 nM), with a residence time of 135 min.
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Introduction
Chemokines are a class of chemoattractant cytokines, and their main action is to control 
the trafficking and activation of leukocytes and other cell types for a range of inflammatory 
and non-inflammatory conditions. One of these, monocyte chemotactic protein-1 (MCP-1/
chemokine ligand 2 (CCL2)), acts on monocytes, memory T cells, and basophils [1]. It creates a 
chemotactic gradient and activates the movement of immune cells to the site of inflammation 
by binding to its cell-surface receptor, chemokine receptor 2 (CCR2) [2]. This CCL2/CCR2 pair is 
overexpressed in several inflammatory conditions, in which excessive monocyte recruitment 
is observed. CCR2 and CCL2 knockout mice and CCR2 or CCL2 antibody-treated rodents show 
decreased recruitment of monocytes and produce considerably decreased inflammatory 
responses [3]. This indicates CCR2 as a potential target for the treatment of several immune-
based inflammatory diseases and conditions, such as multiple sclerosis [4], atherosclerosis 
[5], rheumatoid arthritis [6], diabetes [7], asthma [8], and neuropathic pain [9]. 
In the past decade, there has been an increasing interest in the development of small-
molecule antagonists of the CCR2 receptor, resulting in the disclosure of many different 
chemical classes. However, there are still no selective CCR2 antagonists on the market for the 
treatment of inflammatory diseases. Clinical trials, thus far, have failed mostly because of the 
lack of efficacy, including the one for the CCR2 antagonist MK-0812 (Fig. 1) [10]. 
Fig. 1. CCR2 antagonist MK-0812
It has been suggested that binding kinetics, especially the lifetime of the ligand–
receptor complex, can be used as a predictor for drug efficacy and safety [11, 12]. The 
concept of binding kinetics is often overlooked in the early phase of drug discovery; however, 
incorporation of this parameter could help to decrease the attrition rate in later stages of 
drug development [13]. In this concept of kinetics, an additional pharmacological parameter, 
the ligand–receptor residence time (RT; the reciprocal of the dissociation rate constant koff), is 
defined [14], which is a measure for the duration that a ligand is bound to its target. 
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In this study, we first evaluated several reference CCR2 antagonists using a recently 
developed competition association assay for CCR2 that yielded the respective association 
and dissociation rate constants. As our starting point, we chose compound 1, which was also 
the lead compound in the process that led to the development of MK-0812 by the Merck 
group [10]. The determination of the binding kinetics of several known structures with this 
particular scaffold subsequently allowed us to generate a new series of high-affinity and long-
residence-time CCR2 antagonists based on structure 2, which was previously abandoned by 
other groups in optimization steps because of its modest binding affinity (Fig. 2) [15]. 
Fig. 2. RT and affinity values are both pharmacological parameters that may, however, suggest different 
lead structures.
Materials and Methods 
Chemistry 
Chemicals and reagents. All solvents and reagents were purchased from commercial sources 
and were of analytical grade. Demineralized water is simply referred to as H2O, because 
it was used in all cases, unless stated otherwise (i.e., brine). 1H and 13C nuclear magnetic 
resonance (NMR) spectra were recorded on a Bruker AV 400 liquid spectrometer (1H NMR, 
400 MHz; 13C NMR, 100 MHz) or using a Bruker 500 MHz Avance III NMR spectrometer 
(compounds 22a and 22b) at ambient temperature. Chemical shifts are reported in 
parts per million (ppm), are designated by δ, and are downfield to the internal standard 
tetramethylsilane (TMS). Coupling constants are reported in hertz and are designated 
as J. Analytical purity of the final compounds was determined by high-performance liquid 
chromatography (HPLC) with a Phenomenex Gemini 3 μm C18 110A column (50 × 4.6 mm, 
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3 μm), measuring UV absorbance at 254 nm. The sample preparation and HPLC method for 
compounds 1, 2, 7–9, and 11, 12 were as follows: 0.3–0.8 mg of compound was dissolved in 
1 mL of a 1:1:1 mixture of CH3CN/H2O/t-BuOH and eluted from the column within 15 min at 
a flow rate of 1.0 mL. The elution method was set up as follows: 1–4 min isocratic system of 
H2O/CH3CN/1% TFA in H2O, 80:10:10; from the 4th min, a gradient was applied from 80:10:10 
to 0:90:10 within 9 min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. 
All compounds showed a single peak at the designated retention time and are at least 95% 
pure. High-resolution mass spectral analyses (HRMS) were performed on LTQ-Orbitrap FTMS 
operated in a positive ionization mode with an electrospray ionization (ESI) source, with 
the following conditions: mobile phase A, 0.1% formic acid in water; mobile phase B, 0.08% 
formic acid in CH3CN; gradient, 10–80% B in 26 min; and flow rate, 0.4 mL/min. Preparative 
HPLCs (for compounds 10 and 13–32) were performed on a Waters AutoPurification HPLC–
ultraviolet (UV) system with a diode array detector using a Luna C18 Phenomenex column 
(75 × 30 mm, 5 μm), and a linear gradient from 1 to 99% of mobile phase B was applied. 
Mobile phase A consisted of 5 mM HCl solution, and mobile phase B consisted of acetonitrile. 
The flow rate was 50 mL/min. Liquid chromatography–mass spectrometry (LC–MS) analyses 
were performed using an Onyx C18 monolithic column (50 × 4.6 mm, 5 μm), and a linear 
gradient from 1 to 99% mobile phase B was applied. Mobile phase A consisted of 0.05% TFA 
in water, and mobile phase B consisted of 0.035% TFA in acetonitrile. The flow rate was 12 
mL/min. Separations of enantiomers were accomplished using chiral SFC. The column was 
Phenomenex Lux-4 (250 × 10 mm, 5 μm). The mobile phase condition of 10% MeOH with 
20 mM NH3 and 90% CO2 was applied at a flow rate of 10.0 mL/min. Optical rotations were 
measured on a Perkin-Elmer polarimeter in CHCl3 at 20 °C. Thin-layer chromatography (TLC) 
was routinely consulted to monitor the progress of reactions, using aluminum-coated Merck 
silica gel F254 plates. Purification by column chromatography was achieved by use of Grace 
Davison Davisil silica column material (LC60A, 30–200 μm). The procedure for a series of 
similar compounds is given as a general procedure for all within that series, annotated by the 
numbers of the compounds.
(1S,3R)-methyl-3-((tert-butoxycarbonyl)amino)-1-isopropylcyclopentanecarboxylate 
(3). Synthesis of (1S,3R)-methyl-3-((tert-butoxycarbonyl)amino)-1-
isopropylcyclopentanecarboxylate (3) was achieved following the synthetic approach 
reported by Kothandaraman et al [15]. 
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(1S,3R)-3-(tert-Butoxycarbonylamino)-1-isopropylcyclopentanecarboxylic Acid (4). A 
solution of ester 3 (4.20 g, 14.72 mmol) in EtOH (30 mL) and 4 M aqueous lithium hydroxide 
(LiOH aqueous, 40 mL) was refluxed for 4 h. After concentration in vacuum, the solution was 
acidified with aqueous hydrochloric acid and extracted with DCM/H2O. The organic layer was 
dried over MgSO4 and, after concentration in vacuum, yielded the desired product as a yellow 
powder (3.62 g, 91%). 1H NMR (400 MHz, CDCl3) δ: 10.75 (s, 1H), 6.53
a (s, 0.5H), 5.05b (s, 
0.5H), 3.98 – 3.78 (m, 1H), 2.25 – 1.50 (m, 7H), 1.40 (d, J = 16.8 Hz, 9H), 0.86 (d, J = 6.8 Hz, 
6H); 13C NMR (100 MHz, CDCl3): δ 182.9
a, 181.7b, 157.6b, 155.6a, 80.4b, 79.1a, 56.9, 52.8b, 
51.7a, 38.6b, 38.2a, 35.0b, 34.5a, 33.2a, 32.9b, 32.1a, 31.8b, 28.3, 18.7, 18.2b, 18.0a. a and b are 
indicated for different rotamers.
tert-Butyl(3-((3,5-bis(trifluoromethyl)benzyl)carbamoyl)-3-isopropylcyclopentyl) 
Carbamate (5). Compound 4 (1.53 g, 5.65 mmol) was dissolved in 50 mL of DCM. To this 
mixture 3,5 bis(trifluoromethyl) benzylamine (1.89 g, 5.65 mmol) was added with DiPEA (2.95 
mL, 16.9 mmol), PyBrOP (2.64 g, 5.65 mmol), and DMAP (0.55 g, 4.5 mmol). The reaction 
mixture was stirred for 24 h at room temperature. The product was extracted with DCM/
citric acid solution in water and then with DCM/1 M NaOH. The organic layer was dried with 
MgSO4 and evaporated. The product was purified by column chromatography (0–100% ethyl 
acetate in DCM) to give the product as a yellow oil (2.33 g, 83%). 1H NMR (400 MHz, CDCl3) 
δ: 7.69 (s, 3H), 7.25 (br s, 1H), 5.17 (br.s, 1H), 4.51–4.49 (m, 2H), 3.81 (br s, 1H), 1.99–1.90 
(m, 4H), 1.69–1.72 (m, 2H), 1.50–1.58 (m, 1H), 1.36 (s, 9H), 0.74–0.77 (m, 6 H). 13C NMR (100 
MHz, CDCl3) δ: 178.6, 155.6, 142.1, 132.2, 131.8, 131.5, 131.2, 127.4, 127.3, 124.5, 121.8, 
121.0, 119.1, 78.9, 57.6, 51.6, 42.8, 36.3, 34.6, 33.3, 32.6, 28.2, 18.7, 17.5.
3-Amino-N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropylcyclopentanecarboxamide (6). 
Trifluoroacetic acid (20 mL) was added to a solution of compound 5 (2.33 g, 4.6 mmol) in 
50 mL of DCM. The reaction mixture was stirred for 1 h at room temperature. The reaction 
mixture was neutralized with 1 M NaOH and extracted with DCM. The organic layer was dried 
with MgSO4, filtered, and evaporated to give the product as a yellow crystal (1.55 g, 85%). 
1H 
NMR (400 MHz, CDCl3) δ: 9.16 (br s, 1H), 7.70–7.67 (m, 3H), 4.50–4.39 (m, 2H), 3.61–3.60 (m, 
1H), 2.22–2.15 (m, 1H), 2.02–1.95 (m, 1H), 1.85–1.64 (m, 3H), 1.42–1.37 (m, 2H), 0.82–0.80 
(m, 6H). 13C NMR (100 MHz, CDCl3) δ: 179.4, 142.5, 131.8, 131.5, 131.2, 130.9, 127.3, 127.2, 
124.6, 121.9, 120.4, 119.2, 57.3, 52.2, 42.4, 39.7, 35.3, 33.9, 33.6, 18.8, 16.9.
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General procedure for the synthesis of compounds 1, 2, and 11, 12. Amine 6 was dissolved 
in 4 mL of dichloroethane in a 5 mL reaction tube, and the corresponding ketone (1 equiv) 
was added. Sequentially, acetic acid (1 equiv) and sodium triacetoxyborohoydride (1.5 equiv) 
were added. The reaction mixture was stirred for 18 h at room temperature and then washed 
with 1 M NaOH and H2O. The organic layer was dried with MgSO4, filtered, and evaporated. 
The product was purified by column chromatography (0–100% ethyl acetate in DCM) to give 
the desired product.
(1S,3R)-N-(3,5-Bis(trifluoromethyl)benzyl)-1-isopropyl-3-((tetrahydro-2H-pyran-4-yl)
amino)cyclopentanecarboxamide (1). Yield = 21%. 1H NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 
7.76–7.73 (m, 3H), 4.56–4.53 (m, 2H), 3.98–3.89 (m, 2H), 3.57–3.53 (m, 1H), 3.43–3.28 (m, 
2H), 2.66–2.61 (m, 1H), 2.36–2.30 (m, 1H), 2.03–1.80 (m, 2H), 1.78–1.6 (m, 5H), 1.49–1.40 
(m, 1H), 1.31–1.20 (m, 3H), 0.93–0.89 (m, 6H). 13C NMR (400 MHz, CDCl3) δ: 179.1, 142.4, 
131.8, 131.54, 131.2, 130.9, 127.7, 127.3, 124.6, 121.8, 121.0, 119.2, 66.9, 66.9, 57.5, 54.8, 
51.9, 42.6, 37.1, 35.1, 34.3, 33.7, 33.6, 33.3, 19.5, 17.0. LC–MS: 481+; tR = 7.01 min.
(1S,3R)-N-(3,5-Bis(trifluoromethyl)benzyl)-3-((2,3-dihydro-1H-inden-1-yl)amino)-1-
isopropylcyclopentanecarboxamide (2). Yield = 25% (mixture of diastereomers). 1H NMR 
(400 MHz, CDCl3) δ: 9.48 (s, 1H), 7.76–7.74 (m, 3H), 7.22–7.05 (m, 4H), 4.60–4.50 (m, 2H), 
4.28–4.22 (m, 1H), 3.70–3.60 (m, 1H), 3.00–2.90 (m, 1H), 2.87–2.78 (m, 1H), 2.70–2.34 (m, 
3H), 2.1–1.53 (m, 6H), 0.93–0.89 (m, 6H). 13C NMR (400 MHz, CDCl3) δ: 179.4, 144.5, 144.4, 
144.6, 131.8, 131.5, 127.9, 127.6, 126.3, 126.2, 125.0, 123.5, 123.5, 122.0 121.9, 61.3, 58.0, 
56.6, 42.6, 37.2, 36.0, 34.5, 33.9, 33.7, 33.4, 19.6, 17.0. LC–MS: 513+; tR = 8.12 min.
General procedure for the synthesis of compounds 7–9. Amine 6 (1 equiv) was disolved in 
4 mL of acetonitrile, and coresponding alkylating agent (1.2 equiv) was added. Sequentually, 
DiPEA (1.2 equiv) was added. The reaction mixture was stirred in a microwave for 2 h at 
60 °C and purified with column chromatography (60% ethylacetate, 20% DCM, 20% petroleum 
ether, and 0–3% triethylamine in ethyl acetate).
(1S,3R)-3-(Benzylamino)-N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropylcyclopentane-1-
carboxamide (7). Yield = 27% (as HCl salt). 1H NMR (400 MHz, CDCl3) δ: 9.40 (br s, 1H), 7.73 
(s, 1H), 7.66 (s, 2H), 7.30–7.24 (m, 3H), 7.16–7.13 (m, 2H), 4.44 (d, J = 4.8 Hz, 2H), 3.73 (d, J = 
2.4 Hz, 2H), 3.46–3.41 (m, 1H), 2.41–2.33 (m, 1H), 2.02–1.90 (m, 4H), 1.85–1.78 (m, 2H), 
1.59–1.52 (m, 1H), 0.91 (dd, J1 = 10.8 Hz, J2 = 6.8 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ: 179.4, 
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142.6, 139.0, 132.0, 131.7, 131.3, 131.0, 128.6, 127.8, 127.5, 127.3, 124.6, 121.9, 120.8, 
58.8, 58.7, 57.3, 51.9, 42.5, 35.3, 33.5, 33.1, 19.5, 16.9. LC–MS: 487+; tR: 7.40 min.
General procedure for the synthesis of compounds 10 and 13–32. To a series of 1.5 mL glass 
tubes was added amine 6 in NMP (0.95 M, 0.095 mmol), followed by solutions of different 
ketones (0.5 M, 0.1 mmol) in NMP, and these mixtures were subsequently treated with 
acetic acid (0.1 mmol), followed by 5-ethyl-2-methyl-pyridine borane (PEMB) (0.2 mmol). 
The reaction mixture was heated at 65 °C on a reaction block for 24 h. The reaction mixtures 
were purified directly using an automated mass-guided reverse-phase HPLC, and product-
containing fractions were concentrated to give final products of >90% purity, as judged by 
LC–MS (average of 220 and 254 nm traces).
Biology
Chemicals and reagents. 125I-CCL2 (2200 Ci/mmol) was purchased from Perkin-Elmer 
(Waltham, MA). INCB3344 was synthesized as described previously [16, 17]. [3H]-INCB3344 
(specific activity of 32 Ci mmol–1) was custom-labeled by Vitrax (Placentia, CA), for which 
a dehydrogenated precursor of INCB3344 was provided. Tango CCR2-bla U2OS cells stably 
expressing human CCR2 were obtained from Invitrogen (Carlsbad, CA).
Cell culture and membrane preparation. U2OS cells stably expressing the human CCR2 
receptor (Invitrogen, Carlsbad, CA) were cultured in McCoys5a medium supplemented with 
10% fetal calf serum, 2 mM glutamine, 0.1 mM non-essential amino acids (NEAAs), 25 mM 
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 1 mM sodium pyruvate, 100 IU/
mL penicillin, 100 μg/mL streptomycin, 100 μg/mL G418, 50 μg/mL hygromycin, and 125 
μg/mL zeocin in a humidified atmosphere at 37 °C and 5% CO2. Cell culture and membrane 
preparation were performed as described previously [18]. 
125I-CCL2 displacement assay. Binding assays were performed as described previously [18]. 
[3H]-INCB3344 competition association assay. The kinetic parameters of unlabeled 
ligands at 25 °C were determined using the competition association assay described by 
Motulsky and Mahan [19]. At different time points, 10 μg of U2OS–CCR2 membranes was 
added to 1.8 nM [3H]-INCB3344 in a total volume of 100 μL of assay buffer in the absence 
or presence of competing ligand. To validate the assay, three concentrations of INCB3344 
(1-, 3-, and 10-fold its Ki value of [
3H]-INCB3344 displacement) were used. This validation 
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showed that using a single concentration (that equals the Ki) of unlabeled ligand was 
sufficient to accurately measure kon and koff. Incubation was terminated by dilution with 
ice-cold 50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl buffer supplemented with 
0.05% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Separation 
of bound from free radioligand was performed by rapid filtration through a 96-well GF/B 
filter plate pre-coated with 0.25% polyethylenimine (PEI) using a Perkin-Elmer FilterMate 
harvester (Perkin-Elmer, Groningen, Netherlands). Filters were washed 10 times with ice-cold 
wash buffer. A total of 25 μL of Microscint scintillation cocktail (Perkin-Elmer, Waltham, MA) 
was added to each well, and the filter-bound radioactivity was determined by scintillation 
spectrometry using the P-E 1450 Microbeta Wallac Trilux scintillation counter (Perkin-Elmer). 
Kinetic parameters of unlabeled ligands were calculated using eq 3, as mentioned below in 
the Data Analysis section.
[3H]-INCB3344 dual-point competition association assay. KRI values of unlabeled ligands 
were determined using the dual-point competition association assay as described previously, 
in which radioligand binding was determined at two different time points [20]. Time 
point t1 represents the time at which radioligand binding reached 99.5% of total binding at 
equilibrium.
                                                            t1 = 8 · t1/2,association (1)
The second time point (t2) was arbitrarily set at 4 h, where little but reliably measurable, 
specific binding remained. A total of 10 μg of U2OS–CCR2 membranes were incubated for 50 
min (t1) or 240 min (t2) in a total volume of 100 μL of assay buffer with 1.8 nM [
3H]-INCB3344 
in the absence or presence of unlabeled ligands at 25 °C. The amount of radioligand bound 
to the receptor was measured after co-incubation of the unlabeled ligands at 1-fold their 
respective Ki value in the 
125I-CCL2 displacement assay. Incubations were terminated, and 
samples were obtained as described under the [3H]-INCB3344 Competition Association 
Assay section. KRI values of unlabeled ligands were calculated using eq 2, as mentioned 
below in the Data Analysis section.
Data analysis. All experiments were analyzed using the nonlinear regression curve fitting 
program Prism 5 (GraphPad, San Diego, CA). For radioligand displacement data, Ki values 
were calculated from IC50 values using the Cheng and Prusoff equation [21]. Data of the dual-
point competition association assay were analyzed as described previously [20].
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KRI values were calculated by dividing the specific radioligand binding measured at t1 (Bt1) by 
its binding at t2 (Bt2) in the presence of unlabeled competing ligand as follows:
                                                            KRI = Bt1/ Bt2 (2)
Association and dissociation rates for unlabeled ligands were determined by nonlinear 
regression analysis of the competition association data as described by Motulsky and Mahan 
[19] 
            
                        
KRI = Bt1/ Bt2                                                                   (2) 
 
Association and dissociation rates for unlabeled ligands were determined by nonlinear regression 
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where X is the time (min), Y is the specific binding (disintegrations per minute (DPM)), k1 is kon 
(M–1 min–1) of [3H]-INCB3344 predetermined in association experiments, k2 is koff (min–1) of 
[3H]-INCB3344 predetermined in dissociation experiments, L is the concentration of [3H]-
INCB3344 used (nM), Bmax is the total binding (DPM), and I is the concentration of unlabeled 
ligand (nM). Fixing these parameters into eq 3 allows for the following parameters to be 
calculated: k3 is kon (M–1 min–1) of the unlabeled ligand, and k4 is koff (min–1) of the unlabeled 
ligand. The association and dissociation rates were used to calculate the “kinetic KD” as follows: 
 
KD = koff/ kon                                                                   (4) 
 
The RT was calculated according to the formula RT = 1/koff. 
  
 (3)
where X is the time ( in), Y is the spe ific binding (disinte ti  r i te (DP )), 1 on 
(M–1 min–1) of [3H]-INCB3344 pred t rmined in association experime t 2 koff i
–1  
[3H]-INCB3344 predetermined in dissociation experiments, L is t  c c tration of [3 ]-
INCB3344 used (nM), Bmax is the total binding (DPM), and I is the concentration of unlabeled 
ligand (nM). Fixing these parameters into eq 3 allows for the following parameters to be 
calculated: k3 is kon (M
–1 min–1) of the unlabeled ligand, and k4 is koff (min
–1) of the unlabeled 
ligand. The association and dissociation rates were used to calculate the “kinetic KD” as 
follows:
                                                            KD = koff/ kon (4)
The RT was calculated according to the formula RT = 1/koff.
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Results and discussion
Chemistry. Synthesis of (1S,3R)-methyl-3-((tert-butoxycarbonyl)amino)-1-
isopropylcyclopentanecarboxylate (3) was achieved following the synthetic approach 
reported by Kothandaraman et al. [15]. The desired N-tert-butyloxycarbonyl (Boc)-protected 
ester 3 was saponified to yield acid 4. Subsequently, acid 4 was used in the peptide-
coupling reaction with 3,5-bis(trifluoromethyl)benzylamine to yield amide 5 under bromo-
tris-pyrrolidino phosphoniumhexafluorophosphate (PyBroP) conditions [22]. Removal of 
the N-Boc group with trifluoroacetic acid (TFA) in dichloromethane (DCM) produced amine 6. 
Reductive amination with different ketones under NaBH(AcO)3 conditions afforded the desired 
products 1, 2, and 11, 12. Compounds 7–9 were synthesized by alkylating amine 6 with 
different alkylating agents. Compounds 10 and 13–32 were generated from amine 6 and 
an array of different ketones with 5-ethyl-2-methylpyridine borane complex (PEMB) under 
conditions reported by Burkhardt and Coleridge (Scheme 1) [23]. 
Scheme 1. Synthesis of CCR2 antagonists. Reagents and conditions: (a) 4 M LiOH aqueous, MeOH, 
reflux, 4 h, 91%; (b) 3,5-bis(trifluoromethyl)benzylamine, PyBrOP, N,N-diisopropylethylamine 
(DiPEA), N,N-dimethylaminopyridine (DMAP), DCM, room temperature, 24 h, 83%; (c) TFA, DCM, room 
temperature, 1 h, 85%; (d) corresponding ketone, (AcO)3BHNa, AcOH, DCE, room temperature, 18 h, 
21–86% (compounds 1, 2, and 11, 12); (e) corresponding alkylating agent, DiPEA, CH3CN, 60 °C, 2 h, 14–
54% (compounds 7–9); (f) for array synthesis, corresponding ketone, 5-ethyl-2-methylpyridine borane 
(PEMB), AcOH, N-methylpyrrolidone (NMP), 65 °C, 24 h (compounds 10 and 13–32).
Biology. To determine the binding affinity, all compounds were tested in a 125I-CCL2 
displacement assay on human bone osteosarcoma (U2OS)–CCR2 membrane preparations 
as described previously by our group [18]. Several methods can be used to determine ligand 
binding kinetics (e.g., a kinetic radioligand binding assay [24], surface plasmon resonance 
(SPR) [25], “two-step” competition binding assay [26], and “Tag-lite” Cisbio [27]). Most of 
these assays require special modifications of the target protein or the ligand. Therefore, we 
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chose to use the competition association assay, because this assay allowed us to determine 
the kinetics of unlabeled ligands to the receptor expressed in membrane preparations. In our 
hands, this is the most robust and accurate assay to measure kinetics of unlabeled ligands.
Validation of the [3H]-INCB3344 competition association assay for CCR2. A competition 
association assay was set up to determine the kinetic parameters of unlabeled ligands [19]. 
For this assay, we used the radiolabeled small-molecule CCR2 antagonist [3H]-INCB3344 [28], 
instead of the endogenous agonist protein radioligand 125I-CCL2. Because of the large size of 
CCL2 (8600 Da), there is at best only a partial overlap in the binding site with small-molecule 
antagonists. Because the theoretical model of the competition association assay is based on 
the assumption that unlabeled and radiolabeled ligands should compete for the same binding 
site, we decided to use [3H]-INCB3344 in our assay. This radioligand bears considerable 
chemical resemblance to the compounds reported in this study. We first validated this 
method by measuring the competition association of [3H]-INCB3344 in the absence and 
presence of three different concentrations of INCB3344 (1-, 3-, and 10-fold its Ki) (Fig. 3). 
This resulted in kon and koff values for unlabeled INCB3344 of 0.035 ± 0.010 nM
–1 min–1 and 
0.024 ± 0.002 min–1, respectively, at 25 °C (Table 1). The corresponding RT was 43 ± 2 min. 
These results were in good agreement with kon and koff values of [
3H]-INCB3344 binding from 
“traditional” association and dissociation experiments, 0.054 ± 0.002 nM–1 min–1 and 0.013 ± 
0.002 min–1, respectively [18] (Table 1).
Fig. 3. Competition association assay with [3H]-INCB3344 at 25 ºC in the absence or presence of 1.1, 3.7 
and 11 nM unlabeled INCB3344.
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Table 1. Comparison of equilibrium binding and kinetic parameters of INCB3344 determined using 
different methods
assay KD/Ki (nM) kon (nM
-1 min-1) koff (min
-1)
saturation bindinga 0.90 ± 0.03 NAb NA
displacementc 1.2 ± 0.1 NA NA
association and dissociationd 0.23 ± 0.04 0.054 ± 0.002 0.013 ± 0.002
competition associatione 0.72 ± 0.19 0.035 ± 0.010 0.024 ± 0.002
Data are presented as mean ± S.E.M. of three independent experiments performed in duplicate.
aSaturation binding of 1 - 45 nM [3H]-INCB3344 to CCR2 at 25 ºC.
bNA = not applicable. 
cDisplacement of 3.5 nM [3H]-INCB3344 from CCR2 at 25 ºC.
dAssociation and dissociation of [3H]-INCB3344 measured in standard kinetic assays at 25 ºC.
eAssociation and dissociation of INCB3344 measured in competition association assays at 25 ºC.
Screening of CCR2 antagonists using the dual-point competition association assay. The 
competition association assay described above is laborious and time-consuming, and hence, 
we developed a so-called dual-point competition association assay for CCR2, according to 
principles that we recently established for the adenosine A1 receptor [20]. To this end, we co-
incubated [3H]-INCB3344 with unlabeled antagonists at a concentration equal to their Ki value 
that was determined in the 125I-CCL2 displacement assay. The so-called kinetic rate index (KRI) 
was calculated by dividing the specific radioligand binding at 50 min (t1) by the binding at 240 
min (t2). In this assay, antagonists with a slower dissociation rate and, therefore, a longer RT 
than [3H]-INCB3344 would result in a KRI > 1 (Fig. 4).
Fig. 4. Representative competition association curves of control and long-residence-time compound 
22a. Bt1, specific radioligand binding at the first time point (t1 = 50 min); Bt2, specific radioligand binding 
at the second time point (t2 = 240 min). KRI is defined as Bt1/Bt2, which equaled 1.2 for compound 22a. 
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Structure–affinity relationships (SARs) versus structure–RT relationships
The 3-amino-1-isopropylcyclopentanecarboxamide scaffold has been extensively evaluated 
on the basis of binding affinities for CCR2 and selectivity against other chemokine receptors 
and the human ether-à-go-go-related gene (hERG) channel [15, 29, 30]. Therefore, we decided 
to resynthesize several reported derivatives of compound 1 [15, 31] and determine their 
binding affinity in radioligand displacement assays (Table 2). Introduction of the benzyl group 
yielded compound 7 with an affinity of 437 nM. When the spacer length between the phenyl 
ring and basic nitrogen was extended to ethyl, binding was almost lost (compound 8; Ki = 
2400 nM). Prolonging the chain to propyl allowed us to regain affinity (compound 9; Ki = 
134 nM). Combining the knowledge of compounds 7 and 9 in one structure yielded the 
indane derivative compound 2 with even more improved affinity (Ki = 50 nM). Expanding 
the ring system to tetrahydronaphthalene resulted in an additional increase in affinity 
(compound 10; Ki = 33 nM). Removal of aromatics yielded compound 11 with a cyclohexane 
ring, which showed a decrease in affinity (Ki = 110 nM), but incorporation of heteroatoms in 
the 4 position regained affinity (compounds 1 and 12; Ki = 6.8 and 31 nM, respectively) as 
described by Kothandaraman et al. [15]. On the basis of affinity alone, compound 1 would 
be the logical choice for lead optimization, which yielded the clinical candidate MK-0812 in 
the case of the Merck research group [10]. However, the kinetic evaluation of these known 
structures in a competition association assay allowed us to use an additional parameter, RT. In 
this assay, the best affinity compound 1 had a RT of 2.4 min, while compound 2 had a 4-fold 
longer RT of 9.5 min (Table 2). Structurally closely related compound 10 had a RT of 5.6 min, 
which convinced us to continue with compounds 2 and 10, because they had a longer RT.
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Nr. R Ki (nM) ± S.E.M. (n=3) RT (min)
1
O
6.8 ± 2.2 2.4 ± 0.2
2 50 ± 8 9.5 ± 1.5
7 437 ± 62 -
8 2400 ± 900 -
9 134 ± 35 -
10 33 ± 2 5.6 ± 0.5
11 110 ± 13 1.9 ± 0.4
12
S
31 ± 9 4.3 ± 1.4
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Nr. R Ki (nM) ± SEM (n=3) KRI (n=2)
2 H 50 ± 8 0.7 (0.7/0.7)
13 4-NH2 43 ± 7 0.8 (0.7/0.8)
14 4-OH 86 ± 8 0.6 (0.5/0.8)
15 4-CN 70 ± 11 0.8 (0.7/0.8)
16 4-Me 26 %a -
17 4-OMe 30 %a -
18 5-OMe 6.1 ± 0.7 0.6 (0.6/0.6)
19 5-OH 29 ± 2 0.7 (0.7/0.8)
20 5-F 30 %a -
21 5-Cl 18 ± 1 1.1 (1.1/1.2)
22 5-Br 7.2 ± 0.5 1.1 (1.0/1.1)
23 6-Cl 28 %a -
24 6-Me 55 ± 2 0.8 (0.8/0.8)
25 6-CN 54 ± 4 0.6 (0.6/0.6)
26 4;5-di-OMe 130 ± 6 -
27 5;6-di-OMe 3.9 ± 0.3 0.7 (0.7/0.7)
28 5;6-(-OCH2O-) 6.3 ± 0.8 0.6 (0.6/0.7)
aPercent displacement at 1µM 125I-CCL2.
Using a number of commercially available indanones, we introduced different 
substituents on the indane ring (Table 3) to cover chemical space as broadly as possible. 
The SAR exploration on the 4 position showed that H-bond-accepting and hydrophilic groups 
are tolerated. The 4-NH2 group led to a minor increase (compound 13; Ki = 43 nM), but 
4-OH and 4-CN groups showed a decrease in affinity (compounds 14 and 15; Ki = 86 and 
70 nM, respectively). 4-Me (compound16) and 4-MeO (compound 17) were not tolerated 
on this position (26 and 30% displacement at 1 μM, respectively). On the 5 position, 
methoxy and hydroxyl groups improved the affinity, which had also been suggested for other 
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CCR2 antagonists [30, 32]. The methoxy group (compound 18) showed an 8-fold increase 
in affinity (6.1 nM), while the hydroxyl group (compound 19) displayed a less than 2-fold 
increase compared to the unsubstituted indenyl derivative (29 and 50 nM, respectively). 
On the contrary, the introduction of fluorine, which was previously reported as the best 
substituent in arylpiperidine analogues by Pasternak et al. [30], resulted in a dramatic 
decrease in affinity in the case of the indenyl derivative (compound20; 30% displacement at 
1 μM). 5-Cl substitution yielded better affinity than 5-F (compound 21; 18 nM), and 5-Br was 
better than 5-Cl (compound 22; 7.2 nM). 6-Cl (compound 23) led to a dramatic decrease in 
affinity (28% displacement at 1 μM). However, 6-Me and 6-CN groups were tolerated, having 
similar affinities to the unsubstituted indane ring (compounds 24 and 25; Ki = 55 and 54 nM, 
respectively).
We continued the investigation with the analysis of disubstitution, learning 
that the combination of 4,5 substitution resulted in more than a 2-fold decrease in 
affinity (compound26; Ki = 130 nM). On the contrary, the 5,6-dimethoxy group yielded 
compound 27 with a high affinity of 3.9 nM. Connecting the dimethoxy groups into a dioxolane 
ring yielded a small decrease in affinity (compound 28; Ki = 6.3 nM).
Using the knowledge of the best position for substitution, we continued the 
investigation on the 1,2,3,4-tetrahydronaphthalene ring by introducing substituents on 
the 5 position (Table 4). Electron-donating groups showed very similar results to what we 
found for the indenyl moiety. Compounds 29 and 30 showed good affinity (27 and 35 nM, 
respectively), while electron-withdrawing groups showed a decrease or complete lack of 
affinity (compounds 31 and 32).
After SAR evaluation, the higher affinity compounds were screened in our kinetic assay 
to determine their KRI value [20] (see also Figure 2). A KRI value of <1 indicates that the 
RT of a tested compound is shorter than the RT of the radioligand (less than 43 min in this 
particular case). A KRI value of >1 reflects a RT of more than 43 min.
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Nr. R Ki (nM) ± SEM (n=3) KRI
10 H 33 ± 2 0.6 (0.6/0.5)
29 5-OMe 27 ± 1 0.7 (0.7/0.8)
30 5-OH 35 ± 2 0.8 (0.7/0.8)
31 5-Br 48%a -
32 5-COOH 0%a -
aPercent displacement at 1 µM 125I-CCL2.
Compound 2 in the screen showed a KRI value of 0.7 (RT = 9.5 min). However, 
compounds 21and 22 had higher KRI values (1.1 for both compounds). These compounds 
were tested in a full competition association assay to determine their association and 
dissociation rate constants (Table 5). Increasing the size of the substituent, change from 
5-Cl to 5-Br (compound 21 versus compound 22), also yielded longer RTs (56 and 94 min, 
respectively). Compound 22 was separated in two diastereomers by preparative supercritical 
fluid chromatography (SFC) using a Phenomenex Lux-4 column (Phenomenex, Inc.). The first 
compound to elute (22a) had an affinity of 3.6 nM. However, the second compound (22b) 
to elute had a 100-fold decreased affinity (Ki = 289 nM). These separated diastereomers had 
very similar koff rates (Table 5), which translated to similar RTs (compound 22a, RT = 135 min; 
compound 22b, RT = 77 min), but a significant difference was observed for their kon rates. 
Apparently, the stereochemistry of the indane ring system has a major impact on the 
compound association rate to the receptor, while the dissociation is not affected.
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Nr. R Ki (nM) ± SEM (n=3) kon (nM
-1 min-1) koff (min
-1) RT (min)
21 5-Cl 18 ± 1 0.0027 ± 0.0006 0.020 ± 0.004 56 ± 14
22 5-Br 7.2 ± 0.5 0.010 ± 0.002 0.011 ± 0.0002 94 ± 3
22a 5-Br 3.6 ± 0.9 0.0053 ± 0.0007 0.0074 ± 0.0004 135 ± 8
22b 5-Br 289 ± 94 0.00030 ± 0.00007 0.015 ± 0.004 77 ± 18
Conclusion
We have demonstrated that, next to affinity, additional knowledge of the RT is useful for 
selecting and developing new CCR2 antagonists. (1S,3R)-N-(3,5-Bis(trifluoromethyl)benzyl)-
3-((5-bromo-2,3-dihydro-1H-inden-1-yl)amino)-1-isopropylcyclopentanecarboxamide 
(22a) had a RT of 135 min. In comparison to the best affinity compound from the first SAR 
screening, i.e., compound 1 (Table 1), compound 22a had a 56-fold increased RT while having 
similar affinity. This indicates that affinity and RT do not correlate; moreover, while SAR driven 
hit-to-lead optimizations often fail in later stages of drug development because of the lack of 
efficacy (e.g., MK-0812), it has been shown on other targets that RT is linked to the duration 
of the in vivo antagonist effect [33-35]. Compound 22a may thus be a useful tool to test 
whether prolonged blockade of CCR2 has a beneficial effect on CCR2-related disorders, such 
as neuropathic pain.
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Conclusions and future perspectives
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In this thesis the molecular pharmacology of the chemokine receptor CCR2 has been 
extensively studied and discussed. Insights in the mechanism of action of novel as well as 
existing drug-like molecules for CCR2 were presented. This chapter concludes the findings of 
these studies, to then discuss its impact on drug discovery and to reflect on future directions 
of this research field.
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Conclusions 
Multiple binding sites for small molecules at CCR2
CCR2 is a membrane-bound receptor protein that transduces signals into the cell due to direct 
interactions with a number of signalling molecules. It is activated by its endogenous chemokine 
ligands at the extracellular side, which each most likely bind in a slightly different manner to 
the extracellular and TM domains, given their distinct effects (Chapter 2). Receptor activation 
allows interactions with large proteins such as G proteins and β-arrestins at the intracellular 
side of the GPCR, which is often preceded or followed by additional GPCR-interacting proteins 
(GIPs) [1-3]. Therefore, CCR2, as well as all other GPCRs, naturally possesses multiple binding 
sites for ligands or proteins. In my thesis I conclude that such distinct binding sites also exist 
for chemically-derived small molecule ligands for the chemokine receptor CCR2 (Chapter 3). 
Not only do these ligands bind to the well-established binding sites at the extracellular or 
TM domain regions, but also to the core region of the receptor and at a hitherto unknown 
intracellular binding pocket (Chapters 4 and 5, Fig. 1).
Novel routes towards insurmountable inhibition of CCR2
Throughout this thesis I have presented data on the mechanism of action of orthosteric 
antagonists and allosteric antagonists. In Chapter 3 it was described that the allosteric 
antagonists act in a noncompetitive manner with respect to the endogenous chemokine 
CCL2. This implies that the maximal response of the receptor is suppressed even when high 
concentrations of the agonist CCL2 are present; a phenomenon that has been described 
as insurmountable antagonism in in vitro functional assays [4, 5]. Due to this property, 
insurmountable antagonists are proposed to be highly clinically relevant. This situation is 
particularly relevant for chemokine receptors, since chemokine levels are highly increased 
(1-10 nM) during inflammatory conditions [6-8]. In addition, as discussed in Chapter 2, 
chemokines are sequestered on glycosaminoglycans (GAGs) near the chemokine receptors, 
thereby creating a depot in close proximity to the receptor that further increases the 
local concentration of these ligands. Leukocytes expressing CCR2 that pass the site of 
inflammation, will only be inhibited from chemotaxis towards these sites if a drug can bind 
irrespective of the high local chemokine concentrations; a requirement that is fulfilled by the 
allosteric insurmountable antagonists described in Chapters 3 and 4. The binding site of these 
antagonists was discovered to be located at the intracellular side of the receptor. Since the 
surrounding amino acid residues of these ligands have now been revealed (Chapter 4), this 
may facilitate the design of novel and improved allosteric insurmountable antagonists. 










Fig. 1. Schematic representation of CCR2 with its multiple ligand binding sites throughout the entire 
transmembrane domain. A representative ligand for each of these binding sites is depicted at the top. 
An allosteric mode of action is not the only possibility to obtain insurmountable 
antagonism, since orthosteric antagonists with a long residence time on the receptor can 
manifest a similar inhibition profile [5]. In this latter scenario, the orthosteric antagonists 
are bound to the receptor for such a long time that they prevent agonists from binding and 
thereby diminish their maximum effect. The structure-kinetics relationship (SKR) presented 
in Chapter 6 is among the first examples of a comprehensive medicinal chemistry approach 
that aims to increase ligand residence times. Small structural changes prolonged the 
residence time of these antagonists, revealing the first molecular determinants that can lead 
to insurmountable antagonism via this orthosteric binding pocket. Importantly, SKR-driven 
ligand optimization resulted in final compounds distinct from a situation in which the affinity 
would have driven the optimization process. This emphasizes that SKR should be incorporated 
in early stages of hit-to-lead optimization in order to identify long residence time antagonists. 
In summary, it can be concluded that two distinct paths towards insurmountable 
antagonism for CCR2 have been paved.
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Future perspectives 
A variety of pharmacological topics are covered in thesis, ranging from allosteric modulation 
and insurmountability to ligand binding kinetics and biased signalling. In addition, the 
functioning and regulation of the intertwined chemokine receptor system was discussed, 
along with the challenges to target these receptors in the clinic. The following sections 
will discuss some future perspectives of all these findings for targeting CCR2, and GPCRs in 
general.  
CCR2 as a single drug target
This thesis is mainly focused on the molecular pharmacology of CCR2, without emphasis on 
any particular disease state to which this receptor is associated. However, the complexity and 
functioning of the chemokine receptor system was discussed in Chapter 2, and should also be 
taken into account while speculating on the future directions of disease management through 
CCR2 antagonism. For example in rheumatoid arthritis (RA), patients suffer from joint pain, 
stiffness, and swelling as a result of synovial inflammation. CCR2 is clearly involved in this 
disease, concluded from many in vitro studies as well as in vivo animal studies in which knock-
out or pharmacological blockade of CCR2 decreased disease symptoms [9]. Nevertheless, no 
clinical trial targeting CCR2 in this disease has been proven successful so far [10]. There can be 
multiple reasons for this failure, including inappropriate drug-receptor kinetics or molecular 
mechanisms of action, i.e. surmountable vs. insurmountable antagonism, as discussed in 
Chapters 3, 4 and 6. Additionally, in case of these complex inflammatory diseases it must be 
remembered that multiple chemokines as well as multiple chemokine receptors are involved, 
which can in turn have both synergistic and counteracting modes of action (Chapter 2). In 
case of RA, monocytes in peripheral blood of RA patients expressed higher levels of CCR2 
than CCR5 [11]. In contrast, substantially higher expression of CCR5 compared to CCR2 was 
observed on macrophages in synovial fluid [11]. Yet another study revealed that neither CCR2 
nor CCR5 antagonists were able to block chemotaxis of monocytes towards synovial fluid 
of patients, but inhibition of CCR1 was proven to be effective [12]. In this particular case it 
should be identified which receptor(s) are critical for the migration of monocytes towards the 
synovial compartment in RA in order to know which receptor(s) to target [13]. 
There are several other diseases for which multiple chemokine receptors have been 
found to be involved, which has stimulated the development of dual antagonists, mainly for 
CCR2 and CCR5 [14, 15]. The dual CCR2 and CCR5 antagonist cenicriviroc has made most 
progress so far, since it is has entered phase 3 clinical trials for the treatment of HIV-1 infection, 
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and is currently also in preclinical development for fibrosis, graft-versus-host disease, and 
other indications in which CCR5 and CCR2 play a role [14, 16]. Future results of these ongoing 
trials will demonstrate whether dual inhibition is the key to successful treatments for these 
and other diseases, like RA (see above). For this particular disease, one could think of dual/
triple antagonists that additionally target CCR1, which does not seem impossible in view of 
the high sequence similarity of CCR1, CCR2 and CCR5 [17]. Regarding this polypharmacology 
as an approach [18], the development of dual intracellular antagonists could be another way 
to proceed, given the evidence that such a binding pocket is at least conserved among the 
highly homologous chemokine receptors CCR2 and CCR5 (Chapter 4). 
The INS of ligand binding to GPCRs
Intracellular CCR2 antagonists. In Chapter 4 the discovery of an intracellular binding pocket 
for small molecule antagonists of CCR2 was presented. This is the first time that such a 
binding pocket was extensively mapped on a GPCR by means of mutations, and visualized 
in a homology model of CCR2 upon induced-fit docking of the antagonist CCR2-RA-[R]. 
The most recent review on CCR2 small molecule antagonists includes approximately 30 
different structural scaffolds, of which only 10% is likely to bind to the intracellular pocket 
based on structural similarity with the antagonists presented in this thesis [19]. Therefore, 
the identification of this binding pocket in Chapter 4 will allow chemists to further explore 
this allosteric site. In addition, the radioligand binding studies in Chapter 3 revealed that the 
intracellular and orthosteric antagonists enhanced binding of each other to CCR2. Hence, it 
would be interesting to further study the nature of this enhancement, since a similar level of 
inhibition might be achieved with lower doses of both antagonists due to a synergistic mode 
of action. 
Allosteric modulation of CCR2 signalling by intracellular ligands. Now that the binding 
properties of the intracellular CCR2 antagonists have been elucidated, several future 
research questions arise with respect to the effect of these allosteric ligands on a functional 
level. As mentioned in Chapter 2, CCR2 has been found to function as both a monomer and 
a (hetero)dimer. The allosteric intracellular antagonists might differentially inhibit these 
multimeric complexes compared to the orthosteric antagonists. In addition, a total of eight 
chemokine ligands can bind to CCR2, all exerting distinct actions as described in Chapter 
2. The intracellular antagonists might differentially inhibit these endogenous chemokines 
compared to the competitive orthosteric antagonists (Fig. 2), and depending on their role in 
disease states this could have an impact on their efficacy in vivo. 













Fig. 2. CCR2 can be activated by multiple endogenous chemokines, including CCL2, CCL7, CCL8 and 
CCL11. In this thesis multiple antagonists with a distinct binding site and mechanism of action were 
discovered, among which the orthosteric antagonist INCB3344 and the allosteric antagonist CCR2-RA-
[R]. It remains a question for further research how these two distinct antagonists affect the receptor 
activation that is induced by the multiple endogenous chemokines.
Besides a distinct action in the presence of the different chemokine ligands for CCR2, 
one could also hypothesize that a small molecule ligand might exert biased antagonism itself, 
in which it inhibits certain signalling pathways better than others [20, 21]. There is one study 
that reported such behavior for a set of 24 CCR2 antagonists, in which inhibition of CCL2 
stimulation was compared in five different functional assays [22]. Although the structures of 
these antagonists were not reported, and the effect in a functional assay is dependent on the 
off-rate of the antagonists and the incubation time of the assay, it is at least a first indication 
of biased antagonism for CCR2. Now that the receptor’s distinct antagonist binding sites have 
been revealed, this phenomenon should be further investigated. 
Intracellular CCR2 antagonists in vivo. Speculations on distinct in vivo effects of allosteric 
antagonists compared to orthosteric antagonists can be made based on several clinical 
studies with CCR2 antagonists. Most of the trials involve orthosteric antagonists, and in many 
of these studies enhanced CCL2 plasma levels were previously reported upon administration 
of the antagonists, including for INCB3344 [10, 23, 24]. These enhanced CCL2 levels could in 
turn diminish the inhibitory action of the administered antagonist due to direct competition. 
In contrast, no elevation of systemic CCL2 levels was observed in a recent phase II study 
in type 2 diabetics with the antagonist CCX140-B [25, 26]. Although the chemical identity 
150  |  Chapter 7
of CCX140-B has not been revealed, it is likely to be an allosteric (intracellular) antagonist 
since the associated patent describes a chemical scaffold that closely resembles SD-24 from 
Chapter 4 [27]. The allosteric nature of this ligand might be the cause of different modulation 
of CCL2 plasma levels compared to orthosteric antagonists. As described in Chapter 2, 
CCL2 is scavenged by CCR2 in vivo [28]. This implies that the CCR2-CCL2 complex can be 
internalized to regulate the level of CCL2 in the extracellular environment. So far, the effect 
of small molecule antagonists on this internalization pathway has not been studied for CCR2. 
However, a very recent in vitro study that compared orthosteric and intracellular antagonists 
of CCR4 revealed that orthosteric antagonists were able to induce internalization of CCR4, 
whereas intracellular antagonists left CCR4 surface expression unaffected [29]. Whether this 
phenomenon is also applicable to CCR2, linking the unaffected plasma levels of CCL2 to a 
lack of CCR2 internalization by an allosteric mode of inhibition, remains to be determined. 
However, these studies indicate that orthosteric and allosteric antagonists may differentially 
inhibit the CCR2-CCL2 axis in vivo.
Intracellular ligands for GPCRs. During the last couple of years the intracellular region of 
GPCRs has become of increasing interest, either for therapeutic interventions or to study 
receptor functioning in general [30, 31]. Indications of intracellular GPCR binding pockets 
have been reported previously for CCR4, CCR5, CXCR1, CXCR2 and PAR1 [32-35]. In addition, 
the intracellular CCR2 antagonists CCR2-RA-[R], JNJ-27141491 and SD-24 from Chapters 3 
and 4 have been reported to also bind to CCR1 [36-38]. Together these data suggest that 
an intracellular binding pocket for small molecule antagonists could be a shared feature 
among chemokine receptors, or even GPCRs in general. Such an intracellular antagonist 
binding pocket could be highly interesting for certain GPCRs, for example for those that 
have their endogenous ligand tethered at the extracellular side, like the PAR1 receptor [39]. 
These tethered ligands directly compete with orthosteric antagonists, preventing them to 
sufficiently block the receptor. Besides receptor blockade with long residence time orthosteric 
antagonists, inhibition via an intracellular allosteric site would be beneficial for targeting such 
receptors. For PAR1 this is likely to be possible, since indications of an intracellular binding 
pocket have been reported for this receptor [34]. 
Intracellular antagonists act at the interface of the receptor and its signalling molecules, 
and therefore they most likely act as inverse agonists, inhibiting the basal activity or 
constitutive signalling of the receptor. This is indeed the case for the intracellular CXCR2 
antagonist Sch527123 [32, 40], which has been found efficacious in a Phase II clinical trial 
for asthma [41]. Although the extent of constitutive activity in disease states remains largely 
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unknown, many GPCR antagonists are in fact inverse agonists [42]. Some of these drugs have 
been presented to display higher clinical efficacy than neutral antagonists targeting the same 
receptor [43, 44].
Last but not least, it is tempting to speculate on possibilities to enhance or activate GPCR 
signalling via the intracellular side. Small lipidated peptide sequences named pepducins have 
been proposed to act via the intracellular side of the receptor, and can thereby activate, 
inhibit or modulate various GPCRs, including the chemokine receptor CXCR4 [31, 45, 46]. In 
Chapter 4 the intracellular binding pocket for CCR2 small molecule antagonists was identified, 
which is surrounded by TM-I, II, VI and VII. One of the possible mechanisms of inhibition 
by these antagonists is the fixation of TM-VI, since relatively large outward movements of 
TM-VI are necessary for activation of the receptor [47, 48]. It would be interesting to study 
whether small molecule agonists can be designed that favor this outward movement of TM-
VI, thereby creating a binding site for signalling proteins such as the G protein [49].
The OUTS of ligand binding to CCR2
Several orthosteric CCR2 antagonists were described in Chapter 3, of which INCB3344 was 
radiolabeled and further studied. The binding site of other orthosteric antagonists was 
previously reported to reside in the upper half of the TM domain [50]. A similar location for 
binding of INCB3344 was confirmed in Chapter 4, where the conserved glutamate residue 
E7.39 was identified to be important for binding. In close proximity to this binding site, an 
additional binding pocket for small molecule ligands and sodium ions was discovered (Chapter 
5). This pocket is located in the core domain of the receptor, and allows amiloride analogues 
and sodium ions to modulate CCR2. Besides targeting one particular antagonist binding 
site, inhibition via multiple pockets simultaneously might offer additional opportunities to 
antagonize CCR2. This could for example be established via so-called bitopic ligands that 
would be able to bind both the binding pocket in the core domain as well as the orthosteric 
binding pocket [51].







Fig. 3. Chemical structure of the most potent heteroaroylphenylurea CCR2 antagonist described by 
Laborde et al. [56]. This antagonist inhibits CCR2 in a different manner than the antagonists that bind 
to sites 1, 2 and 3, and was previously suggested to interact with extracellular domains of the receptor. 
This raises the question if a fourth small molecule binding site exists in CCR2.
Binding and activation of CCR2 by its endogenous chemokines is highly dependent 
on the extracellular loops (ECLs) as well as the N-terminus [52]. The role of the ECLs in 
antagonist binding to CCR2 has not yet been deciphered, but the results on chimeric CCR2-
CCR5 receptors in Chapter 4 suggest that these loops may also be involved in the binding 
of the orthosteric antagonist INCB3344. A general analysis of the extracellular domains for 
class A GPCRs has previously revealed that these parts of the receptor can host allosteric 
binding sites [53]. For CCR2, there is one particular antagonist described in literature that 
has been suggested to mediate its inhibitory action via extracellular domains of the receptor 
[54, 55]. This heteroaroylphenylurea CCR2 antagonist is structurally different from all of 
the antagonists reported in this thesis [56], and is also unique compared to all other CCR2 
antagonist chemotypes [19]. Interestingly, this antagonist does not inhibit binding of CCL2 to 
the receptor, while it inhibits CCL2-induced chemotaxis in vitro as well as in vivo [56]. A lack 
of chemokine displacement was previously also reported for the CCR5 antagonist aplaviroc 
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[57] as well as the CXCR1 antagonist repertaxin [58], and is indicative of an allosteric mode of 
action. Whether this heteroaroylphenylurea antagonist indeed binds to a pocket within the 
extracellular domains remains to be determined (Fig. 3), but it does inhibit the receptor in a 
very distinct manner compared to the antagonists described in this thesis. 
Keeping up with kinetics
In Chapter 6 the kinetics of antagonist binding to CCR2 were explored. Although this 
study was solely focused on orthosteric antagonists, a similar approach can be applied to 
the intracellular antagonists in the future. In fact, it has already been demonstrated that 
intracellular antagonists have potential to result in prolonged receptor blockade, since a 
residence time of 29 hours at room temperature was previously measured for the intracellular 
CXCR2 antagonist Sch527123 [59].
Long residence time antagonists are proposed to lead to enhanced clinical efficacy 
and patience compliance, due to a prolonged receptor blockade, increased selectivity and a 
decreased dosing frequency [60]. Recently a short residence time antagonist for CCR2 was 
found to enhance vaccine immunity only after a multi-dose treatment regime, due to its poor 
pharmacokinetic properties [61]. Increasing the residence time of such ligands could lead to 
longer-lasting in vivo blockade, as was previously also reported for antagonists of the NK1 
receptor [62]. To identify whether administration of long residence time antagonists results 
in more efficacious CCR2 blockade in vivo, comparative studies with short residence time 
antagonists should be performed. Additionally, long residence time antagonists can be used 
for structure elucidation of CCR2, since attempts to crystallize GPCRs have been proven to 
be more successful in the presence of long residence time ligands that stabilize the receptor 
complex [63].
Although several marketed and highly efficacious drugs were determined to slowly 
dissociate from their target receptor in retrospect [64], it is not solely the receptor residence 
time that is related to the clinical efficacy and duration of action [65]. Factors such as the 
association rate of a drug to its receptor, plasma protein binding, pharmacokinetics and 
rebinding of a drug to its target all contribute to the level of receptor occupancy and the 
duration of the effect [66-70]. Hence, chemists, pharmacologists and computational 
biologists should join forces and study the influence of drug binding kinetics on drug action at 
a molecular as well as a systems level in order to unravel the determinants for clinical success 
per target and disease [69, 71]. 
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Final notes 
Altogether the molecular mechanisms of action of orthosteric and allosteric antagonists for 
CCR2 have been explored and detailed throughout this thesis. In addition, these ligands, with 
their distinct binding sites, were effective tools to study receptor modulation by physiologically 
relevant sodium ion concentrations and small molecule amiloride analogues. The discovery of 
the three different ligand binding sites throughout the entire transmembrane domain of the 
receptor illustrates that a GPCR behaves as an allosteric machine, rather than as the classically 
described receptor with a ligand binding site at the extracellular side and a signalling domain 
at the inside of the cell. In concert with the currently expanding insight in the structure and 
signalling capacities of GPCRs, the data presented in this thesis allow to better fine-tune the 
pharmacological modulation of the chemokine receptor CCR2, and GPCRs in general.
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This thesis has provided novel insights in the molecular mechanism of action of antagonists 
for the chemokine receptor CCR2. CCR2 belongs to the protein family of G protein-coupled 
receptors (GPCRs). It is involved in several inflammatory diseases and therefore many 
small molecule antagonists targeting this receptor have been developed over the years. 
Unfortunately all clinical candidates tested so far appeared to lack efficacy in man, which 
stresses the need for a better understanding of their mechanism of action.
Chapter 1 introduces the main subjects that were discussed in this thesis. Prior to our 
study of CCR2, the entire family of chemokine receptors and its endogenous chemokines 
were introduced and discussed in Chapter 2. Chemokine receptors are widely expressed on a 
variety of immune cells and play a crucial role in normal physiology as well as in inflammatory 
and infectious diseases. The existence of 23 chemokine receptors and 48 chemokine ligands 
guarantees a tight control and fine-tuning of the immune system. In this chapter the multiple 
regulatory mechanisms of chemokine signalling at a systemic, cellular, and molecular level 
were discussed. In particular, this chapter was focused on the impact of biased signalling at the 
receptor level, an emerging concept in molecular pharmacology. An improved understanding 
of these mechanisms may provide a framework for more effective drug discovery and 
development at a target class that is so relevant for immune function.
A selection of reference CCR2 antagonists was studied in a variety of pharmacological 
binding and functional assays as described in Chapter 3. All these antagonists displaced the 
endogenous agonist 125I-CCL2 from CCR2 with nanomolar affinity. Two antagonists, INCB3344 
and CCR2-RA, were radiolabeled to study the binding site in greater detail. It was discovered 
that [3H]-INCB3344 and [3H]-CCR2-RA bind to distinct binding sites at CCR2, the latter being the 
first allosteric radioligand for CCR2. Besides the binding properties of the antagonists, CCR2 
inhibition was examined in multiple functional assays, including a novel label-free whole-
cell assay. INCB3344 competitively inhibited CCL2-induced G protein activation, whereas 
CCR2-RA showed a noncompetitive (insurmountable) or allosteric mode of inhibition. These 
findings demonstrated that the CCR2 antagonists described in this chapter can be classified 
into two groups with different binding sites and thereby different modes of inhibition.
In Chapter 4 the binding site of the allosteric antagonist CCR2-RA-[R] was identified. A 
chimeric CCR2/CCR5 receptor approach was used to obtain insight into the binding site of the 
allosteric antagonists, and additionally eight single point mutations were introduced in CCR2 
to further characterize the putative binding pocket. All constructs were studied in radioligand 
binding as well as functional IP turnover assays, providing evidence for an intracellular 
binding site for CCR2-RA-[R]. The most important residues for binding were found to be the 
highly conserved tyrosine Y7.53 and phenylalanine F8.50 of the NPxxYX(5,6)F motif, as well as V
6.36 
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at the bottom of TM-VI and K8.49 in helix-VIII. In addition, the antagonists JNJ-27141491 and 
SD-24 were identified to bind at the same binding pocket as CCR2-RA-[R], albeit with distinct 
orientations. This chapter demonstrated for the first time the presence of an allosteric 
intracellular binding site for CCR2 antagonists. 
In Chapter 5, yet another binding pocket was revealed via which amiloride analogues 
and sodium ions were discovered to modulate CCR2. In radioligand binding studies the 
amiloride analogue HMA allosterically inhibited binding of the agonist 125I-CCL2, the 
orthosteric antagonist [3H]-INCB3344 and the intracellular antagonist [3H]-CCR2-RA-[R]. 
Differently, sodium ions only allosterically inhibited 125I-CCL2 binding, while they enhanced 
binding of [3H]-CCR2-RA-[R]. Three residues located in the core of the transmembrane 
domain, D2.50, W6.48 and H7.45, turned out to be important for modulation of the antagonist 
radioligands, since mutation of these residues abolished or diminished the allosteric effects 
induced by HMA and sodium ions. Upon induced-fit docking of HMA in a homology model 
of CCR2, its interactions with D2.50, W6.48 and H7.45 were visualized, and additional surrounding 
residues of this binding pocket were predicted. 
Chapter 6 was focused on the design of high-affinity and long-residence-time orthosteric 
CCR2 antagonists, which share the same binding site as INCB3344. A new competition 
association assay was developed for CCR2, which allowed investigation of the relationship 
between the structure of the ligand and its receptor residence time (i.e., structure–kinetic 
relationship (SKR)) next to a traditional structure–affinity relationship (SAR). By applying 
combined knowledge of SAR and SKR, the hit-to-lead process of cyclopentylamines as CCR2 
antagonists was re-evaluated. Affinity-based optimization yielded a compound with good 
binding (Ki = 6.8 nM) but very short residence time (2.4 min). However, when the optimization 
was also based on residence time, the hit-to-lead process yielded a new high-affinity CCR2 
antagonist (3.6 nM), with a residence time of 135 min.
In summary this thesis revealed novel ins and outs of ligand binding to CCR2, 
presenting three separate binding pockets via which this receptor can be pharmacologically 
modulated. Different routes towards insurmountable antagonism of CCR2 were described, 
either via noncompetitive or via long residence time antagonists, as concluded in Chapter 
7. These results may allow a more rational design of future antagonists, and are equally 
important to understand the outcomes of studies with existing CCR2 antagonists. In concert 
with the currently expanding insight in the structure and signalling capacities of GPCRs, the 
data presented in this thesis allow to better fine-tune the pharmacological modulation of the 
chemokine receptor CCR2, and GPCRs in general.
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In dit proefschrift zijn verschillende benaderingen onderzocht die leiden tot inhibitie van de 
chemokine receptor CCR2, een receptor die behoort tot de klasse van G-eiwit gekoppelde 
receptoren (GPCRs). CCR2 is betrokken bij diverse ziektebeelden, en daarom is er een 
groot aantal antagonisten voor deze receptor ontwikkeld gedurende de afgelopen jaren. 
Desondanks is er nog geen enkel geneesmiddel gericht tegen CCR2 op de markt gebracht, 
omdat geen van alle antagonisten effectief is gebleken in klinische studies. Om deze situatie te 
kunnen verbeteren is een beter begrip van het werkingsmechanisme van CCR2 antagonisten 
noodzakelijk, waarmee de doelstelling van het onderzoek in dit proefschrift is geformuleerd.
In Hoofdstuk 1 werden de belangrijkste begrippen en onderwerpen van dit onderzoek 
geintroduceerd. Vervolgens werd de familie van chemokines en chemokine receptoren 
uitvoeriger toegelicht en besproken in Hoofdstuk 2. In totaal bestaan er 23 verschillende 
chemokine receptoren, die door één of meerdere van de 48 chemokine liganden kunnen 
worden geactiveerd. In dit hoofdstuk werden de veelzijdige regulatiemechanismen van 
chemokine signalering op een systemisch, een cellulair en een moleculair niveau beschreven. 
De nadruk lag hierbij op ‘biased signalling’ dat plaatsvindt op moleculair niveau, een fenomeen 
dat momenteel van grote interesse is in de moleculaire farmacologie. Een beter begrip van 
al deze factoren tezamen zal bijdragen aan de ontwikkeling van effectievere geneesmiddelen 
gericht op chemokine receptoren.
In Hoofdstuk 3 werd een selectie van CCR2 antagonisten bekend uit de literatuur 
bestudeerd in diverse farmacologische radioligand binding studies en functionele studies. 
Al deze antagonisten verdrongen de endogene agonist 125I-CCL2 van CCR2 met nanomolaire 
affiniteit. Twee antagonisten, INCB3344 en CCR2-RA, werden voorzien van een radioactief 
label zodat de binding van deze moleculen gedetailleerd kon worden bestudeerd. [3H]-
INCB3344 en [3H]-CCR2-RA bleken op twee verschillende plekken aan de receptor te binden, 
aangezien deze antagonisten elkaar niet verdrongen van de receptor. Vervolgens werd inhibitie 
van CCR2 bestudeerd in functionele studies. INCB3344 inhibeerde CCL2-geinduceerde G 
eiwit activatie op een competitieve manier, terwijl CCR2-RA een niet-competitief en allosteer 
karakter vertoonde in deze studies. Deze resultaten toonden aan dat de CCR2 antagonisten 
die in dit hoofdstuk beschreven werden, geclassificeerd kunnen worden in twee groepen met 
een verschillende bindingsplek en een verschillend werkingsmechanisme.
In Hoofdstuk 4 werd de zoektocht naar de bindingsplek van de allostere antagonisten CCR2-
RA-[R], JNJ-27141491 en SD-24 beschreven. Allereerst werd een benadering met chimere 
CCR2/CCR5 receptoren gebruikt om inzicht te krijgen in de locatie van de bindingsplaats, 
waarna acht puntmutaties werden geintroduceerd in de receptor om deze bindingsplaats 
verder te karakteriseren. De receptorconstructen werden bestudeerd in radioligand binding 
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studies en functionele studies, die beiden bewijs leverden voor de aanwezigheid van een 
intracellulaire bindingsplek voor CCR2-RA-[R], JNJ-27141491 en SD-24. De meest belangrijke 
aminozuren voor de binding van deze liganden waren de zeer geconserveerde tyrosine Y7.53 
en de fenylalanine F8.50 in het NPxxYX(5,6)F motief, samen met de valine V
6.36 aan de onderkant 
van TM-VI en de lysine K8.49 in helix-VIII. Door middel van deze resultaten werd voor het 
eerst de aanwezigheid van een allostere intracellulaire bindingsplek voor CCR2 antagonisten 
aangetoond. 
In Hoofdstuk 5 werd de ontdekking van een derde bindingsplaats in de CCR2 receptor 
beschreven, waardoor amiloride-derivaten en natrium-ionen de receptor kunnen moduleren. 
In radioligand binding studies werd aangetoond dat het amiloride-derivaat HMA de binding 
van de agonist 125I-CCL2, de orthostere antagonist [3H]-INCB3344 en de intracellulaire 
antagonist [3H]-CCR2-RA-[R] op allostere wijze remde. In diezelfde studies werd ontdekt dat 
natrium ionen enkel de agonist 125I-CCL2 remden, terwijl de binding van [3H]-CCR2-RA-[R] op 
allostere wijze werd verhoogd. Drie aminozuren die zich in het hart van de receptor bevinden, 
D2.50, W6.48 en H7.45, bleken belangrijk te zijn voor deze allostere modulatie, omdat mutatie van 
deze aminozuren het effect van HMA en de natrium-ionen deed verminderen of verdwijnen. 
Door middel van dit onderzoek werd aangetoond dat CCR2 ten minste drie bindingsplaatsen 
voor synthetische liganden van de CCR2 receptor heeft.
Hoofdstuk 6 was gericht op het ontwerp van orthostere CCR2 antagonisten met een 
hoge affiniteit en lange verblijfstijd op de receptor. Deze antagonisten deelden de CCR2 
bindingsplaats van INCB3344. Een competitie associatie studie werd opgezet voor CCR2, die 
het mogelijk maakte om de relatie tussen de structuur van het ligand en zijn verblijfstijd 
op de receptor te onderzoeken (structuur–kinetiek relatie (SKR)), alsmede de traditionele 
structuur–affiniteit relatie (SAR). Door de opgedane kennis van SAR en SKR te combineren, 
werd het optimalisatieproces van cyclopentylamine CCR2 antagonisten opnieuw geëvalueerd. 
Optimalisatie op basis van affiniteit resulteerde in een antagonist met hoge affiniteit (Ki = 
6.8 nM) maar zeer korte verblijfstijd (2.4 min). Daarentegen, wanneer de optimalisatie 
geschiedde op basis van de verblijfstijd, leidde dit tot de ontdekking van een nieuwe CCR2 
antagonist met hoge affiniteit (Ki = 3.6 nM) en een verblijfstijd van 135 minuten.
Samengevat biedt dit proefschrift nieuw inzicht en uitzicht op de binding en werking 
van liganden voor de CCR2 receptor. Er zijn drie verschillende bindingsplaatsen voor 
liganden van deze receptor ontdekt en gelokaliseerd, waardoor CCR2 op verschillende 
wijzen farmacologisch kan worden gemoduleerd. De conclusies van deze bevindingen en 
het toekomstperspectief voor dit onderzoek zijn beschreven in Hoofdstuk 7. Deze resultaten 
kunnen leiden tot een rationeler ontwerp van toekomstige antagonisten, en zijn even zo 
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belangrijk om uitkomsten van studies met huidige CCR2 antagonisten te interpreteren. In 
samenhang met de huidige ontwikkeling van de kennis over de structuur en signalerings-
capaciteiten van GPCRs, biedt dit werk mogelijkheden om de farmacologische modulatie van 
de CCR2 receptor op precieze wijze te reguleren, alsmede van GPCRs in het algemeen.
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